BEST AVAILABLE COPY





G01N 33/569, A61K 39/21

(1) Publication number:

0 199 301 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (4) Date of publication of patent specification: 29.12.93 (5) Int. Cl.⁵ C07K 13/00, C12N 15/00, C12P 21/02, C12P 21/00,
- (21) Application number: 86105371.8

opilication number. do rossi i.a

② Date of filing: 18.04.86

The file contains technical information submitted after the application was filed and not included in this specification

- Recombinant acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS.
- Priority: 19.04.85 US 725021
- 43 Date of publication of application: 29.10.86 Bulletin 86/44
- Publication of the grant of the patent:29.12.93 Bulletin 93/52
- Designated Contracting States:
 AT BE CH DE FR GB IT LI NL SE
- (5) References cited: EP-A- 0 152 030 EP-A- 0 173 529 EP-A- 0 181 150 WO-A-84/04327 US-A- 4 520 113

SCIENCE, vol. 228, no. 4695, 5th April 1985, pages 93-96; N. CHANG et al.: "Expression in Escherichia coli of open reading frame gene segments of HTLV-III"

Proprietor: F. HOFFMANN-LA ROCHE AG
Postfach 3255
CH-4002 Basel(CH)

Proprietor: THE GOVERNMENT OF THE UNIT-ED STATES OF AMERICA as represented by the Secretary of the DEPARTMENT OF HEALTH AND HUMAN SERVICES

Washington, DC 20231(US)

2 Inventor: Crowl, Robert Mitchell
115 Anderson Parkway
Cedar Grove, N.J. 07009(US)
Inventor: Gallo, Robert Charles
8513 Thornden Terrace
Bethesda Maryland 20817(US)
Inventor: Reddy, Eragam Premkumar
51 South Mountain Avenue
Montclair, N.J. 07042(US)
Inventor: Shaw, George Mead
2101 Inverness Cliffs
Birmingham Alabama 35243(US)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

NATURE, vol. 313, no. 6002, 7th February 1985, pages 450-458; M.A. MUESING et al.: "Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus"

NATURE, vol. 313, no. 6000, 24th January 1985, pages 277-284, London, GB; L. RATNER et al.: "Complete nucleotide sequence of the AIDS virus, HTLV-III"

SCIENCE, vol. 226, no. 4679, 7th December 1984, pages 1165-1171; G.M. SHAW et al.: "Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome"

Inventor: Wong-Staal, Flossie Yeeching 18703 Ginger Court Germantown Maryland 20874(US)

Representative: Lederer, Franz, Dr. et al Lederer, Keller & Riederer Patentanwälte Lucile-Grahn-Strasse 22 D-81675 München (DE)

Description

5

The present invention relates to an envelope protein of an acquired immune deficiency syndrome (AIDS) virus, essentially free of other proteins, with the amino acid sequence:

ValTrpLysGluAla ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr ${\tt PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValValIncysThrHisGlyIleArgProValIncysThrHisGlyIleAr$ SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArqSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsnAsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AshMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AläArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

35

40 Or -

45

50

CysProLysValSer $\label{problem} Phe GluProlle Prolle His Tyr Cys Ala Pro Ala GlyPhe Ala Ile Leu Lys Cys Asn Asn Lys Through Market Mark$ PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArqProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AshThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAshSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle ${\tt SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn}$ AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaargIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

25

30

35

40

5

10

15

20

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeupheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

45

50

or

5

10

METTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn As nGly SerGluIle Phe Arg ProGlyGlyGlyAspMETArg AspAsnTrp Arg SerGluLeu Tyr LysTyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

15

20

25

30

METArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlrArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAshAlaSerTrpSerAshLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer.

It also relates to an expression vector comprising a gene coding for an envelope protein as defined above, to transformants and methods for the production of said proteins and a method for detecting the presence of AIDS antibodies in human blood.

Background of the Invention

ΔN

From 1981 to date, there have been more than eight thousand (8,000) people diagnosed as having acquired immune deficiency syndrome (AIDS) [N.Y. Times. A-11 January 11, 1985]. AIDS has been characterized by the onset of severe opportunistic infections secondary to an effect on the body's immune system [Gottlieb. M.S. et al., "Pneumocystis Carinii Pneumonia and Mucosal Candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency", N. Eng. J. Med. 305, 1426-1431 (1981)]. The disease has been found in male homosexuals, patients receiving blood products, intravenous drug addicts, and individuals originating from Haiti and Central Africa (Piot, P. et al., "Acquired immunodeficiency syndrome in a heterosexual population in Zaire", Lancet 11, 65-69 (1984)]. The causative agent was suspected to be of viral origin as the epidemiological pattern of AIDS was consistent with a transmissable disease. At least three (3) retroviruses have been isolated from cultured T-cells of several patients with AIDS, or from white blood cells of persons at risk for the disease. A novel human retrovirus called lymphadenopathy-associated virus (LAV) was discovered and its properties were consistent with its etiological role in AIDS. That virus was isolated from a patient with lymphadenopathy and hence the name [Montagnier, L. et al., "A New Human T-lymphotropic retrovirus: characterization and possible role in lymphadenopathy and acquired immune deficiency syndromes. In Human T-Cell Leukemia/Lymphoma Virus, R.C. Gallo, M. Essex and L. Gross, eds. (Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory) pp. 363-370]. Other human retroviruses, specifically two subgroups of the human T-cell leukemia/lymphoma/lymphotropic virus, types I and III have been isolated [HTLV I: Poiesz, B.J. et al., "Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma", PNAS (USA) 77, 7415-7419 (1980); HTLV-III: Popovic, M. et al., "Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS", Science 224, 497-500 (1984)]. Still another virus, the AIDS-associated retrovirus (ARV), was proposed as the causative agent [Levy, J.A. et al., "Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS", Science 225, 840-842 (1984)]. Both the HTLV-III and ARV retroviruses display biological and sero-epidemiological properties similar to LAV [Levy J.A. et al., supra, Popovic, M. et al., supra]. As seen from the above, at least three (3) retroviruses have been postulated as the etiologic agent of AIDS: LAV; ARV; and, HTLV subtypes I and III.

LAV, HTLV III and ARV-II genomes have been molecularly cloned [Schüpbach, J. et al., "Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS", Science 224, 503-505 (1984); Alizon, M. et al., "Molecular Cloning of lymphadenopathy - associated virus", Nature 312, 757-760 (1984)]. The complete nucleotide sequence of the proviral genome of LAV, ARV and HTLV III has been determined [Ratner, L. et al., "Complete nucleotide sequence of the AIDS virus, HTLV III", Naure 313, 277-284 (1985); Sanchez-Pescador, R. et al., "Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2)", Science 227, 484-492 (1985); Wain-Hobson, S. et al., "Nucleotide sequence of the AIDS virus, LAV", Cell 40, 9-17 (1985)].

Shaw et al., Science 226, 1165-1171 (1984), describes the molecular cloning and analysis of the full-length HTLV-III proviral genome comparing various DNA-clones.

Another analysis of the HTLV-III genom is shown by Muesing et al., Nature 313, 450-458 (1985).

Chang et al., Science 228, 93-96 (1985), describes the expression of small DNA fragments fused to DNA sequences encoding the λ Cl protein and β -galactosidase resulting in unpurified env polypeptides fused to the λ Cl protein at their amino termini and to β -galactosidase at their carboxyl termini.

One reason for the difficulty in determining the etiologic agent of AIDS was due to the reactivity of various retroviral antigens with serum samples from AIDS patients. For example, serum samples from AIDS patients have been shown to react with antigens of HTLV I and HTLV III [HTLV-I: Essex, M. et al., "Antibodies to Cell Membrane Antigens Associated with Human T-Cell Leukemia Virus in Patients with AIDS", Science 220, 859-862 (1983); HTLV-III: Sarngadharan, M.G. et al., "Antibodies Reactive With Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients With AIDS", Science 224, 506-508 (1984)]. Envelope gene products of HTLV demonstrated antigenicities cross-reactive with antibodies in sera from adult T-cell leukemia patients [Kiyokawa, T. et al., "Envelope proteins of human T-cell leukemia virus: Expression in Escherichia coli and its application to studies of env gene functions", PNAS (USA) 81, 6202-6206 (1984)]. Adult T-cell leukemias (ATL) differ from acquired immune deficiency syndrome (AIDS) in that HTLV-I causes T-cell malignancies, that is uncontrolled growth of T-cell. In AIDS rather than cell growth there is cell death. In fact this cytopathic characteristic of HTLV III was critical to determining ultimately the specific retroviral origin of the disease. Thus the etiologic agent of AIDS was isolated by use of immortalized human neoplastic T cell lines (HT) infected with the cytopathic retrovirus characteristic of AIDS, isolated from AIDS afflicted patients. Seroepidemiological assays using this virus showed a complete correlation between AIDS and the presence of antibodies to HTLV III antigens [Sarngadharan, M.G. et al., supra; Schüpbach, J. et al., supra]. In addition, nearly 85% of patients with lymphadenopathy syndrome and a significant proportion of asymptomatic homosexual men in AIDS endemic areas were also found to carry circulating antibodies to HTLV III. Taken together, all these data indicate HTLV III to be the etiologic agent for AIDS.

Until the successful culturing of AIDS virus using H-9 cell line [PCT application, publication no. WO 85/04897] the env AIDS protein of the AIDS virus had not been isolated, characterized or synthesized. This in major part is due to the fact that the virus is cytopathic and thus isolation of the virus was not possible [Popovic, M. et al., supra]. Once the human T-cell line resistant to the cytopathic effects of the virus was discovered, a molecular clone of proviral DNA could be achieved.

The need for a sensitive and rapid method for the diagnosis of AIDS in human blood and its prevention by vaccination is very great. Virtually all the assays/tests presently available are fraught with errors. In fact the Center for Disease Control (CDC) has indicated that presently available tests be used solely for screening units of blood for antibody to HTLV III. The CDC went further by stating that the presently available ELISA tests can not be used for general screening of high risk pupulations or as a diagnostic test for AIDS [Federal Register 50(48), 9909, March 12, 1985]. The errors have been traced to the failure to use a specific antigenic protein of the etiologic agent for AIDS. The previously used proteins were derived from a viral lysate. Since the lysate is made from human cells infected with the virus, i.e. the cells used to grow the virus, the lysate will contain human proteins as well as viral proteins. Thus preparation of a pure antigen of viral protein is very difficult. The antigen used produced both false positive and false negative results

[Budiansky, S., "AIDS Screening, False Test Results Raise Doubts", Nature 312, 583(1984)]. The errors caused by the use of such lysate proteins/peptides can be avoided by using a composition for binding AIDS antibodies which is substantially free of the non-AIDS specific proteins. Compositions that are substantially pure AIDS envelope protein can be used as antigens.

The AIDS envelope protein of the instant invention has been established to have conserved epitopes which permit its use to screen for, diagnose and/or prevent by vaccination the infection by AIDS virus. The instant invention demonstrates that the envelope protein with its conserved epitopes includes all the variants which have been claimed as the sole etiologic agent.

The envelope AIDS protein of the present invention may be produced by conventionally known methods. The processes by which the novel protein may be produced can be divided into three groups: (1) chemical synthesis; (2) preparation of a gene prepared by chemical synthesis which is inserted into a host and a protein is produced by the host; and (3) a corresponding gene obtained biotechnically is inserted into a host and a protein is produced by the host.

In one embodiment of this invention, recombinant DNA techniques are utilized by which env AIDS DNA from a natural source is introduced into a cell to produce the env AIDS protein. One method of obtaining DNA which encodes env AIDS is to read the genetic code in reverse and synthesize an oligodideoxynucleotide which should encode the env AIDS amino acid sequence. As the env protein has not been isolated or characterized this approach cannot be pursued.

Alternatively gene expression can be obtained using recombinant DNA technology if DNA isolated from natural sources is used instead of synthetic DNA.

Summary of the invention

This invention is directed to the engineering of HTLV III env gene into suitable expression vectors; transformation of host organisms with such expression vectors; and production of envelope AIDS protein (env AIDS) by culture of such transformed cells. Another aspect of the present invention relates to the isolation and use of the resulting recombinant env AIDS protein.

Another aspect of the present invention is the identification and determination of the proviral DNA sequence. More specifically, this aspect of the invention relates to determination and comparison of the proviral nucleotide sequence of the envelope genes of the purported etiologic agent of AIDS i.e. lymphadenopathy-associated virus (LAV), AIDS-associated retrovirus (ARV) and the human T-cell leukemia/lymphoma/lymphotropic virus type III (HTLV III).

A further aspect of this invention relates to a diagnostic method for testing human blood for the presence of antibodies to the env AIDS protein. This aspect of the invention overcomes the problems of all previously used blood tests for AIDS. One of the problems is the use of compositions to bind AIDS antibody which contain proteins or peptides which were not derived solely from the AIDS etiologic agent. A composition using homogeneous envelope AIDS protein of this invention overcomes the nonspecificity of the prior tests or assays. Yet another aspect of this invention is a diagnostic method for detecting and/or determining the presence of the antigen in human blood.

Another aspect of this invention is to use the env AIDS proteins of the instant invention as antigens suitable for providing protective immunity against AIDS when incorporated into a vaccine.

Brief Description of the Drawings

- Fig. 1. The nucleotide sequence of the envelope gene of the HTLV-III proviral genome (HXB-3).
 - Fig. 2. Comparison of the amino acid sequence of the env protein of the five purported etiologic agents of AIDS. Amino acid sequences are aligned to give maximum homology.
- Fig. 3. Construction of the pEV/env44-640 expression plasmids. The upper left panel shows a simplified restriction site map of the 3.15 Kb EcoRI-Xhol segment of the HTLV-III genome which contains the env coding region (cross-hatched arrow). The right panel shows the structure and pertinent sequences of the pEV-vrf plasmids. The solid black region represents the synthetic ribosome binding site sequences upstream of the ATG initiation codon (overlined). See Example 2 for a detailed description of the env expression plasmid constructions.
- Fig. 4. Western blot analysis of env coded antigens produced in E. coli. Total bacterial proteins were resolved by SDS-PAGE, electro-blotted onto a nitrocellulose filter, and env encoded proteins were detected by reacting with human sera as described in Example 5: a) negative control, cells containing pJCL-E30 (p21T) induced at 42 °C for 2 hours; b) uninduced control, cells containing pEV3/env44-640 maintained at 30 °C; c) pEV3/env44-640; d) pEV1/env44-640; and e) pEV3/env205-640 induced at 42 °C for 2 hours.

Fig. 5. Recognition of bacterially synthesized HTLV-III env gene products by antibodies in AIDS patient sera. Bacterial lysates containing recombinant env proteins were subjected to Western blot analysis as described in Example 5. Individual strips were then incubated with a 1000-fold dilution of individual sera followed by treatment with ¹²⁵ I-labeled protein A. (upper part) Serum samples were from the following donors: (lane 1) normal healthy donor; (lanes 2-18) AIDS patient sera collected from the West Coast of the USA. (Lower part) Serum samples were taken from the following donors: (lane 1) donor found to be HTLV-1(+) by Elisa using disrupted virus; (lanes 4, 5, 11 and 15) healthy, normal donors; (lanes 2, 3, 6, 8, 10, 12, 13, 14, 16, 17 and 18) AIDS patient sera from the East Coast of the USA.

Fig. 6A. The amino acid sequence of the AIDS envelope protein.

Fig. 6B. The amino acid distribution of the AIDS envelope protein.

Fig. 7. Construction of the expression vector pRC23. The Shine-Dalgarno sequence (SD) is overlined and the location of the synthetic ribosome binding site sequence in the plasmid is represented by the solid black segment. The plasmid contains the entire sequence of pBR322 and thus confers resistance to both ampicillin (amp^R) and tetracycline (tet^R).

Fig. 8. Construction of the pEV-vrf vectors. The synthetic oligonucleotides for each plasmid which were placed downstream of the SD sequence in pRC23 are shown with the locations of the restriction enzyme cleavage sites. The ATG initiation codon is overlined, and the placement of the additional A-T base pairs is designated by the rectangle. The plasmids confer resistance to amplicillin only.

20 Detailed Description of the Invention

10

In the description the following terms are employed:

Nucleotide: A monomeric unit of DNA consisting of a sugar moiety (pentose), a phosphate, and either a purine or pyrimidine base (nitrogenous heterocyclic). The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose). That combination of a base and a sugar is called a nucleoside. Each nucleotide is characterized by its base. The four DNA bases are adenine ("A"), guanine ("G"), cytosine ("C") and thymine ("T").

DNA Sequence: A linear array of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.

Codon: A DNA sequence of three nucleotides (a triplet) which encodes through mRNA an amino acid, a translation start signal or a translation termination signal. For example, the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG encode for the amino acid leucine ("Leu"). TAG, TAA and TGA are translation stop signals and ATG is a translation start signal.

Reading Frame: The grouping of codons during translation of mRNA into amino acid sequences. During translation the proper reading frame must be maintained. For example, the sequence GCTGGTTGTAAG may be translated in three reading frames or phases, each of which affords a different amino acid sequence:

GCT GGT TGT AAG=Ala-Gly-Cys-Lys
G CTG GTT GTA AG=Leu-Val-Val
GC TGG TTG TAA G=Trp-Leu-(STOP)

Polypeptide: A linear array of amino acids connected one to the other by peptide bonds between the α-amino and carboxy groups of adjacent amino acids.

Genome: The entire DNA of a cell or a virus. It includes inter alia the structural genes coding for the polypeptides of the substance, as well as operator, promoter and ribosome binding and interaction sequences, including sequences such as the Shine-Dalgarno sequences.

Structural Gene: A DNA sequence which encodes through its template or messenger RNA ("mRNA") a sequence of amino acids characteristic of a specific polypeptide.

Transcription: The process of producing mRNA from a structural gene.

Translation: The process of producing a polypeptide from mRNA.

Expression: The process undergone by a structural gene to produce a polypeptide. It is a combination of transcription and translation.

<u>Plasmid</u>: A circular double-stranded DNA molecule that is not a part of the main chromosome of an organism containing genes that convey resistance to specific antibiotics. When the plasmid is placed within

a unicellular organism, the characteristics of that organism may be changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance (Tet^R) transforms a cell previously sensitive to tetracycline into one which is resistant to it. A cell transformed by a plasmid is called a "transformant".

Cloning Vehicle: A plasmid, phage DNA or other DNA sequences which are able to replicate in a host cell, which are characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contain a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is often called a vector.

<u>Cloning</u>: The process of obtaining a population of organisms or DNA sequences derived from one such organism or sequence by asexual reproduction.

Recombinant DNA Molecule or Hybrid DNA: A molecule consisting of segments of DNA from different genomes which have been joined end-to-end outside of living cells and have the capacity to infect some host cell and be maintained therein.

The nomenclature used to define the peptides or proteins is that used in accordance with conventional representation such that the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus to the right. By natural amino acid is meant one of the amino acids commonly occurring in natural proteins comprising Gly, Ala, Val, Leu, Ile, Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gln, Cys, Met, Phe, Tyr, Pro, Trp and His. By Nle is meant norleucine, and by Nva is meant norvaline. Where L and D forms are possible, it is the L-form of the amino acid that is represented unless otherwise expressly indicated. In addition, amino acids have been designated by specific letters of the alphabet such that: A=Alanine; B=Aspartic Acid or Asparagine; C=Cysteine; D=Aspartic Acid; E=Glutamic Acid; F=Phenylalanine; G=Glycine; H=Histidine; I=Isoleucine; K=Lysine; L=Leucine; M=Methionine; N=Asparagine; P=Proline; Q=Glutamine; R=Arginine; S=Serine; T=Threonine; V=Valine; W=Tryptophan; Y=Tyrosine; Z=Glutamine or Glutamic Acid.

In accordance with the present invention, the search for the envelope protein of the etiologic agent for acquired immune deficiency syndrome (AIDS) has led to the isolation and sequencing of the proviral gene of the AIDS virus. It has now been discovered, for what is believed to be the first time that the postulated etiologic agents of AIDS, lymphadenopathy-associated virus (LAV), AIDS-associated retrovirus (ARV) and human T-cell leukemia/lymphoma/lymphotropic virus (HTLV III) are in fact variants of the same virus. For purposes of this invention, in the specification and claims the virus causing AIDS will be referred to herein as AIDS virus. AIDS virus will be understood to include the variants which have been postulated as the causative agents of AIDS, namely LAV, ARV and HTLV III. The envelope protein of the AIDS virus (env AIDS) is a 97,200 dalton protein with 32 potential N-glycosylation sites. Nucleotide sequence analysis of the AIDS envelope gene of the putative etiologic agents of AIDS demonstrates that all the viruses are variants of the same virus. That means that there is approximately 1 to 20% divergence or variation from the sequence of the envelope gene of HTLV III and the sequences of the envelope genes of the other viruses LAV and ARV-2. The amino acid sequence of the env AIDS is set forth in Figure 6(a). The amino acid distribution is set forth in Figure 6(b).

The nucleotide sequence of the envelope gene is shown in Figure 1. The proviral DNA sequence, using methods known to one of ordinary skill in the art such as the chemical degradation method of Maxam and Gilbert of the M13 sequencing system of Messing which is a modification of the dideoxy nucleotide chain termination method of Sanger, was analyzed to determine the location of the region coding for the envelope protein. The location of an open reading frame, i.e. a long stretch of triplet codons not interrupted by a translational stop codon, for the envelope gene was determined. The open reading frame coding for the env gene is 863 amino acids and contained an ATG codon at the eighth position from the 5' end of the reading frame. The ATG codon is known to be a universal translation-initiation codon.

The integrated proviral genome of HTLV-III was cloned from the genomic DNA of H9 cells infected with HTLV-III [Shaw, G.M. et al., "Molecular characterization of Human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome", Science 226, 1165-1171 (1984)]. Since the HTLV-III provirus was found to lack Xbal restriction sites, a genomic library was constructed by using Xbal digested H9/HTLV-III DNA. There are several methods available to one of ordinary skill in the art for screening the bacterial clones containing the AIDS env protein cDNA. These include, for example, RNA selection hybridization, differential hybridization with a synthetic probe or screening for clones that produce the desired protein by immunological or biological assays. From the genomic library, colonies of cells transformed with DNA that contains the HTLV III sequences were selected by hybridization screening of the library with HTLV III cDNA. The DNA insert of the hybridization-positive clone, HXB-3, was excised from the

plasmid DNA and sequenced.

The predicted product of the env gene shares many features in common with the envelope gene products of other retroviruses. Thus, a hydrophobic region is seen in the middle of the protein (amino acids 519-534) which includes a processing site for the cleavage of the precursor protein into exterior and transmembrane proteins. Similarly, the amino terminal end contains a short stretch of hydrophobic amino acids (amino acids 17-37) which constitutes a potential signal sequence. The HTLV-III envelope precursor differs from the other retroviral envelope protein precursors in that it contains an additional stretch of 180 amino acids at the carboxy terminus.

Polymorphism within the Envelope Region of AIDS Virus

The recent publication of the nucleotide sequences of LAV, ARV-2 and HTLV-III [Ratner, L., et al., supra; Sanchez-Pescadon, R., et al., supra; Wain-Hobson, S., et al., supra] allows a detailed comparison of these various isolates obtained from AIDS patients from different parts of the world. HTLV-III clones were isolated from AIDS patient lymphocytes obtained from the east coast of the United States, while LAV was: isolated from a French man and ARV was isolated from a patient in California. A comparison of the sequence data confirms the earlier observations made using restriction enzyme site analysis which showed approximately 10% variation. The present analysis shows that the various isolates show the greatest amount of conservation in the gag and pol regions while the most divergence occurs in the env region. A comparison of the five env sequences is presented in Figure 2. With respect to the envelope gene, HTLV-III and LAV are more closely related to each other than the ARV clone. Approximately 1.6% divergence was observed between the HTLV-III (HXB-3) and LAV sequence. Among the HTLV sequences, the divergence was about 1.6%. However, approximately 17% divergence was observed between HTLV-III and ARV-2 and this was more pronounced in the extracellular region of the envelope gene product (Figure 2). This high rate of divergence could be due to the geographical location from where the two isolates were derived or the time of isolation of these variants. ARV-2 was isolated from the west coast of the United States more recently. The HTLV-III isolates for which the nucleotide sequences have been determined were all obtained from the east coast of the United States a year earlier. LAV was obtained from a French patient who appears to have acquired the virus in New York about the same period. The observed differences in the sequence probably reflect divergent evolution of strains separated in time or geography or both. Within the env region, the highest level of divergence is in the extracellular portion of the protein.

Expression Vector

A wide variety of host/cloning vehicle combinations may be employed in cloning the double-stranded DNA. For example, useful cloning vehicles may consist of segments of chromosomal, nonchromosomal and synthetic DNA sequences, such as various known bacterial plasmids, e.g. plasmids from E. coli such as pBR322, phage DNA, and vectors derived from combinations of plasmids and phage DNAs such as plasmids which have been modified to employ phage DNA or other expression control sequences or yeast plasmids. Useful hosts may include microorganisms, mammalian cells, plant cells and the like. Among them microorganisms and mammalian cells are preferably employed. As preferable microorganisms, there may be mentioned yeast and bacteria such as Escherichia coli, Bacillus subtilis, Bacillus stearothermophilus and Actinomyces. The above-mentioned vectors and hosts may also be employed for the production of a protein from a gene obtained biologically as in the instant invention. Of course, not all host/vector combinations may be equally efficient. The particular selection of host/cloning vehicle combination may be made by those of skill in the art after due consideration of the principles set forth without departing from the scope of this invention.

Furthermore, within each specific cloning vehicle, various sites may be selected for insertion of the double-stranded DNA. These sites are usually designated by the restriction endonuclease which cuts them. For example, in pBR322 the EcoRI site is located just outside the gene coding for ampicillin resistance. Various sites have been employed by others in their recombinant synthetic schemes. Several sites are well recognized by those of skill in the art. It is, of course, to be understood that a cloning vehicle useful in this invention need not have a restriction endonuclease site for insertion of the chosen DNA fragment. Instead, the vehicle could be joined to the fragment by alternative means.

The vector or cloning vehicle and in particular the site chosen therein for attachment of a selected DNA fragment to form a recombinant DNA molecule is determined by a variety of factors, e.g., number of sites susceptible to a particular restriction enzyme, size of the protein to be expressed, susceptibility of the desired protein to proteolytic degradation by host cell enzymes, contamination of the protein to be

expressed by host cell proteins difficult to remove during purification, expression characteristics, such as the location of start and stop codons relative to the vector sequences, and other factors recognized by those of skill in the art. The choice of a vector and an insertion site for a particular gene is determined by a balance of these factors, not all selections being equally effective for a given case.

There are several known methods of inserting DNA sequences into cloning vehicles to form recombinant DNA molecules which are equally useful in this invention. These include, for example, direct ligation, synthetic linkers, exonuclease and polymerase-linked repair reactions followed by ligation, or extension of the DNA strand with DNA polymerase and an appropriate single stranded template followed by ligation.

It should, of course, be understood that the nucleotide sequences of the DNA fragment inserted at the selected site of the cloning vehicle may include nucleotides which are not part of the actual structural gene for the desired polypeptide/protein or may include only a fragment of the complete structural gene for the desired protein. It is only required that whatever DNA sequence is inserted, a transformed host will produce a protein/peptide having an immunological activity to the AIDS env protein or that the DNA sequence itself is of use as a hybridization probe to select clones which contain DNA sequences useful in the production of polypeptides/proteins having an immunological activity to the AIDS env protein.

The cloning vehicle or vector containing the foreign gene is employed to transform a host so as to permit that host to express the protein or portion thereof for which the hybrid DNA codes. The selection of an appropriate host is also controlled by a number of factors recognized by the art. These include, for example, compatibility with the chosen vector, toxicity of proteins encoded by the hybrid plasmid, ease of recovery of the desired protein, expression characteristics, biosafety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for expression of a particular recombinant DNA molecule.

A preferred embodiment of the instant invention is to express segments of the AIDS env protein in E. coli by inserting restriction fragments isolated from the cloned proviral genome into the versatile pEV-vrf (variable reading frame) expression plasmids (for details of construction see Example 2). These versatile pEV-vrf plasmids are derivatives of pBR322 which contain the phage lambda P_L promoter, a synthetically-derived ribosome-binding site, and convenient cloning sites (EcoRI, BamHI, Clal and HindIII) just downstream to the initiation codon (Figure 8). A set of three plasmids was constructed to accomodate all three translational reading frames. The P_L promotor is regulated by a temperature-sensitive cI repressor encoded on the compatible plasmid pRK248clts [ATCC 33766; Bernard, H.U. and Helinski, D.R., "The use of the λ phage promotor P_L to promote gene expression in hybrid plasmid cloning vehicles", Meth. Enzymol. 68, 482-492 (1979)]. These expression plasmids have been used to produce substantial amounts of several heterologous proteins in E. coli including v-bas p21 [Lacal, J.C. et al., "Expression of Normal and Transforming H-ras genes in E. coli and purification of their encoded p21 proteins", PNAS 81, 5305-5309 (1984)] and murine interleukin-1 [Lomedico, P.T. et al., "Cloning and Expression of Murine Interleukin-1 cDNA in E. coli", Nature 312, 458-462 (1984)].

In the present synthesis the preferred initial cloning vehicle is the bacterial plasmid pBR322 (ATCC 37017) and the preferred initial restriction endonuclease sites therein are the EcorRI and HindIII sites (Figure 3). Insertion of proviral DNA contained within the genome of H9 cells into these sites provides a large number of bacterial clones each of which contains one of the proviral DNA genes or fragments thereof present in the genome of H9 cells. Only a very few of these clones will contain the gene for env AIDS or fragments thereof.

The preferred host for initial cloning and expression of the env AIDS gene in accordance with this invention is E. coli MC 1061 [Casadaban, M.J. and Cohen, S.M., "Analysis of Gene Control Signals by DNA Fusion and Cloning in E. coli", J. Mol. Biol., 138, 179-207 (1980)].

The coding sequences for amino acid residues #44 to 640 of the env protein are located downstream of the P_L promoter between the KpnI and HindIII sites on the restriction map as shown in Figure 3. Aside from the location of these convenient restriction sites, these sequences were chosen for bacterial expression experiments because they did not include the amino-terminal signal peptide as well as the hydrophobic transmembrane segment at the carboxyl end. These sequences were excluded to avoid possible toxicity problems which can occur when hydrophobic proteins are over-produced in bacterial cells. In a preferred embodiment of this invention an expression plasmid was constructed that would direct the synthesis of this segment of the env gene product (designated pEV/env 44-640), an intermediate construction was first made by inserting a 2400 bp EcoRI-HindIII fragment between the EcoRI and HindIII sites in the pEV-vrf plasmids. The HTLV-III sequences (600 bp) between the EcoRI and the KpnI site were then removed from the intermediate construction as shown in Figure 3. These plasmid constructions were carried out with all three pEV-vrf plasmids so that subsequent deletions could be made and the correct reading frame maintained. In addition, the constructions made in the incorrect reading frames served as important controls in the

expression experiments described below.

In another embodiment of this invention, a second set of expression plasmids were constructed in a similar fashion by deleting sequences between EcoRI and Stul sites which occur 483 bp downstream of the env gene. Again these deletions (designated pEV/env 205-640) were made in all three reading frames. The translation termination codon used in all of the env expression plasmids is presumably an in-frame TAA located 23 bp downstream of the HindIII site in the plasmid. Thus, 8 amino acid residues at the carboxyl terminus are encoded by pBR322 sequences contained within the pEV-vrf expression plasmids.

Expression of ENV AIDS

10

There are several approaches to screen for bacterial clones containing env AIDS cDNA. These include, for example, RNA selection hybridization, differential hybridization, hybridization with a synthetic probe and screening for clones that produce the desired protein by immunological or biological assays. Two methods are available to screen using immunological assay: screening of bacterial colonies for the presence of protein using antibody; and, preferably, the bacterial lysates are electrophoresed, blotted onto a nitrocellulose paper and then probed with the antibody.

In a preferred embodiment of this invention, cultures of the E. coli strain MC 1061 transformed with pRK248clts and the pEV 1, 2, or 3/env 44-640 (or pEV 1, 2 or 3/env 205-640) were grown in M9 medium at 30 °C to mid-log phase and then induced by shifting to 42 °C for 2 hr. Samples of the bacterial cultures were then taken and subjected to SDS-polyacrylamide gel electrophoresis, followed by Western blot analysis to detect env proteins. The protein blots were treated with antisera to env AIDS proteins isolated either from immunized rabbits or from AIDS patients previously shown to contain high titer antibodies to AIDS antigens. This was followed by incubation with ¹²⁵I-labelled Staphylococcous aureus protein A, washing and autoradiography. Similar results were obtained with both sera except that the human serum was found to contain much higher titers of anti-HTLV-III antibodies and was devoid of all background reactivity with the E. coli proteins. For this reason human antibodies were used in all subsequent characterization.

Figure 4 shows the pattern of reactivity of the env AIDS proteins synthesized in bacteria (recombinant proteins) with anti-HTLV-III antibodies. The open reading frame in pEV3/env 44-640 encodes a protein that should migrate as a 68 Kd band on the gel. In fact, a 68 Kd band is observed in the lane corresponding to the induced cells containing pEV3/env 44-640 (lane C). However, in addition to the 68 Kd band, these cells synthesized proteins of 35 Kd, 25 Kd and 17 Kd which specifically cross-reacted with anti-HTLV-III antibodies. No HTLV-III cross-reacting bands are evident in the uninduced control (Lane b) or in a second negative control sample (Lane a) of induced cells containing a plasmid that directs the synthesis of v-bas p21 oncogene product (Lacal, J.C. et al., supra). The appearance of multiple bands synthesized from the env gene sequences was an unexpected result. Another unexpected result was the synthesis of env gene products from the plasmid (pEV1/env 44-640) where the insert was placed in the wrong reading frame with respect to the initiator codon immediately downstream of the PL promoter (Lane d). In this case, E. coli cells containing plasmid pEV1/env. 44-640 synthesized a 63 Kd protein in addition to the 35 Kd, 25 Kd and 17 Kd proteins. These results could be readily explained when the nucleotide sequence of the envelope gene (Fig. 1) was examined. About 155 bases downstream to the KpnI site is an ATG codon which appeared to be utilized for the synthesis of the env gene product by the expression plasmid pEV1/env 44-640. Internal translation initiation is also the likely explanation for the appearance of the 35Kd, 25Kd and 17Kd proteins. Initiation codons which are preceded by so-called Shine-Dalgarno sequences (AGGA) are found within the env coding region at locations that are consistent with the sites of the observed protein products.

To confirm the above interpretation and to rule out the possibility that the smaller proteins are not formed as a result of premature termination or from proteolytic cleavage of the larger product, another deletion mutant in which sequences between the KpnI and StuI sites were deleted were constructed. This expression plasmid contains the coding sequences from amino acid positions 205-640 which could code for a protein of 49 Kd. Analysis of the proteins induced from E. coli harboring this plasmid verified that, in fact, these cells synthesize a 49 Kd protein in addition to the 35 Kd, 25 Kd and 17 Kd proteins (lane e, Fig. 4). From these results, it was concluded that pEV3/env 44-640 expression plasmid directs the synthesis of a 68 Kd protein in addition to several additional smaller polypeptides (i.e., 35Kd, 25Kd and 17Kd) produced from all of the env expression plasmids resulting from internal translation initiation within the env gene.

Screening of AIDS SERA

Because anti-HTLV-III antibodies are found in more than 90% of the AIDS patients, it was of interest to see if the bacterially synthesized env gene products could be used as diagnostic tools for the detection of these antibodies. For this analysis, total cell protein from an induced bacterial culture was fractionated by SDS-PAGE and transferred to a nitrocellulose filter by Western blotting technique. Strips of the filter containing transferred proteins were reacted with 1000-fold diluted human sera, and the antigen-antibody complexes formed were detected by incubation of the strips with 125-I-labelled Staphylococus aureus protein A followed by autoradiography. Prominent bands corresponding to reaction of the antibody to the 68 Kd, 35 Kd, 25 Kd and 17 Kd proteins were consistently observed when the serum used was from patients with AIDS syndrome. The results of such assays with different human sera are presented in Figure 5. The negative controls used were normal human sera and serum from a patient with HTLV-I infection. No reaction was observed with sera from healthy individuals or from HTLV-I infected individuals. The patient sera were derived from all parts of the United States including California and all AIDS patients' sera tested so far were found to be positive. The results suggest that these antibodies are mainly directed against the protein back-bone of the molecule.

It appears, therefore, that the env gene products constitute the best diagnostic reagents for the detection of AIDS associated antibodies. The env gene product of the instant invention encompasses a large portion of the protein molecule and contains both the conserved and divergent portions of the molecule. In spite of the divergence observed between HTLVIII and ARV-2 sequences the recombinant env proteins of the instant invention synthesized by the bacteria react with AIDS patient sera derived from both geographical locations of the United States. One hundred percent (100%) of AIDS patient sera (50 individual samples, 25 derived from the East Coast of the United States and 25 derived from California) tested showed high reactivity. This is strong evidence for the presence of conserved epitopes within the molecule against which the immune system could mount an antibody reaction. The human immune system may thus be mounting an immune response against conserved epitopes of the envelope molecule, as suggested by the reactivity of the AIDS patient sera. The observed divergence between various isolates of HTLV-III thus may not pose a problem for the use of recombinant protein as a vaccine. The 68Kd protein is ideally suited for such a purpose since it encompasses a large portion of the gene product and has the unique structural feature of containing both the extracellular hydrophilic region and the membrane associated hydrophobic regions. This structural feature makes it well suited for encapsulation into liposomes which have been used as vehicles for vaccination against other vital envelope proteins.

Based on these discoveries it is proposed that in the practice of screening blood for AIDS only AIDS envelope protein or a variant of said protein be utilized. Utilizing the env AIDS protein of the instant invention, human blood can be screened for the presence of antibodies to the AIDS virus. This and other techniques are readily determined, once, as taught for the first time by the present invention, the envelope AIDS protein has been recognized to be the envelope protein of the etiologic agent of AIDS. The foregoing and other objects, features and advantages of the invention will be apparent from the following examples of preferred embodiments of the invention.

Example 1

Molecular cloning and nucleotide sequence analysis of the HTLV-III proviral genome.

The integrated proviral genome of HTLV-III was recently cloned from the genomic DNA of H9 cells infected with HTLV-III [Shaw, G.M. et al., supra]. The proviral genome which was obtained by using Xbal digested H9/HTLV-III DNA contained two internal EcoRI sites within the viral genome and two additional sites in the cloning vector λ JI. These sites were used for further subcloning of the three DNA fragments of 5.5Kb, 4.5Kb and 1.1Kb into pBR322 (ATCC No. 37017). Nucleotide sequence analysis of the proviral genome was determined by the chemical degradation method of Maxam, A.M. and Gilbert, W., "Sequencing end-labelled DNA with base-specific chemical cleavages", Meth. Enzymol. 65, 499-560 (1980). For the sequence analysis, DNA inserts from the three subclones were isolated by electroelution and further cleaved with appropriate restriction enzymes. The DNA fragments were labelled at their 5'ends with γ -32P-ATP using polynucleotide kinase, or at their 3' ends with α -32P-NTP by filling in with DNA polymerase I (Klenow fragment). The DNA fragments labelled at the two ends were cleaved with a second enzyme and the fragments labelled at a single end were purified on 5% acrylamide gels and used for sequence analysis. For the sequence analysis of the env gene, a shotgun approach was utilized where the 4.5 EcoRI fragment was cleaved with one of the following enzymes: BgIII, HindIII, XhoI, AvaII, HinfI and

Sau3A and the restriction fragments labelled and sequenced as described above. The nucleotide sequence of the envelope gene used in the present invention is shown in Figure 1.

Example 2

Construction of pEV/env 44-640

pRC2 is a derivative of pBR322 containing a unique BgI II site adjacent (on the amp^R side) to the EcoRI site in the plasmid. This plasmid was constructed in the following manner. 20 µg of pBR322 plasmid DNA were digested with EcoRI and then split into two reactions. In one, the protruding 5' single-stranded termini were removed with SI nuclease; in the other reaction, the termini were filled-in by inorporating deoxynucleotides with the Klenow fragment of DNA polymerase I. Both reactions were terminated by phenol extraction followed by ethanol precipitation. Approximately 1 µg of DNA from each reaction was mixed with 90 pmoles of phosphorylated BgIII linkers (CAGATCTG, purchased from Collaborative Research) and incubated with T4 DNA ligase at 15 °C for 18 hours. The ligation products were then digested with BgIII and Pstl and subjected to gel electrophoresis in 1% agarose. The 3600 bp and 760 bp fragments from both reactions were recovered from the gel. For the construction of pRC2, the 3600 bp from the Klenow reaction was ligated to the 760 bp fragment from the SI reaction. To construct a plasmid with the BgIII site on the other side of EcoRI (tet^R side), designated pRCI, the 3600 bp fragment from the S1 reaction was ligated to the 760 bp fragment from the Klenow reaction. E. coli strain RRI (ATCC No. 31343) was transformed with the ligation mixtures, and transformants were selected on LB agar plates containing 50 µg/ml ampicillin. Transformants containing the expected plasmid constructions were identified by restriction analysis of the isolated plasmid DNA. DNA sequence analysis confirmed that the SI nuclease treatment precisely removed the 5' single-stranded termini.

pRC23 (see Figure 7) was constructed by inserting into pRC2 a 250 bp BgIII-HaeIII fragment containing the λ P_L promoter joined to a pair of complementary synthetic oligonucleotides comprising a model ribosome-binding site (RBS). The HaeIII site is located within the 5' non-coding region of the λ N gene 115 bp downstream of the P_L transcriptional initiation site. Approximately 1 μ g of a 450 bp BgIII-HpaI fragment isolated from phage λ DNA was digested with HaeIII. 200 ng of the resulting digestion products were mixed with 60 pmoles each of phosphorylated synthetic oligonucleotides containing the model RBS. The ligated molecules were digested with BgIII and EcoRI and separated on a 5% polyacrylamide gel. The 270 bp ligation product was recovered from the gel, mixed with gel purified pRC2 vector that had been digested with BgIII and EcoRI, and incubated with T4 DNA ligase at 15 °C for 15 hours. The ligation mixture was used to transform strain RRI(pRK248Clts). Transformants selected on ampicillin-containing medium were screened by restriction analysis of the isolated plasmid DNA. The expected plasmid construction, pRC23, was confirmed by further restriction enzyme digestions and by DNA sequence analysis across the EcoRI junction (Fig. 7).

For the construction of the pEV-vrf set of plasmids (see Figure 8), plasmid pRC23 was digested with EcoRl and HindIII and the pRC23/EcoRl-HindIII vector isolated by preparative agarose gel electrophoresis. The mixture of synthetic oligonucleotides (32, 33, and 34 nucleotides) was combined with the mixture of the complementary sequences, heated to $58\,^{\circ}$ C for 5 minutes in 150 mM NaCl, and cooled slowly to allow annealing. 0.1 pmoles of the synthetic duplexes were added to 0.07 pmoles of the pRC23/EcoRl-HindIII vector and incubated with T4 DNA ligase at 15 $^{\circ}$ C for 15 hours. Strain RRI (λ cl857) was transformed with the ligation products. Six ampicillin resistant transformants were selected for DNA sequence analysis. Of the six, two contained the expected sequence for pEV-vrf1, one for pEV-vrf2, and three for pEV-vrf3 (Fig. 3).

For the expression of the AIDS env gene, one µg of a 2400 bp EcoRI - HindIII DNA fragment, which was isolated from the cloned HTLV-III proviral genome by preparative agarose gel electrophoresis, was mixed with 0.1 µg of EcoRI - HindIII digested vector DNA (pEV-vrf1, -2, or -3). After heating at 65 °C for 3 minutes, the mixtures were chilled on ice, and 20 µl ligation reactions were assembled, containing 50 mM Tris-HCl (pH 7.4), 10 mM MgCl₂, 10 mM DTT, 0.3 mM ATP, and 200 units of T₄ DNA ligase. After incubation at 15 °C for 4 hours, the reactions were terminated by heating at 65 °C for 5 minutes. The ligation products were used to transform E. coli strain MC1061 containing plasmid pRK248clts. Transformants were selected on Luria broth agar containing 50 µg/ml ampicillin at 30 °C for 18 hours. Plasmid DNA was isolated from 1 ml of each culture and subjected to restriction analysis. All 12 isolates contained the expected plasmid construction. These intermediate constructions were then used to make pEV1, -2, and -3/env 44-640 by deleting the 600 bp between the EcoRI and KpnI sites as described below.

Approximately 0.5 µg of plasmid DNA was digested with KpnI and EcoRI. The resulting termini were then treated with the Klenow fragment of DNA polymerase I in the presence of all four deoxyribonucleotides

(at 100 µM) at 37 °C for 30 minutes. This step results in the "filling-in" of the 5' overhang of the EcoRI terminus and the removal of the 3'overhang of the KpnI terminus. Upon recirculization of the linear plasmid and blunt-end ligation of these termini, an EcoRI site is regenerated. Transformants containing plasmids with the expected deletion were identified by restriction analysis.

A second set of deletion derivatives, designated pEV/env 205-640 was constructed in a similar fashion. A portion of the linear plasmid that had been digested with EcoRI and KpnI and treated with Klenow, as described above, was further digested with Stul. Again, upon recircularization and blunt-end ligation, the EcoRI site was regenerated; however, an additional 483 bp of env coding sequences were removed.

10 Example 3

Bacterial Growth and Induction of env Gene Expression

Cultures of E. coli strain MC 1061 transformed with plasmid pRK248clts and the pEV1, -2, or -3/env plasmids were grown in M9 medium containing 0.5% glucose and 0.5% casamino acids at 30 °C to mid-log phase and then induced by shifting to 42 °C for 2 hr. The cells were collected by centrifugation and processed as described in Examples 4 and 5.

Example 4

20

30

40

50

Expression and Purification of Env AIDS

A homogeneous recombinant viral env AIDS was purified according to the following procedure. The env AIDS protein expressed by a microbe tends to associate with the membrane fractions of the host microbe, principally the inner membrane of the microbe. The following purification method was designed to deal with this finding.

This purification method comprises:

- (a) lysis of transformed microbial cells producing recombinant env AIDS protein;
- (b) separation of env AIDS associated cellular membranes from other cellular components;
- (c) extraction of env AIDS from associated membranes; and
 - (d) chromatographic purification of the resultant extraction solution containing env AIDS to yield a substantially pure recombinant viral env protein.

More specifically, the preferred purification method for the preparation of substantially pure recombinant viral env protein comprises:

- (a) cultivating a transformed organism containing a DNA sequence which codes for viral env protein;
- (b) causing a culture of the transformed organism of step (a) to accumulate the env protein;
- (c) lysing the culture of transformed organisms of step (b) to form a cell lysate mixture;
- (d) isolating the cell membrane components of the cell lysate mixture of step (c);
- (e) washing the isolated cell membrane components with an extraction solution to yield a wash solution containing env protein; and
- (f) chromatographically purifying the wash solution of step (e) to yield a substantially pure env AIDS protein.

In carrying out this method it is preferred that the cells be lysed by sonification, although it is forseeable that other known methods such as enzyme or mechanical lysis could also be used. It is preferred that the cell membrane component, specifically the inner and outer membranes, be isolated from other cellular components by methods such as centrifugation. It has been found that env AIDS expressed by the transformed microorganism tends to become associated with the cellular membranes. Therefore, isolation of these membranes during the purification process ensures high purification levels and high purity env AIDS at the end of the purification procedure.

Once the cell membranes are isolated from the lysate mixture, they are washed with an extraction solution, preferably salt solutions and a detergent to yield a second solution containing approximately 50% env AIDS protein. Preferably the cell membranes are washed in four separate steps with the salt solutions and detergent although it is forseeable that certain of these steps could be combined, rearranged or eliminated. The first step of washing the cell membrane may be done with a salt solution, preferably 1M NaCl. In the second step the cell membrane is washed with a detergent solution, preferably 1% Triton X-100. In the third step, the cell membrane is washed with another salt solution, 1.75M to 3.5M guanidine HCl. The final wash is also with a salt solution preferably about 7M Guanidine HCl. The wash solution which results from the fourth and final wash comprises about 50% env AIDS.

The final 50% env AIDS wash solution is then further purified by a chromatography step, preferably reverse phase high performance liquid chromatography (HPLC). The HPLC step yields env AIDS protein in a substantially 100% pure form. It is also foreseeable that monoclonal antibody affinity chromatography columns utilizing env AIDS polyclonal or monoclonal antibodies, could be used as an alternative to HPLC.

Example 5

Polyacrylamide gel electrophoresis and Western blot analysis

Cells were lysed by resuspending the cell pellets (approximately 10⁸ cells) in TG buffer (10 mM Tris, pH 7.4, 10% glycerol), mixed with an equal volume of 2 x sample buffer [Laemmli, U.K., "Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4", Nature 227, 680-685 (1970)] and incubated at 95°C for five (5) minutes. Cell debris were pelleted by centrifugation and the cleared lysates were subjected to SDS-PAGE analysis [Laemmli, U.K., supra]. For Western blot analysis, the proteins from the acrylamide gel were electroblotted onto a 0.1 µm nitrocellulose membrane (Schleicher and Schuell) for 16 hr at 50V, in 12.5 mM Tris, 96 mM glycine, 20% methanol, 0.01% SDS at pH 7.5. Processing of the blot was carried out using the methods described by Towbin, H. et al. ["Electrophoretic Transfer of Proteins From Polyacrylamide Gels to Nitrocellulose Sheets: Procedure and Some Applications", Proc. Natl. Acad. Sci. U.S.A., 76, 4350-4354, (1979)]. For treatment with the human sera, the blots were incubated with a 1000 fold dilution of the sera in antibody buffer (20 mM sodium phosphate buffer, pH 7.5, containing 0.5 M NaCl, 1% BSA and 0.05% Tween 20) for 2-6 hr. The blots were then washed twice with phosphate buffered saline containing 0.05% Tween 20 and then incubated with 125-l-labelled Staphylococous aureus protein A for an additional period of 1 hr. The blot was then washed twice in PBS-Tween 20 buffer, dried and autoradiographed.

Example 6

25

Immunization with Env Protein of AIDS Virus

It is clear that in spite of the divergence observed between HTLVIII and ARV-2 sequences, the recombinant proteins synthesized by the bacteria react well with AIDS patients' sera derived from both geographical locations of the United States. One hundred percent (100%) of the AIDS patients' sera tested showed high reactivity (50 individual samples, 25 from the east coast of the United States and 25 from the west coast of the United States). Thus all the env proteins contain at least one conserved epitope. All of the human sera from AIDS patients tested contained antibodies to the env proteins of the instant invention. This strongly suggests that these env proteins with the conserved epitopes would be immunogenic in man.

It will be readily appreciated that the env proteins of the instant invention can be incorporated into vaccines capable of inducing protective immunity against the AIDS virus. By methods known in the art, the specific amino acids conprising the epitopes of the env protein may be determined. Peptides may then be synthesized, comprising an amino acid sequence corresponding to an epitope of an env AIDS protein either in monomeric or multimeric form. These synthetic peptides may then be incorporated into vaccines capable of inducing protective immunity against AIDS virus. Techniques for enhancing the antigenicity of such peptides include incorporation into a multimeric structure, binding to a highly immunogenic protein carrier, for example, keyhold limpet hemocyanin, or diphtheria toxoid, and administration in combination with adjuvants or any other enhancers of immune response. In addition, the vaccine composition may comprise antigens to provide immunity against other diseases in addition to AIDS.

An amino acid sequence corresponding to an epitope of an env protein either in monomeric or multimeric form (peptide) may be obtained by chemical synthetic means or by purification from biological sources including genetically modified microorganisms or their culture media. The peptide may be combined in an amino acid sequence with other peptides including fragments of other proteins, as for example, when synthesized as a fusion protein, or linked to other antigenic or non-antigenic peptides of synthetic or biological origin. The term "corresponding to an epitope of a env protein" will be understood to include the practical possibility that, in some instances, amino acid sequence variations of a naturally occurring peptide may be antigenic and confer protective immunity against AIDS infection. Possible sequence variations include, without limitation, amino acid substitutions, extensions, deletions, interpolations and combinations thereof. Such variations fall within the contemplated scope of the invention provided the peptide containing them is antigenic and antibodies elicited by such peptide cross-react with naturally occurring env protein or non-variant repeated peptides of env protein, to an extent sufficient to provide

protective immunity when administered as a vaccine. Such vaccine compositions will be combined with a physiologically acceptable medium. The size and shape of epitopes found in carbohydrate antigens have been extensively studied, but less is known about the structure of epitopes from protein molecules. Some epitopes of protein antigens have been defined at the level of their tertiary structure. In every instance, the epitopes were formed not by the primary sequences alone, but by the juxtaposition of residues brought together by the folding of the polypeptide chain(s) of the native molecule. In addition, the structure of the 68Kd env protein of the instant invention makes it particularly well suited for use as a vaccine. The 68Kd env protein comprises a large portion of the gene product which (a) was shown to be reactive with all the AIDS sera tested; and (b) has the unique structural feature of containing both an extracellular hydrophilic region and the transmembrane hydrophobic regions. The latter structural feature makes it well suited for use as a vaccine using liposome encapsulation to create a vehicle for administration.

Routes of administration, antigen dose, number and frequency of injections are all matters of optimization within the scope of ordinary skill in the art, particularly in view of the fact that there is experience in the art in providing protective immunity by the injection of other related antigens to provide immunity in other viral infections. It is anticipated that the principal value of providing immunity to AIDS infection will be for those individuals who have had no previous exposure to AIDS, e.g., individuals who are in the high risk population, such as homosexuals, drug addicts and people from Haiti and Central America and individuals who may be receiving blood transfusions. It is also anticipated that temporary immunity for infants may be provided by immunization of mothers during pregnancy.

Example 7

20

25

Diagnostic Test for AIDS

It is clear that the env gene proteins of the instant invention may be used as diagnostic reagents for the detection of AIDS-associated antibodies. It is also apparent to one of ordinary skill that a diagnostic assay for AIDS using polyclonal or monoclonal antibodies to the AIDS env protein of the instant invention may be used to detect the presence of the AIDS virus in human blood. In one embodiment a competition immunoassay is used where the antigenic substance, in this case the AIDS virus, in a blood sample competes with a known quantity of labelled antigen, in this case labelled AIDS env protein, for a limited quantity of antibody binding sites. Thus, the amount of labelled antigen bound to the antibody is inversely proportional to the amount of antigen in the sample. In another embodiment, an immunometric assay may be used wherein a labelled AIDS-env antibody is used. In such an assay, the amount of labelled antibody which complexes with the antigen-bound antibody is directly proportional to the amount of antigen (AIDS virus) in the blood sample. In a simple yes/no assay to determine whether the AIDS virus is present in blood, the solid support is tested to detect the presence of labelled antibody. In another embodiment, monoclonal antibodies to AIDS env protein may be used in an immunometric assay. Such monoclonal antibodies may be obtained by methods well known in the art, particularly the process of Milstein and Kohler reported in Nature 256, 495-497 (1975).

The immunometric assay method is as follows: Duplicate samples are run in which 100 μ l of a suspension of antibody immobilized on agarose particles is mixed with 100 μ l of serum and 100 μ l of soluble ¹²⁵ l-labelled antibody. This mixture is for specified times ranging from one quarter hour to twenty four hours. Following the incubation periods the agarose particles are washed by addition of buffer and then centrifuged. After removal of the washing liquid by aspiration, the resulting pellet of agarose particles is then counted for bound ¹²⁵ l-labelled antibody. The counts obtained for each of the complexes can then be compared to controls.

While the invention has been described in terms of certain preferred embodiments, modifications obvious to one with ordinary skill in the art may be made without departing from the scope of the invention. For example, it is understood that the env AIDS DNAs described herein represent only the precise structure of two naturally occurring gene segments. It is expected that slightly modified alleles will be found encoding for similarly functioning proteins, and such gene segments and proteins are considered to be equivalents for the purpose of this invention. It is also suspected that other variants in addition to those described herein will be found and that the envelope protein of said variants will differ slightly. These variant envelope proteins are likewise considered within the scope of the invention. DNA having equivalent codons is considered within the scope of the invention, as are synthetic gene segments that encode homologous proteins of the viral envelope.

Various features of the invention are set forth in the following claims.

Claims

10

20

Claims for the following Contracting States: BE, CH, DE, FR, GB, IT, LI, NL, SE

1. An envelope protein of an acquired immune deficiency syndrome (AIDS) virus, essentially free of other proteins, with the amino acid sequence:

ValTrpLysGluAla ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr ${\tt HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn}$ METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArqProValVal ${\tt SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr}$ AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly ${\tt AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer}$ LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu ${\tt IleValThr His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr Gln$ ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly ${\tt AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn}$ LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIle CysThrThrAla Val ProTrpAsnAla SerTrpSerAsnLysSerLeuGluGlnIle Trp ${\tt AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer}$

or

50

CysProLysValSer

 ${\tt PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr}$ PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal ${\tt SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr}$ ${\tt AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn}$ AsnThrArqLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArqGlnAlaHisCysAsnIleSerArqAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArqIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArqAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

25

or .

30-

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

50

45

or

METTyrAlaProProIle

SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsnAsnAsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

5

10

or

20 .

METARGASPASNTRPARGSERGIULEUTYRLYS TYRLYSVAlValLySIleGluProLeuGlyValAlaProThrLySAlaLySArgArgValValGlnArg GluLySArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLySGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLySAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer.

30

- An expression vector comprising a gene coding for an envelope protein of an AIDS virus as defined in claim 1 downstream of a promoter sequence enabling transcription, translation and thus expression of said envelope protein in a host cell.
 - 3. An expression vector according to claim 2, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:

40

45

50

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAGAAGTAGTATTGGTAAATGTGACAGAAATTTTAAC **ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG** CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC **AATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCŢTTCAATATCAGCACA** GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAAAAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG **AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA** ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

30

25

10

or an equivalent thereof.

4. An expression vector according to claim 2, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:

40

45

50

TGTCCAAAGGTATCC

TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGAATTTCACG **AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC **AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA <u>AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG</u> **AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

or an equivalent thereof.

5. An expression vector according to claim 2, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:

30

25

or an equivalent thereof.

6. An expression vector according to claim 2, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:

ATGTATGCCCCTCCCATC

AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAAA** GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGCAACAAT TTGCTGAGGGCTATTGAGGGGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG** AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

or an equivalent thereof.

15

- 7. An expression vector according to claim 2, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:
- ATGAGGGACAATTGGAGAAGTGAATTATAAA GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**
- 8. An expression vector according to any one of claims 2 to 7, which is a plasmid capable of replication in gram-negative and/or gram-positive bacteria.
 - 9. An expression vector according to claim 8 which is capable of replication in an E. coli strain.
- 10. An expression vector according to claim 8 which is capable of replication in a B. subtilis strain.
 - 11. The expression vector pEV1, -2, or -3/env 44-640.
 - 12. The expression vector pEV1, -2, or -3/env 205-640.

- 13. A transformant carrying an expression vector as claimed in any one of claims 2 to 12.
- 14. A transformant according to claim 13 which is an E. coli strain.
- 15. A transformant according to claim 14 which is an E. coli MC 1061 strain.
 - 16. A transformant according to claim 13 which is a B. subtilis strain.
 - 17. A transformant according to claim 13 which is a mammalian cell.

50

18. A method of producing an envelope protein of an acquired immune deficiency syndrome virus as claimed in claim 1 comprising:

transforming a host cell with an expression vector as claimed in any one of claims 2 to 12; culturing said host cell so that said AIDS env protein is expressed; and extracting and isolating said AIDS env protein.

55

19. A method according to claim 18, wherein the expression vector is pEV1, -2 or -3/env 44-640.

- 20. A method according to claim 18, wherein the expression vector is pEV1, -2 or -3/env 205-640.
- 21. A method of testing human blood for the presence of antibodies to the viral etiologic agent of AIDS which comprises mixing a composition containing an envelope protein of an AIDS virus as claimed in claim 1 with a sample of human blood and determining whether said envelope AIDS protein binds to AIDS antibodies present in the blood sample.
- 22. A method according to claim 21 which comprises the use of the Western Blotting Analysis.
- 23. A method according to claim 21 which comprises the use of an ELISA-technique, wherein an envelope protein of an AIDS virus as claimed in claim 1 is coated on a solid phase and contacted with the sample and after washing contacted with an enzyme-labeled non-human IgG.
 - 24. A method according to claim 21, wherein the Double-Antigen-Method is used.
 - 25. A method for the determination of AIDS virus, wherein antibodies against an envelope protein of an AIDS virus according to claim 1 are used.
- 26. A method according to claim 25, wherein the antigen in the sample and a protein as claimed in claim 1 in labeled form compete with an antibody against a protein as claimed in claim 1.
 - 27. A method according to claim 25, wherein a sandwich method is performed using two antibodies against a protein as claimed in claim 1.
- 28. A method according to claim 27, wherein one antibody is on a solid phase and the other antibody is labeled.
 - 29. A method according to claim 27, wherein two different monoclonal antibodies are used.
- 30. A vaccine eliciting immunity to AIDS comprising as an active ingredient a protein as claimed in claim 1.
 - 31. Antibodies raised against a protein as claimed in claim 1.
 - 32. The antibodies of claim 31 which are monoclonal antibodies.
 - 33. The use of a protein as claimed in claim 1 for the preparation of a protective immunisation vaccine.
 - 34. The use of a protein as claimed in claim 1 for testing human blood for the presence of AIDS virus.

40 Claims for the following Contracting State: AT

- A process for the preparation of an envelope protein of an acquired immune deficiency syndrome (AIDS) virus, essentially free of other proteins, comprising:
- transforming a host cell with an expression vector comprising a gene coding for an envelope protein of an AIDS virus with the amino acid sequence:

50

35 .

15

ValTrpLysGluAla · Thr Thr Thr LeuPheCysAlaSer AspAlaLysAlaTyr AspThr GluVal His AsnVal TrpAlaThr ${\tt HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn}$ METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys. ${\tt ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr}$ AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr ${\tt SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn}$ ${\tt AspThrThrSerTyrThrLeuThrSerCysAsnThrSerValIleThrGlnAlaCysProLysValSer}$ ${\tt PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr}$ ${\tt PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal}$ ${\tt SerThrGlnLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr}$ ${\tt AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn}$ AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly ${\tt AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer}$ LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu ${\tt IleValThr HisSerPhe Asn CysGlyGlyGluPhe Phe Tyr CysAsn SerThr Gln LeuPhe Asn Ser}$ ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

35

30

40

45

50

CysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr SerThrGlnLeuLeuAsnGlySerLeuAlaGluGluGluValVallleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly ${ t AsnMETA}$ rg ${ t GlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer}$ LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ${\tt ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle}$ SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn ${ t AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys}$ TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly ${\tt AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn}$ LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly Lys Leu Ile Cys Thr Thr Ala Val Pro Trp Asn Ala Ser Trp Ser Asn Lys Ser Leu Glu Gln Ile Trp Asn Ala Val Pro Trp Asn Ala ValAsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

40

45

10

15

20

25

30

35

METTYrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrTrrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

55

or

- METArgAspAsnTrpArgSerGluLeuTyrLys
 TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
 GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
 AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
 LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
 AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
 LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
 AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer
- downstream of a promoter sequence enabling transcription, translation and expression of said envelope protein in said host cell; culturing said host cell so that said envelope protein of an AIDS virus is expressed; and extracting and isolating said envelope protein of an AIDS virus.
 - 2. A process according to claim 1, wherein the host cell is a bacterium.
 - 3. A process according to claim 2, wherein the bacterium is E. coli.
 - 4. A process according to claim 3, wherein the plasmid is pEV1, -2, or -3/env 44-640.
- 25 5. A process according to claim 3, wherein the plasmid is pEV1, -2, or -3/env 205-640.
 - 6. A process for the preparation of an expression vector comprising a gene coding for an envelope protein of an AIDS virus, which process comprises constructing an expression vector having an insertion site, wherein a gene coding for an envelope protein of an AIDS virus as defined in claim 1 may be inserted which insertion site is downstream of a promoter sequence enabling transcription, translation and thus expression of said envelope protein in a host cell.
 - 7. A process according to claim 6, characterized in that as said gene coding for an envelope protein of an AIDS virus a gene comprising the nucleotide sequence

35

30

20

40

45

50

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC **AATAGTAGCGGGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA** agcataagaggtaaggtgcagaaagaatatgcatttttttataaacttgatataataccaatagataat GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG aatacaagaaaaaaatccgtatccagaggggaccaggggggcatttgttacaataggaaaaatagga AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA **ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC 20 AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC**

30

or an equivalent thereof is used.

8. A process according to claim 6, characterized in that as said gene coding for an envelope protein of an AIDS virus a gene comprising the nucleotide sequence

TGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCRATGGRACAGGACCATGTRCARATGTCAGCACAGTACAATGTACACATGGRATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG AATACAAGAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA ARATTARGAGRACAATTTGGARATRATARARCARTARTCTTTRAGCRATCCTCRGGRGGGGACCCRGRA **ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAARTTAGATGTTCATCAARTATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAAA GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG** AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

or an equivalent thereof is used.

5

25

40

A process according to claim 6, characterized in that as said gene coding for an envelope protein of an AIDS virus a gene comprising the nucleotide sequence

or an equivalent thereof is used.

10. A process according to claim 6, characterized in that as said gene coding for an envelope protein of an

AIDS virus a gene comprising the nucleotide sequence

or an equivalent thereof is used.

11. A process according to claim 6, characterized in that as said gene coding for an envelope protein of an AIDS virus a gene comprising the nucleotide sequence

or an equivalent thereof is used.

10

- 12. A process according to any one of claims 6 to 11, wherein the expression vector is a plasmid capable of replication in gram-negative bacteria.
- 13. A process according to claim 12, wherein the plasmid is capable of replication in an E. coli strain.
- 14. A process for the preparation of a transformant carrying an expression vector comprising a gene coding for an envelope protein of an AIDS virus, which process comprises transforming a microorganism with an expression vector obtained according to any one of claims 6 to 13 and cultivating the transformed microorganism.
- 15. A procss according to claim 14, wherein the microorganism is an E. coli strain.
- 15. A process according to claim 15, wherein the microorganism is an E. coli MC 1061 strain.
 - 17. A process of testing human blood for the presence of antibodies to the viral etiologic agend of AIDS which process comprises mixing a composition containing an envelope protein of an AIDS virus obtained according to claim 1 with a sample of human blood and determining whether said envelope AIDS protein binds to AIDS antibodies present in the blood sample.
 - 18. A process according to claim 17 which comprises the use of the Western Blotting Analysis.
- 19. A process according to claim 17 which comprises the use of an Elisa-technique, wherein an envelope protein of an AIDS virus obtained according to claim 1 is coated on a solid phase and contacted with the sample and after washing contacted with an enzyme-labeled non-human IgG.
 - 20. A process according to claim 17, wherein the Double-Antigen-Method is used.
- 21. A process for the determination of AIDS virus, wherein antibodies against an envelope protein of an AIDS virus obtained according to claim 1 are used.
 - 22. A process according to claim 21, wherein the antigen in the sample and a protein obtained according to claim 1 in labeled form compete with an antibody against a protein obtained according to claim 1.
 - 23. A process according to claim 21, wherein a sandwich method is performed using two antibodies against a protein obtained according to claim 1.
- 24. A method according to claim 23, wherein one antibody is on a solid phase and the other antibody is labeled.
 - 25. A method according to claim 23, wherein two different monoclonal antibodies are used.
- 26. An envelope protein of an AIDS virus whenever prepared by a process as claimed in any one of claims
 1 to 5.
 - 27. An expression vector comprising a gene coding for an envelope protein of an AIDS virus whenever prepared by a process as claimed in any one of claims 6 to 13.
- 28. A transformant carrying an expression vector comprising a gene coding for an envelope protein of an AIDS virus whenever prepared by a process as claimed in any one of claims 14 to 16.
 - 29. An expression vector comprising a gene coding for an envelope protein of an AIDS virus as defined in claim 1 downstream of a promoter sequence enabling transcription, translation and thus expression of said envelope protein in a host cell.
 - **30.** An expression vector according to claim 29, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCACCACAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC **AATAGTAGCGGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA** GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG **AATACAAGAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA** AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAAGAGCAGTAGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG** AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

30

or an equivalent thereof.

31. An expression vector according to claim 29, wherein said gene coding for an envelope protein for an AIDS virus is a gene comprising the nucleotide sequence:

TGTCCAAAGGTATCC

TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAAGTAGTAATTAGATCTGTCAATTTCACG **AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACCACCTGTTTAATAGT** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA** Gararaggergtgggrataggrecttigttectteggttettggreggreggragergertett GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG** AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

or an equivalent thereof.

32. An expression vector according to claim 29, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:

or an equivalent thereof.

25

40

33. An expression vector according to claim 29, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:

or an equivalent thereof.

34. An expression vector according to claim 29, wherein said gene coding for an envelope protein of an AIDS virus is a gene comprising the nucleotide sequence:

- 35. An expression vector according to any one of claims 29 to 34 which is a plasmid capable of replication in gram-negative bacteria.
- 36. An expression vector according to claim 35 which is capable of replication in an E. coli strain.
- 37. The expression vector pEV1, -2, or -3/env 44-640.
- 38. The expression vector pEV1, -2, or -3/env 205-640.
- 39. A transformant carrying an expression vector as claimed in any one of claims 29-38.
 - 40. A transformant according to claim 39 which is an E. coli strain.
 - 41. A transformant according to claim 40 which is an E. coli MC 1061 strain.
 - 42. Antibodies raised against a protein obtained according to claims 1 to 5 and 26.
 - 43. The antibodies of claim 42 which are monoclonal antibodies.
- 44. A vaccine eliciting immunity to AIDS comprising as an active ingredient a protein obtained according to claims 1 to 5 and 26.
 - 45. The use of a protein as claimed in claim 1 for the preparation of a protective immunisation vaccine.

25 Patentansprüche

30

35

40

45

50

55

Patentansprüche für folgende Vertragsstaaten: BE, CH, DE, FR, GB, IT, LI, NL, SE

 Ein Hüllprotein eines Erworbenen-Immunschwäche-Syndrom-(AIDS)-Virus, weitgehend frei von anderen Proteinen, mit der Aminosäuresequenz:

ValTrpLysGluAla ${\tt ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr}$ ${\tt HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn}$ METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ${\tt ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr}$ ${\tt AsnSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr}$ SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer ${\tt PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr}$ ${\tt PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal}$ ${\tt SerThrGlnLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr}$ ${\tt AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn}$ AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ${\tt ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle}$ SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGlullePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly ${\tt AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn}$ ${\tt LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln}$ AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

oder

30

35

40

50

55

CysProLysValSer

PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGinLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn ${\tt AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly}$ AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu ${\tt IleValThr HisSerPhe Asn CysGlyGlyGluPhe Phe Tyr CysAsn Ser Thr Gln LeuPhe Asn Ser}$ ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg ${\tt GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly}$ AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

20

5

10

15

oder

25

30

35

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

40

oder

45

METTYRALAPROPROILE
SerGlyGinIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

55

oder

METArqAspAsnTrpArqSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArqArqValValClnArq GluLysArqAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArqGlnLeuLeuSerGlyIleValGlnGlnAsnAsn LeuLeuArqAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArqIleLeuAlaValGluArqTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArqGluIleAsnAsnTyrThrSer.

- 2. Ein Expressionsvektor enthaltend ein Gen kodierend für ein Hüllprotein von einem AIDS-Virus gemäss Anspruch 1, abwärts von einer Promotorsequenz die die Transkription, Translation und damit die Expression des besagten Hüllproteins in einer Wirtszelle ermöglicht.
 - 3. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA
CATGCCTGTGTACCCCACAGACCCCACCCAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC

GTGTGGAAGGAAGCA

20

25

30

35

5

10

ATGTGGAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC **AATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT** GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAGGGGTAGTAATTAGATCTGTCAATTTCACG AATACAAGAAAAAATCCGTATCCAGAGGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA **ARATTARGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA** ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC

AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA
TATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCACCAAGGCAAAGAGAAGAGTGGTGCAGAGA
GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC
GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGCAGAACAAT
TTGCTGAGGGCTATTGAGGCCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG

40

GCAAGAATCCTGGCAGAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA

AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG
AATCACACGACGTGGATGGGACAGAGAAATTAACAATTACACAAGC

oder ein Äquivalent davon.

50

4. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:

TGTCCAAAGGTATCC

TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTÁCAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG GRCARTGCTARARCCRTRATAGTRCAGCTGRACACATCTGTRGRARTTRATTGTRCARGRCCCRACARC **AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGCCCAGAA** ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGCGACAATTGGAGGAGTGAATTATATAAA** GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTCGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA *AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG* **AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

oder ein Äquivalent davon.

25 ·

5. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:

oder ein Äquivalent davon.

Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:

50

ATGTATGCCCCTCCCATC

AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAAA GAAAAAAGGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

oder ein Äquivalent davon.

15

- 7. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:
- ATGAGGGACAATTGGAGAAGTGAATTATATAAA GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGGTATTGAGGGGGAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA aaactaatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttgg AATCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC

oder ein Äquivalent davon. 30

- 8. Ein Expressionsvektor gemäss einem der Ansprüche 2 bis 7, der ein Plasmid ist, das sich in gramnegativen und/oder gram-positiven Bakterien replizieren kann.
- Ein Expressionsvektor gemäss Anspruch 8, welcher fähig ist, in einem E. coli Stamm zu replizieren.
 - 10. Ein Expressionsvektor gemäss Anspruch 8, welcher fähig ist, in einem B. subtilis Stamm zu replizieren.
 - 11. Der Expressionsvektor pEV1, -2, oder -3/env 44-640.

- 12. Der Expressionsvektor pEV1, -2, oder -3/env 205-640.
- 13. Ein Transformant der einen Expressionsvektor gemäss einem der Ansprüche 2 bis 12 trägt.
- 14. Ein Transformant gemäss Anspruch 13, der ein E. coli Stamm ist.
 - 15. Ein Transformant gemäss Anspruch 13, der ein E. coli MC 1061 Stamm ist.
 - 16. Ein Transformant gemäss Anspruch 13, der ein B. subtilis Stamm ist.

50

- 17. Ein Transformant gemäss Anspruch 13, welcher eine Säugetierzelle ist.
- 18. Ein Verfahren zur Herstellung eines wie in Anspruch 1 beanspruchten Hüllproteins eines Erworbenen-Immunschwäche-Syndrom-Virus gekennzeichnet durch:
 - Transformieren einer Wirtszelle mit einem Expressionsvektor wie in einem der Ansprüche 2 bis 12 beansprucht; Kultivieren besagter Wirtszelle, so dass besagtes AIDS env Protein exprimiert wird; und Extrahieren und Isolieren des besagten AIDS env Proteins.

- 19. Ein Verfahren gemäss Anspruch 18, worin der Expressionsvektor pEV1, -2 oder -3/env 44-640 ist.
- 20. Ein Verfahren gemäss Anspruch 18, worin der Expressionsvektor pEV1, -2 oder -3/env 205-640 ist.
- 21. Ein Verfahren zum Testen von humanem Blut auf das Vorhandensein des viralen Verursachers von AIDS, gekennzeichnet durch Mischen einer Zusammensetzung enthaltend ein Hüllprotein eines AIDS Virus gemäss Anspruch 1 mit einer Probe von humanem Blut und Bestimmen ob das besagte Hüllprotein an in der Blutprobe vorhandene AIDS Antikörper bindet.
- 22. Ein Verfahren gemäss Anspruch 21, gekennzeichnet durch die Verwendung der Western Blot Analyse umfasst.
- 23. Ein Verfahren gemäss Anspruch 21, gekennzeichnet durch die Verwendung einer ELISA Technik, wobei ein Hüllprotein eines AIDS Virus gemäss Anspruch 1 auf eine Festphase aufgebracht wird, mit der Probe in Kontakt gebracht wird und nach Waschen mit einem enzymmarkiertem nicht-humanem IgG zusammengebracht wird.
 - 24. Ein Verfahren gemäss Anspruch 21, worin das Doppel-Antigen-Verfahren verwendet wird.
- 25. Ein Verfahren zur Bestimmung von AIDS-Viren, worin Antikörper gegen das Hüllprotein eines AIDS-Virus gemäss Anspruch 1 verwendet werden.
 - 26. Ein Verfahren gemäss Anspruch 25, worin das Antigen in der Probe und ein Protein gemäss Anspruch 1 welches markiert ist, um einen Antikörper gegen ein Protein gemäss Anspruch 1 konkurrieren.
 - 27. Ein Verfahren gemäss Anspruch 25, worin ein Sandwichverfahren unter Verwendung von zwei Antikörpern gegen ein Protein gemäss Anspruch 1 durchgeführt wird.
- 28. Ein Verfahren gemäss Anspruch 27, worin ein Antikörper an der Festphase ist und der andere Antiköper markiert ist.
 - 29. Ein Verfahren gemäss Anspruch 27, worin zwei verschiedene monoklonale Antikörper verwendet werden.
- 35. Ein Immunität gegen AIDS bewirkender Impfstoff, enthaltend als aktiven Bestandteil ein Protein gemäss Anspruch 1.
 - 31. Antikörper erzeugt gegen ein Protein gemäss Anspruch 1.
- 40 32. Die Antikörper gemäss Anspruch 31, welche monoklonale Antiköper sind.
 - 33. Die Verwendung eines Proteins gemäss Anspruch 1 für die Herstellung eines schützenden immunisierenden Impfstoffs.
- 45 34. Die Verwendung eines Proteins gemäss Anspruch 1 zum Testen von humanem Blut auf das Vorhandensein von AIDS-Viren.

Patentansprüche für folgenden Vertragsstaat: AT

1. Ein Verfahren für die Herstellung eines Hüllproteins eines Erworbenen-Immunschwäche-Syndrom-(AIDS)-Virus, welches im wesentlichen frei von anderen Proteinen ist, gekennzeichnet durch: Transformieren einer Wirtszelle mit einem Expressionsvektor enthaltend ein Gen kodierend für ein Hüllprotein eines AIDS-Virus mit der Aminosäuresequenz:

55

ValTrpLysGluAla

Thr Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Lys Asp Thr Glu Val His Asn Val Trp Ala Thr Lys Asp Thr Glu Val His Asn Val Trp Ala Thr Lys Asp Thr Glu Val His Asn Val Trp Ala Thr Lys Asp Thr Glu Val His Asn Val Trp Ala Thr Lys Asp Thr Glu Val His Asp Thr GluHisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMBTArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLyS TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArqAlaValGly1leGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArqIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

30

35

oder

40

45

50

CysProLysValSer

PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr ${\tt PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal}$ SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArqGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrTrpMETGluTrpAspArqGluIleAsnAsnTyrThrSer

oder

25

30

35

10

15

20

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlmGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuTheUeUGlyTleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

40

oder

45

METTYrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

55

oder

METArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

15

abwärts von einer Promotorsequenz, die die Transkription, Translation und damit die Expression des Hüllproteins in einer Wirtszelle ermöglicht; Kultivieren der Wirtszelle, so dass das Hüllprotein eines AIDS-Virus expremiert wird; und Extrahieren und Isolieren des Hüllproteins von einem AIDS-Virus.

- 20 2. Ein Verfahren gemäss Anspruch 1, worin die Wirtszelle ein Bakterium ist.
 - 3. Ein Verfahren gemäss Anspruch 2, worin das Bakterium E. coli ist.
 - 4. Ein Verfahren gemäss Anspruch 3, worin das Plasmid pEV1, -2 oder 3/env 44-640 ist.

25

30

- 5. Ein Verfahren gemäss Anspruch 3, worin das Plasmid pEV1, -2 oder 3/env 205-640 ist.
- 6. Ein Verfahren für die Herstellung eines Expressionsvektors enthaltend ein Gen kodierend für ein Hüllprotein von einem AIDS-Virus, gekennzeichnet durch das Konstruieren eines Expressionsvektors mit einer Inserierungsstelle, worin das in Anspruch 1 definierte Gen kodierend für ein Hüllprotein eines AIDS-Virus inseriert werden kann, wobei die Inserierungsstelle aufwärts einer Promotorsequenz liegt, die die Transkription, Translation und damit Expression des Hüllproteins in einer Wirtszelle ermöglicht.
- 7. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllprotein eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

40

45

50

GTGTGGAAGGAAGCA ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCACCCACAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC **ARTAGTAGCGGGGAGARTGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA** AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA 10 TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG **AAATTAAGAGAACAATTTGGAAATAATAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA** ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC 20 **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAAGGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTCGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGGCATCAAGCAGCTCCAG 25 GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC**

oder ein Aequivalent davon verwendet wird.

30

8. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllprotein eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

35 TGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCRACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG **ANTACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGGAGCATTTGTTACAATAGGAAAAATAGGA** AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA **ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACACTGTTTAATAGT** CCATGCAGAATAAAACATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC aatgggtccgagatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaa GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC**

oder ein Aequivalent davon verwendet wird.

 Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllprotein eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

20

oder ein Aequivalent davon verwendet wird.

10. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllprotein eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

25

oder ein Aequivalent davon verwendet wird.

40

55

11. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllprotein eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

oder ein Aequivalent davon verwendet wird.

12. Ein Verfahren gemäss einem der Ansprüche 6 bis 11, worin der Expressionsvektor ein Plasmid ist, das zur Replikation in gram-negativen Bakterien fähig ist.

- 13. Ein Verfahren gemäss Anspruch 12, worin das Plasmid zur Replikation in einen E.coli Stamm fähig ist.
- 14. Ein Verfahren für die Herstellung eines Transformanten, der einen Expressionsvektor enthaltend ein Gen kodierend für ein Hüllprotein eines AIDS-Virus trägt, welches Verfahren Transformieren eines Mikroorganismus mit einem Expressionsvektor gemäss einem der Ansprüche 6 bis 13 und Kultivieren des transformierten Mikroorganismus umfasst.
- 15. Ein Verfahren gemäss Anspruch 14, worin der Mikroorganismus ein E. coli Stamm ist.
- 16. Ein Verfahren gemäss Anspruch 15, worin der Mikroorganismus ein E. coli MC 1061 Stamm ist.
 - 17. Ein Verfahren zum Testen von humanem Blut auf das Vorhandensein des viralen Verursachers von AIDS, gekennzeichnet durch Mischen einer Zusammensetzung enthaltend ein Hüllprotein eines AIDS-Virus erhalten gemäss Anspruch 1 mit einer Probe von humanem Blut und Bestimmen, ob das Hüllprotein an in der Blutprobe vorhandene AIDS Antikörper bindet:
 - 18. Ein Verfahren gemäss Anspruch 17, gekennzeichnet durch die Verwendung der Western Blot Analyse.
- 19. Ein Verfahren gemäss Anspruch 17, gekennzeichnet durch die Verwendung einer ELISA-Technik, wobei ein Hüllprotein eines AIDS-Virus erhalten gemäss Anspruch 1 auf eine Festphase aufgebracht, mit der Probe in Kontakt gebracht und nach Waschen mit einem enzymmarkierten nichthumanem IgG zusammengebracht wird.
 - 20. Ein Verfahren gemäss Anspruch 17, worin die Doppel-Antigen-Methode verwendet wird.

25

35

50

21. Ein Verfahren zur Bestimmung von AIDS-Viren, worin Antikörper gegen das gemäss Anspruch 1 erhaltene Hüllprotein eines AIDS-Virus verwendet werden.

- 22. Ein Verfahren gemäss Anspruch 21, worin das Antigen in der Probe und ein Protein erhalten gemäss Anspruch 1, welches markiert ist, um einen Antikörper gegen ein Protein erhalten gemäss Anspruch 1 konkurrieren.
 - 23. Ein Verfahren gemäss Anspruch 21, worin ein Sandwichverfahren unter Verwendung von zwei Antikörpern gegen ein gemäss Anspruch 1 erhaltenes Protein durchgeführt wird.
 - 24. Ein Verfahren gemäss Anspruch 23, worin ein Antikörper an der Festphase ist und der andere Antikörper markiert ist.
- 25. Ein Verfahren gemäss Anspruch 23, worin zwei verschiedene monoklonale Antikörper verwendet werden.
 - Ein Hüllprotein von einem AIDS-Virus, hergestellt durch ein Verfahren gemäss einem der Ansprüche 1 bis 5.
- 45 27. Ein Expressionsvektor, enthaltend ein Gen kodierend für ein Hüllprotein eines AIDS-Virus, hergestellt durch ein Verfahren gemäss einem der Ansprüche 6 bis 13.
 - 28. Ein Transformant tragend einen Expressionsvektor enthaltend ein Gen kodierend für ein Hüllprotein eines AIDS-Virus, hergestellt durch ein Verfahren gemäss einem der Ansprüche 14 bis 16.
 - 29. Ein Expressionsvektor enthaltend ein Gen kodierend für ein Hüllprotein von einem AIDS-Virus gemäss Anspruch 1, abwärts von einer Promotorsequenz, die die Transkription, Translation und damit die Expression des besagten Hüllproteins in einer Wirtszelle ermöglicht.
- 30. Ein Expressionsvektor gemäss Anspruch 29, worin das für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACGACCCCAACCCACAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC atgtggaaaaatgacatggtagaacagatgcatgaggatataatcagttatgggatcaaagcctaaag CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC artagtagtagcgggagartgataatggagaaaggagataaaaaactgctctttcaatatcagcaca agcataagaggtaaggtgcagaaagaatatgcatttttttataaacttgatataataccaatagataat GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC tttgagccaattcccatacattattgtgccccgctggttttgcgattctaaaatgtaataataagacg ttcaatggaacaggaccatgtacaaatgtcagcacagtacaatgtacacatggaattaggccagtagta tcaactcaactgetgitaaatggcagtetagcagaagaagaggtagtaattagatetgtcaatttcacg **ANTACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGGAGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTRACGCACAGTTTTRATTGTGGAGGGGRATTTTTCTACTGTRATTCAACACACTGTTTAATAGT** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAAA** Gaaaaagggcagtgggaataggagctttgttccttgggttcttgggagcagcagcaggaagcactatgggc GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG** ARTCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC

30 .

oder ein Aequivalent davon enthält.

31. Ein Expressionsvektor gemäss Anspruch 29, worin das besagte, für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

TGTCCAAAGGTATCC

TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAAACATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAARTTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC aatgggtccgagatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaa GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA ARACTRATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC**

oder ein Aequivalent davon enthält.

32. Ein Expressionsvektor gemäss Anspruch 29, worin das für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

oder ein Aequivalent davon enthält.

25

33. Ein Expressionsvektor gemäss Anspruch 29, worin das besagte, für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

ATGTATGCCCCTCCCATC

30

35

40

oder ein Aequivalent davon enthält.

34. Ein Expressionsvektor gemäss Anspruch 29, worin das für ein Hüllprotein eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

TA GA GC

oder ein Aequivalent davon enthält.

- 35. Ein Expressionsvektor gemäss einem der Ansprüche 29 bis 34, der ein Plasmid ist, das sich in gramnegativen Bakterien replizieren kann.
- 36. Ein Expressionsvektor gemäss Anspruch 35, welcher fähig ist, in einen E. coli Stamm zu replizieren.
- 37. Der Expressionsvektor pEV1, -2, oder 3/env 44-640.
- 38. Der Expressionsvektor pEV-1, 2, oder 3/env 205-640.
- 10 39. Ein Transformant, der einen Expressionsvektor gemäss einem der Ansprüche 29 bis 38 trägt.
 - 40. Ein Transformant gemäss Anspruch 39, der ein E. coli Stamm ist.
 - 41. Ein Transformant gemäss Anspruch 40, der ein E. coli MC 1061 Stamm ist.
 - 42. Antikörper erzeugt gegen ein wie gemäss Ansprüchen 1 bis 5 und 26 erhaltenes Protein.
 - 43. Die Antikörper von Anspruch 42, welche monoklonale Antikörper sind.
- 20 44. Ein Impfstoff der Immunität gegen AIDS bewirkt, enthaltend als aktiven Bestandteil ein Protein erhalten gemäss Ansprüchen 1 bis 5 und 26.
 - 45. Die Verwendung eines wie in Anspruch 1 beanspruchten Proteins zur Herstellung eines schützenden, immunisierenden Impfstoffs.

Revendications

15

25

30

35

45

50

55

Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, NL, SE

1. Protéine d'enveloppe d'un virus du syndrome de l'immunodéficience acquise (SIDA), pratiquement exempte d'autres protéines, ayant la séquence d'aminoacides suivante:

ValTrpLysGluAla ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer PheGluProlleProlleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspasnalaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGinAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGinIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArglieLysGlnPhelleAsnHETTrpGlnGluValGlyLysAlaHETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AshGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAshTrpArgSerGluLeutyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgOinLeuLeuSerGlyIleValGinGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AshHisthethetephetGlutepaspaegGluileashashtyethesee

CysProLysValSer PheGluProlleProlleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AshThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGinAlaHisCysAsnileSerArgAlaLysTrpAsnAlaThrLeuLysGinIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThfLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGinLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArglleLeuAlaValGluArgTyrLeuLysAspGlnGinLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGinIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

ou

25

30

35

40

10

15

20

METArgGinAlaHisCysAsnileSerArgAlaLysTrpAsnAlaThrLeuLysGinIleAlaSer
LysLeuArgGluGinPheGlyAsnAsnLysThrIleIlePheLysGinSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGinLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGinLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisteuLeuGlnLeuThrValTrpGlyIleLysGinLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGinIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

45.

50

ou

METTYrAlaProProlle SerGlyGlnIleArqCysSerSerAsnIleThrGlyLeuLeuLeuThrArqAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArqProGlyGlyGlyAspMETArqAspAsnTrpArqSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArqArqValValGlnArq GluLysArqAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArqGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArqAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArqIleLeuAlaValGluArqTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArqGluIleAsnAsnTyrThrSer

ou

15

10 -

METARGASPASNTRPARGSERGIULEUTYRLYS
TYRLYSVAIVAILYSIIEGIUPROLEUGIYVAIAIAPROTHRLYSAIALYSARGARGVAIVAIGINARG
GIULYSARGAIAVAIGIYIIEGIYAIALEUPHELEUGIYPHELEUGIYAIAAIAGIYSERTHRMETGIY
AIAAIASERMETTHRLEUTHRVAIGINAIAARGGINLEULEUSERGIYIIEVAIGINGINGINASNASN
LEULEUARGAIAIIEGIUAIAGINGINHISLEULEUGINLEUTHRVAITRPGIYIIELYSGINLEUGIN
AIAARGIIELEUAIAVAIGIUARGTYRLEULYSASPGINGINLEULEUGIYIIETRPGIYCYSSERGIY
LYSLEUIIECYSTHRTHRAIAVAIPROTRPASNAIASERTRPSERASNLYSSERLEUGIUGINIIETRP
ASNKISTHRTHRTFPHETGIUTRPASPARGGIUIIEASNASNTYRTHRSER.

25

20

- 2. Vecteur d'expression comprenant un gène codant pour une protéine d'enveloppe d'un virus du SIDA telle que définie dans la revendication 1 en aval d'une séquence de promoteur permettant la transcription, la traduction et, par conséquent, l'expression de cette protéine d'enveloppe dans une culture hôte.
- 3. Vecteur d'expression selon la revendication 2, dans lequel ce gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

35

30

40

45

50

GTGTGGAAGGAAGCA ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCAAGAAGTAGTATTGGTAAATGTGACAGAAATTTTAAC atgtggaaaaatgacatggtagaacagatgcatgaggatataatcagtttatgggatcaaagcctaaag CCRTGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATAATACCAATAGATAAT GRIACIACCAGCIAIACGITGACAAGTIGIAACACCTCAGTCATTACACAGGCCTGTCCAAAGGIATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAAAAAGACG TICAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCRACTCRACTGCTGTTRAATGGCRGTCTAGCAGRAGRAGRGGTAGTRATTAGATCTGTCRATTTCRCG aatacaagaaaaaatccgtatccagaggggaccagggggggatttgttacaataggaaaatagga aaattaagagaacaatttogaaataataaaacaataatetttaagcaateetcaggaggggaeeeaga attgtaacgcacagtttaattgtggaggggaatttttctactgtaattcaacacaactgtttaatagt acticgttiaatagtacticgagtactgaaccgtcaaataacactgaacgaactgaccactaccactc CCRTGCAGARTAAACARTTTRTRAACRTGTGGCAGGRAGTRGGRAAAGCARTGTRTGCCCCTCCCRTG ageogrerarttrgrtgtterterratattrergogeteetrttracagagatogtogtratraerae aatgggtccgagatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaa GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC **CCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT** TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG **CCAAGAATCCTCGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA** AAACTAATTTGCACCACTGCTGCGTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGTAATTACAATTACACAAGC**

30 ou un équivalent de celle-ci

5

10

15

20

25

55

4. Vecteur d'expression selon la revendication 2, dans lequel ce gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

35 TGTCCXAAGGTATCC TITGAGCCAATTCCCATACATTATTSTGCCCCSGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAGAGTAGTAATTAGATCTGTCAATTTCACG GACAATGCTAAAACCATRATAGTACAGCTGAACACCATCTGTAGAAATTRATTGTACAAGACCCAACAAC AATACAAGAAAAAATCCGTXTCCAGAGGGGACCAGGGAGCATTTGTTACAATAGGAAAAATAGGA 40 aaattaagagaacaatttogaaataataaaacaataatetttaagcaatectcaggaggggacccaga**a ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT ACTTGGTTTRATAGTACTTGGAGTACTGAAGGGTCRAATAACACTGAAGGAAGTGACACAATCACACTC** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATG 45 AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATCCGTCCGAGATCTTCAGACCTCGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA GAZAZAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTCGGTTCTTCGGAGCAGCAGCAGCACCTATGGGC CCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT 50 TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG CCAAGAATCCTCGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGCGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTACAAATTACACAAGC

ou un équivalent de celle-ci

5. Vecteur d'expression selon la revendication 2, dans lequel ce gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivantes :

20

10

15

6. Vecteur d'expression selon la revendication 2, dans lequel le gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

25

30

35

ou un équivalent de celle-ci.

7. Vecteur d'expression selon la revendication 2, dans lequel ce gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

50

- Vecteur d'expression selon l'une quelconque des revendication 2 à 7, qui est un plasmide capable de se répliquer dans des bactéries gram-négatives et/ou gram-positives.
 - 9. Vecteur d'expression selon la revendication 8, qui est capable de se répliquer dans une souche d'E.coli.

- Vecteur d'expression selon la revendication 8, qui est capable de se répliquer dans une souche de B.subtilis.
- 11. Vecteur d'expression pEV1, -2 ou -3/env. 44-640
- 12. Vecteur d'expression pEV1, -2 ou 3/env. 205-640.

15

20

- 13. Transformant portant un vecteur d'expression selon l'une quelconque des revendications 2 à 12.
- 14. Transformant selon la revendication 13, qui est une souche d'E.coli.
 - 15. Transformant selon la revendication 14, qui est une souche d'E.coli MC 1061.
 - 16. Transformant selon la revendication 13, qui est une souche de B.subtilis.
 - 17. Transformant selon la revendication 13, qui est une cellule de mammifère.
 - 18. Procédé de préparation d'une protéine d'enveloppe d'un virus du syndrome d'immunoficience acquise selon la revendication 1, consistant à :
 - transformer une cellule hôte avec un vecteur d'expression selon l'une quelconque des revendications 2 à 12;
 - cultiver cette cellule hôte de façon que cette protéine d'enveloppe du SIDA soit exprimée ; et extraire et isoler cette protéine d'enveloppe du SIDA.
- Procédé selon la revendication 18, dans lequel le vecteur d'expression est pEV1, -1, -2 ou -3/env.44-640
 - 20. Procédé selon la revendication 19, dans lequel le vecteur d'expression est pEV1, -2 ou -3/env. 205-640.
- 21. Procédé de détection dans le sang humain de la présence d'anticorps pour l'agent étiologique viral du SIDA, qui consiste à mélanger une composition contenant une protéine d'enveloppe d'un virus du SIDA, selon la revendication 1, avec un échantillon de sang humain et de déterminer si cette protéine d'enveloppe du SIDA se lie aux anticorps du SIDA présents dans l'échantillon de sang.
- 22. Procédé selon la revendication 21 qui consiste à utiliser l'analyse par "Western Blotting".
 - 23. Procédé selon la revendication 21 qui comprend l'utilisation d'une technique ELISA, dans laquelle une protéine d'enveloppe d'un virus du SIDA, selon la revendication 1, est appliquée sur une phase solide et mise en contact avec l'échantillon et, après lavage, mise en contact avec une IgG non humaine marquée par une enzyme.
 - 24. Procédé selon la revendication 21, dans lequel on utilise la Méthode du Double Antigène.
- 25. Procédé pour la détermination du virus du SIDA, dans lequel on utilise des anticorps contre une protéine d'enveloppe d'un virus du SIDA, selon la revendication 1.
 - 26. Procédé selon la revendication 25, dans lequel l'antigène présent dans l'échantillon et une protéine selon la revendication 1, sous forme marquée entrent en compétition avec un anticorps contre une protéine selon la revendication 1.
 - 27. Procédé selon la revendication 25, dans lequel on applique une méthode sandwich en utilisant deux anticorps contre une protéine selon la revendication 1.
- 28. Procédé selon la revendication 27, dans lequel un anticorps est sur une phase solide et l'autre anticorps est marqué.
 - 29. Procédé selon la revendication 27, dans lequel on utilise deux anticorps monoclonaux différents.

- Vaccin déclenchant l'immunité au SIDA comprenant comme ingrédient actif une protéine selon la revendication 1.
- 31. Anticorps formés contre une protéine selon la revendication 1.
- 32. Anticorps selon la revendication 31, qui sont des anticorps monoclonaux.
- 33. Utilisation d'une protéine selon la revendication 1, pour la préparation d'un vaccin d'immunisation protectrice.
- 34. Utilisation d'une protéine selon la revendication 1 pour détecter dans le sang humain la présence du virus du SIDA.

Revendications pour l'Etat contractant suivant : AT

1. Procédé pour préparer une protéine d'enveloppe d'un virus du syndrome de l'immunodéficience acquise (SIDA), essentiellement exempte d'autres protéines, qui consiste :

à transformer une cellule hôte avec un vecteur d'expression comprenant un gène codant pour une protéine d'enveloppe d'un virus du SIDA ayant la séquence d'acides aminés suivante :

ValTrpLysGluAla

ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METT:pLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuT:pAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerileArqGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerValIleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal Ser Thr Gln Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu Val Valle Arg Ser Val Asn Phe Through Control of the ContAspasnalaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly ASNMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyTLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

55

50

10

CVSProLvsValSer

PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspasnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArqGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

οù

20

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

40 **2**0U

METTYrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

55

ou.

METArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

en aval d'un promoteur permettant la transcription, la traduction et l'expression de cette protéine d'enveloppe dans la cellule hôte; à cultiver cette cellule hôte de façon à exprimer la protéine d'enveloppe d'un virus du SIDA; et à extraire et à isoler la protéine d'enveloppe d'un virus du SIDA.

- 2. Procédé selon la revendication 1, dans lequel la cellule hôte est une bactérie.
- 3. Procédé selon la revendication 2, dans lequel la bactérie est E. coli.
- 4. Procédé selon la revendication 3, dans lequel le plasmide est pEV1, -2 ou -3/env 44-640.
- 5. Procédé selon la revendication 3, dans lequel le plasmide est pEV1, -2 ou -3/env 205-640.
- 6. Procédé pour préparer un vecteur d'expression comprenant un gène codant pour une protéine d'enveloppe d'un virus du SIDA, procédé qui consiste à construire un vecteur d'expression portant un site d'insertion, dans lequel on peut insérer un gène codant pour une protéine d'enveloppe d'un virus du SIDA selon la revendication 1, le site d'insertion se trouvant en aval d'un promoteur permettant la transcription, la traduction et donc l'expression de la protéine d'enveloppe dans une cellule hôte.
 - 7. Procédé selon la revendication 6, caractérisé en ce qu'on utilise en tant que gène codant pour une protéine d'enveloppe du virus du SIDA un gène comprenant la séquence nucléotidique suivante :

35

15

20

. 40 .

45

50

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC A TOTOGRARA TORCA TOGTAGRACAGA TOCA TORGGA TATRA TORGTTTA TOGGA TORRAGOCTARAGO CCRTGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC ANTAGTAGTAGCCGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA **ACCATRAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT** GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGRGCCRATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTRATAATAAGACG TTCRATGGRACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCRACTCRACTGCTGTTRAATGGCAGTCTAGCAGAAGAAGAGTAGTAATTAGATCTGTCRATTTCACG AATACAAGAAAAAATCCCTRTCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA **AMATTANGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **ANTOGGTCCGAGATCTTCAGACCTGGAGGAGGAGTATGGAGGACAATTGGAGAAGTGAATTATAAA** GANANAGAGCAGTGGGATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACCGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAATTACACAAGC**

30 ou un de ses équivalents.

35

45

8. Procédé selon la revendication 6, caractérisé en ce qu'on utilise en tant que gène codant pour une protéine d'enveloppe d'un virus du SIDA un gène comprenant la séquence nucléotidique suivante :

TGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCRATGGARCAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG <u>GACRA TGCTRAAACCATAR TAGTACAGCTGRACACATCTGTAGAAR TTAATTGTACAAGACCCAACAAC</u> ANTACAAGAAAAAAATCCGTATCCAGAGGGGAACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AATRTGAGRCAAGCRCATTGTAACATTAGTRGAGCRARATGGRATGCCRCTTTRAARCRGATAGCTRGC <u>AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA</u> <u>ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACACTGTTTAATAGT</u> ACTTGGTTTARTAGTACTTGGAGTACTGAAGGGT@AARTAACACTGAAGGAAGTGACACARTCACACTC CCRTGCRGRATARARCRATTTRIARACRTGTGGCACARGTRGGRARAGCRRTGTRTGCCCCTTCCCRTC AGCGGACARATTAGATGTTCATCARATATTACAGGGCTGCTATTAACARGAGATGGTGGTARTAACAAC aatgggtccgagatcttcagacctggaggaggagatatgagggacaattggagaggtgaattatataaa TATARAGTAGTARARATTGRACCATTAGGAGTAGCACCCACCRAGGCARAGAGAGAGTGGTGCAGAGA Gaaaaaagagcagtgggaataggagctttgttccttcggttcttgggagcagcaggaagcactatgggc GCRGCGTCRATGRCGCTGRCGGTRCRGGCCRGRCRATTATTGTCTGGTRTRGTGCRGCRGCRGRRCRAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCRAGAATCCTGGCTGTGGRAAGATACCTRAAGGATCRACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTRATTTGCRCCRCTGCTGCCTTGGRATGCTRGTTGGAGTRATRAATCTCTGGRRCRGATTTTGG AATCACACGACGTGGATGGAGTGGGACAGAGTTACACAAGC**

ou l'un de ses équivalents.

- 9. Procédé selon la revendication 6, caractérisé en ce qu'on utilise comme gène codant pour une protéine d'enveloppe du virus du SIDA un gène comprenant la séquence nucléotidique suivante :
- 20 ou l'un de ses équivalents.

25

55

- 10. Procédé selon la revendication 6, caractérisé en ce qu'on utilise comme gène codant pour une protéine d'enveloppe d'un virus du SIDA un gène comprenant la séquence nucléotidique suivante :

ou l'un de ses équivalents.

40 11. Procédé selon la revendication 6, caractérisé en ce qu'on utilise en tant que gène codant pour une protéine d'enveloppe d'un virus du SIDA un gène comprenant la séquence de nucléotides suivante :

atgagggacaattggagaagtgaattatataa

- - ou l'un de ses équivalents.

12. Procédé selon l'une quelconque des revendications 6 à 11, dans lequel le vecteur d'expression est un plasmide pouvant subir une réplication dans des bactéries gram-négatives.

- Procédé selon la revendication 12, dans lequel le plasmide peut subir une réplication dans une souche de E. coli.
- 14. Procédé pour préparer un transformant portant un vecteur d'expression, qui comprend un gène codant pour une protéine d'enveloppe d'un virus du SIDA, ce procédé consistant à transformer un microorganisme avec un vecteur d'expression obtenu selon l'une quelconque des revendications 6 à 13, et à cultiver le micro-organisme transformé.
 - 15. Procédé selon la revendication 14, dans lequel le micro-organisme est une souche de E. coli.

10

15

- 16. Procédé selon la revendication 15, dans lequel le micro-organisme est une souche de E. coli MC 1061.
- 17. Procédé pour détecter dans le sang humain la présence d'anticorps contre l'agent étiologique viral du SIDA, qui consiste à mélanger une composition contenant une protéine d'enveloppe du virus du SIDA obtenue selon la revendication 1, avec un échantillon de sang humain, et à déterminer si la protéine d'enveloppe du SIDA se lie aux anticorps anti-SIDA présents dans l'échantillon sanguin.
- 18. Procédé selon la revendication 17, qui consiste à utiliser une analyse par "Western Blotting".
- 19. Procédé selon la revendication 17, qui consiste à utiliser une technique de liaison enzymatique Elisa, dans laquelle une protéine d'enveloppe d'un virus du SIDA obtenue selon la revendication 1 est appliquée sur une phase solide et mise en contact avec l'échantillon et, après lavage, mise en contact avec une IgG non humaine marquée par une enzyme.
- 25. Procédé selon la revendication 17, dans lequel on utilise la Méthode du Double Antigène.
 - 21. Procédé pour la détermination du virus du SIDA, dans lequel on utilise des anticorps contre une protéine d'enveloppe d'un virus du SIDA obtenue selon la revendication 1.
- 22. Procédé selon la revendication 21, dans lequel l'antigène présent dans l'échantillon et une protéine obtenue selon la revendication 1 sous forme marquée entrent en concurrence avec un anticorps contre une protéine obtenue selon la revendication 1.
 - 23. Procédé selon la revendication 21, dans lequel on utilise une méthode sandwich en utilisant deux anticorps contre une protéine obtenue selon la revendication 1.
 - 24. Procédé sleon la revendication 23, dans lequel un anticorps se trouve sur une phase solide et l'autre anticorps est marqué.
- 40° 25. Procédé selon la revendication 23, dans lequel on utilise deux anticorps monoclonaux différents.
 - 26. Protéine d'enveloppe d'un virus du SIDA, préparée par un procédé selon l'une quelconque des revendications 1 à 5.
- 45 27. Vecteur d'expression comprenant un gène codant pour une protéine d'enveloppe d'un virus du SIDA, préparée par un procédé selon l'une quelconque des revendications 6 à 13.
 - 28. Transformant portant un vecteur d'expression comprenant un gène codant pour une protéine d'enveloppe d'un virus du SIDA, préparé par un procédé selon l'une quelconque des revendications 14 à 16.
 - 29. Vecteur d'expression comprenant un gène codant pour une protéine d'enveloppe d'un virus du SIDA selon la revendication 1, en aval d'un promoteur permettant la transcription, la traduction et donc l'expression de la protéine d'enveloppe dans une cellule hôte.
- 55 30. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante:

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTTGGTAAATGTGACAGAAAATTTTAAC ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC aatagtagtagceggagaatgataatggagaaaggagagataaaaaactgctctttcaatatcagcaca GRIACTRECAGETRIACGTTGACRAGTTGTRACAECTERGTERTTACREAGGCCTGTECRAAGGTRTEC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCRATGGRACAGGRCCATGTRCRARTGTCRGCACAGTRCRATGTRCRCRTGGRATTRGGCCRGTAGTR TCRACTCRACTGCTGTTRAATGGCAGTCTAGCAGAAGRAGAGGGTAGTAATTAGATCTGTCAATTTCRCG GACRATGCTRAAACCRTRATAGTRCAGCTGRACACATCTGTAGARATTRATTGTRCAAGACCCRACAAC aatacaagaaaaaatccgtatccagaggggaccagggaggagcatttgttacaataggaaaaatagga aarttragrgracratttggrartratraaacratratctttragcratcctcrggrggggrcccrgra ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCRTGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC aatgggtccgagatcttcagacctggaggggggagatatgagggacaattggaggagtgaattatataaa GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCRGCGTCRATGACGCTGRCGGTRCAGGCCRGACAATTRTTGTCTGGTRTRGTGCRGCRGCRGRACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG gcragratectggctgtggraagrtreetraaggrterrergetetggggtttgggttgetetggr AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

30

ou l'un de ses équivalents.

31. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante:

35

TGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCRATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG **ANTACANGANANANTCCGTATCCAGAGGGGACCAGGGAGGAGCATTTGTTACANTAGGANANTAGGA ARATTARGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA** ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCRTGCAGARTARAACARTTTRTARACRTGTGGCAGGRAGTAGGARAAGCARTGTRTGCCCCTCCCRTC ageogrearattagrigiterterrattaetgegetgetattarergagrtggtggtrattarerre antogotcccagatetteagaeetggaggagatatgagggaeanttcgagaagtgaattatataaa 50 GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCRATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG 55 AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

ou l'un de ses équivalents

32. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante:

ARATTARGAGAACARTTTGGAARTRATAAAACARTRATCTTTRAGCARTCCTCRGGAGGGGACCCRGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCOGRCAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC aatgegteegagatetteagacetegaggaggagatatgagggacaattggagaagtgaattatataaa GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCRGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGGCTATTGAGGGGGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA aaactaatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttgg **AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

ou l'un de ses équivalents.

33. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séguence de nucléotides suivante:

25

ATGTATGCCCCTCCCATC

AGCGGACAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **ANTOGOTECGAGATETTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAAA** GRARARAGGGCAGTGGGARTAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCRATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA ANACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **ARTCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

ou l'un de ses équivalents.

34. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante:

ATGAGGGACAATTGGAGAAGTGAATTATATAA gaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggc GCRGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG gcaagaatectggctgtggaaagataectaaaggateaacagetectgggatttggggttgetetgga AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC**

35. Vecteur d'expression selon l'une quelconque des revendications 29 à 34, qui est un plasmide pouvant subir une réplication dans des bactéries gram-négatives.

- Vecteur d'expression selon la revendication 35, qui peut subir une réplication dans une souche de E.
 coli.
- 37. Vecteur d'expression pEV1, -2 ou -3/env 44-640.
- 38. Vecteur d'expression pEV1, -2 ou -3/env 205-640.

25

35

50

- 39. Transformant portant un vecteur d'expression selon l'une quelconque des revendications 29 à 38.
- 40. Transformant selon la revendication 39, qui est une souche de E. coli.
 - 41. Transformant selon la revendication 40, qui est une souche de E. coli MC 1061.
 - 42. Anticorps produits contre une protéine obtenue selon les revendications 1 à 5 et 26.
 - 43. Anticorps selon la revendication 42, qui sont des anticorps monoclonaux.
 - 44. Vaccin déclenchant une immunité au SIDA, comprenant comme principe actif une protéine obtenue selon les revendications 1 à 5 et 26.
 - 45. Utilisation d'une protéine selon la revendication 1 pour préparer un vaccin d'immunisation protectrice.

FIGURE 1

	·	
1	ATTCTGCAACAACTGCTGTTTATCCATTTTCAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCG	69
70	ACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGC	138
139		207
208	AAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGAAGACCTCCTCAAGGCAGTCAGA	276
277	A A A STATE OF THE OWN	345
346	The state of the s	414
415	THE PROPERTY OF THE PROPERTY O	483
484	The state of the s	552
553	ATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAA	621
	ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA	690
691	THE TOTAL PROPERTY OF THE PROP	759
	ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG	828
829	The state of the s	897
898	The state of the s	966
967	The state of the s	1035
1036	The state of the s	1104
1105		1173
1174	The state of the s	1242
1243		1311
1312	GACAATGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATT	1380
	THE PROPERTY OF THE PROPERTY O	
450	AATATGAGACAAGCACATTGTAACATTAGTAGAGCAAAATGGAATGCCACTTTAAAACAGATAGCTAGC	1518
519	AAATTAAGAGAACAATTTGGAAATAATAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA	1587
588	ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT	1656
657	ACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAG	1725
726	CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC	1794
.795	AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC	1863
864	AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA	1932
933	The state of the s	2001
2002	GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC	2070
	GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT	2139
140	TTGCTGAGGGCTATTGAGGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG	2208
209	GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA	2277
278		2346
347	AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATT	2415
	GAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTG	
485	TGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTG	2553
	GTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTGTAGTGAATAGAGTTAGGCAGGGATATTCACCATTA	2622
623	TCGTTTCAGACCCACCTCCCAATCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGA	2691
	${\tt GAGAGAGAGAGAGAGCGATCCATTCGATTAGTGAACGGATCCTTAGCACTTATCTGGGACGATCTGCGG}$	2760
761	${\tt AGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTT}$	2829
830	$\tt CTGGGACGCGGGGGGAGCCCTCAAATATTGGTGGAATCTCCTACAATATTGGAGTCAGGAGCTA$	
899	AAGAATAGTGCTGTTAGCTTGCTCAATGCCACAGCTATAGCAGTAGCTGAGGGGACAGATAGGGTTATA	2967
968	GAAGTAGTACAAGAAGCTTATAGAGCTATTCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGG	3036
	${\tt ATTTTGCTATAAGATGGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTGCTGTAAGGGAAAG}$	3105
106	AATGAGACGAGCTGAGCCAGCAGCAGCAGCAGCAGCATCTCGAGA	3156


FIGURE 2 (3 pages)

	٠ ٦		•									50
HXB-3	MRV	KEK	-YQHI	LWRWGI	NRWGTI	MLLGI	MLMI	CSAT:	EKLW	VTV	VYYGVPV W I	EATT
BH-10												
BH-8											F .	
LAV ARV-2	к	CMD D	٠,		K		I					
ARV-Z	K	GTRRI	N	-		-					-	
	51			•							100	
HXB-3	TLF	CASDAKA	YDTEV	HNVW	THAC	/PTDI	NPO	EVVL	VNVT	ENE	NMWKNDM	
BH-10				. 0			_					
BH-8												
LAV ARV-2									_			
ARV-2		R						(G		N	
		*										
	101											150
HXB-3	VEO	MHEDIISI	WDOS	LKPCV	KLTPI	cvsi	KCTI	DLKNI	חייים	NSS	SSGR	MIME
BH-10	_										501	
BH-8												
LAV		_						G 1		•		M
ARV-2		Q				T	N	G I	Ą		NWKEEI	
	151							•				200
HXB-3	KGE	I KNCSFN I	STSI	RGKVC	KEYAF	FYKL	DIII	P I DNI)T	TSY	TLTSC	NTSV
BH-10	•			_					-			
BH-8			K									
LAV			_									_
ARV-2			T .	DI	N L	RN	vv	F	AST	N	NYRLIH	R
											•	
	201										250	
HXB-3	ITO	ACPKVSFE	PIPI	HYCAP	AGFAI	LKCN	Inkte	NGTO	ያ የ	NVS	туостна	
BH-10											11201110	
BH-8												
LAV								A				
ARV-2				T				K				
	251	÷									300	
HXB-3	TRPI	/VSTQLLL	NGST	ווחקקע	VIRSV	חשתו	NIZVT	. T T V A	1 NIT	:VF	INCTEEN	
BH-10	7111.		.1435	V	viksv A		MUV 1	TIV	Q Q	J V Ľ	INCIREN	
BH-8					••				ď			
LAV					· A				Q			
ARV-2	1				D	N			E	A		

	301 350
HXB-3 BH-10 BH-8	NNTRKKIRIQRGPGRAFVTIGKIGNMRQ-AHCNISRAKWNATLKQIASKLR S N D D
LAV ARV-2	S SY HTRIGDIRK QNEVK
	351 400
HXB-3 BH-10 BH-8	EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTW
LAV ARV-2	VN MR TN-RLNH
	401 450
HXB-3 BH-10 BH-8	STEGSNNTEGSDTITLPCRIKQFINMWQEVGKAMYAPPISGQIRCSSNIT K I K I
LAV ARV-2	K N I I G S
٠	451 500
HXB-3 BH-10	GLLLTRDGG-NNNNGSEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTK - S E
BH-8 LAV	- S E
ARV-2	T VT DT V I I
	501 550
HXB-3 BH-10	AKRRVVQREKRAVGI-GALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQ
BH-8	<u> </u>
LAV ARV-2	- R V M V L
-,	-551 600
HXB-3 BH-10 BH-8 LAV ARV-2	QQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSG G V R
MR V - 2	Ψ

```
601
                                                          650
 HXB-3
         KLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQ
BH-10
                                  NM
 BH-8
                                  NM
 LAV
                                  NM
 ARV-2
                              D
                                 DNM
                                       QE
                                                  NT YT
       651
                                                          700
HXB-3 NQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
BH-10
BH-8
LAV
                                           I
ARV-2
                                 S
      701
                                                          750
HXB-3
        VLSVVNRVRQGYSPLSFQTHLPIPRGPDRPEGIEEEGGERDRDRSIRLVN
BH-10
BH-8
            I
                               N
LAV
            I
                               T
ARV-2
                            R
                               V
                                        D
                                                            D
      751
                                                          800
        GSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLL
HXB-3
BH-10
BH-8
LAV
ARV-2
         F
               E
                           R
                                    AA T
                                          I
                                                          S.
      801
                                                          850
HXB-3
        QYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQEAYRAIRHIPRRIRQG
BH-10
                                            G.
BH-8
                                           A
LAV
                                            G C
ARV-2
           I
                               T
                                         AR
                                                  L H
      851 856
HXB-3
        LERILL
BH-10
BH-8
LAV
           L
      " - " designates a deletion of one amino acid. An empty space
```

denotes identity with HXB-3 sequence.




<u>Figure 4</u>

a b c d e
kD
-93

68
-45

35
-31

Figure 5



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

FIGURE 6A


METAR


VallysGluLysTyrGlnHisleuTrpArgTrpGlyTrpArgTrpGlyThrMEILeuLeuGlyMEILeu METIleCysSerAlaThrGluLysLeuTrpValThrValTyrTyrGlyValProValTrpLysGluAla ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerValIleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThr#ETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaVaiProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrTrpHETGluTrpAspArgGluIleAsnAsnTyrThrSerLeuIleHisSerLeuIle GluGluSerGlnAsnGlnGluLysAsnGluGlnGluLeuLeuGluLeuAspLysTrpAlaSerLeu TrpAsnTrpPheAsnIleThrAsnTrpLeuTrpTyrIleLysLeuPheIleMETIleValGlyGlyLeu ValGlyLeuArgIleValPheAlaValLeuSerValValAsnArgValArgGlnGlyTyrSerProLeu SerPheGlnThrHisLeuProIleProArgGlyProAspArgProGluGlyIleGluGluGluGluGlyGly GluArgAspArgAspArgSerIleArgLeuValAsnGlySerLeuAlaLeuIleTrpAspAspLeuArg SerLeuCysLeuPheSerTyrHisArgLeuArgAspLeuLeuLeuIleValThrArgIleValGluLeu LeuGlyArgArgGlyTrpGluAlaLeuLysTyrTrpTrpAsnLeuLeuGlnTyrTrpSerGlnGluLeu LysAsnSerAlaValSerLeuLeuAsnAlaThrAlaIleAlaValAlaGluGlyThrAspArgValIle GluValValGlnGluAlaTyrArgAlaIleArgHisIleProArgArgIleArgGlnGlyLeuGluArg IleLeuLeu

FIGURE 6B

AMINO ACID DISTRIBUTION OF AIDS ENV PROTEIN

	Name	Number of Residues
A	Alanine	47
В	Aspartic Acid-Asparagine	. 0
C	Cysteine	21
D	Aspartic Acid	27
E	Glutamic Acid	49
F	Phenylalanine	26
G	Glycine	58
H	Histidine	14
I	Isoleucine	63
K	Lysine	44
L	Leucine	83
M	Methionine	17
N	Asparagine	60
P	Proline	29
Q	Glutamine	42
R	Arginine	52
S	Serine	57
T	Threonine	60
V	Valine	56
W	Tryptophan	31
Y	Tyrosine	20
7.	Glutamine-Glutamic Acid	0





(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



EP 0 199 301 B2

(12)

NEW EUROPEAN PATENT SPECIFICATION

- (45) Date of publication and mention of the opposition decision: 09.07.1997 Bulletin 1997/28
- (45) Mention of the grant of the patent: 29.12.1993 Bulletin 1993/52
- (21) Application number: 86105371.8
- (22) Date of filing: 18.04.1986

(51) Int. Cl.⁶: **C07K 14/16**, C12N 15/00, C12P 21/02, C12P 21/00, G01N 33/569, A61K 39/21

(54) Recombinant acquired immune deficiency syndrome (AIDS) viral envelope protein fragments and method of testing for AIDS

Rekombinantes Viren-Überzugsprotein assoziiert mit "Acquired Immune Deficiency Syndrome" (AIDS) und Verfahren zur Testung von AIDS

Protéine recombinante d'enveloppe du virus du syndrome d'immunodéficience acquise (SIDA) et procédé pour l'analyse du SIDA

- (84) Designated Contracting States: AT BE CH DE FR GB IT LI NL SE
- (30) Priority: 19.04.1985 US 725021
- (43) Date of publication of application: 29.10.1986 Bulletin 1986/44
- (73) Proprietors:
 - F. HOFFMANN-LA ROCHE AG 4002 Basel (CH)
 - THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN **SERVICES** Washington, DC 20201 (US)
- (72) Inventors:
 - Crowl, Robert Mitchell Cedar Grove, N.J. 07009 (US)
 - · Gallo, Robert Charles Bethesda Maryland 20817 (US)
 - Reddy, Eragam Premkumar Montclair, N.J. 07042 (US)
 - · Shaw, George Mead Birmingham Alabama 35243 (US)
 - Wong-Staal, Flossle Yeeching Germantown Maryland 20874 (US)

- (74) Representative: Lederer, Franz, Dr. et al Lederer, Keller & Riederer Patentanwälte Prinzregentenstrasse 16 80538 München (DE)
- (56) References cited:

EP-A- 0 152 030 EP-A- 0 181 150

EP-A-0 173 529 WO-A-84/04327

US-A- 4 520 113

- · SCIENCE, vol. 228, no. 4695, 5th April 1985, pages 93-96; N. CHANG et al.: "Expression in Escherichia coll of open reading frame gene seaments of HTLV-III"
- NATURE, vol. 313, no. 6002, 7th February 1985, pages 450-458; M.A. MUESING et al.: "Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus"
- NATURE, vol. 313, no. 6000, 24th January 1985, pages 277-284, London, GB; L. RATNER et al.: "Complete nucleotide sequence of the AIDS virus, HTLV-III"
- SCIENCE, vol. 226, no. 4679, 7th December 1984, pages 1165-1171; G.M. SHAW et al.: "Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired Immune deficiency syndrome"

Description

The present invention relates to an envelope protein fragments of an acquired immune deficiency syndrome (AIDS) virus, essentially free of other proteins, with the amino acid sequence:

5

10

15

20

ValTrpLysGluAla Th:ThrThrLeu?heCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HishlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METTrolysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLvs ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerileArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspTh:ThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCys?roLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGinLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyPrcGlyArgAlaPheValThrIleGlyLysIleGly AshMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAshAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IlevalThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AshGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAshTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlrArg GluLyshrqAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaxlaserMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlakrgileLeuklaValGlukrgTyrLeuLyskspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AshHisThrTrpMETGluTrpAspArgGluIleAshAshTyrThrSer

35

40

45

55

30

or

CysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuAsnGlySerLeuAlaGluGluValValIleArgSerValAsnPheThr AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsaMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAshSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrleuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AshHisThrThrTrpMETGluTrpAspArgGluIleAshAshTyrThrSer

or

5

10

15

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

20

25

30

METTYrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

35

METArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGinLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer.

45

40

It also relates to an expression vector comprising a gene coding for an envelope protein as defined above, to transformants and methods for the production of said proteins and a method for detecting the presence of AIDS antibodies in human blood.

Background of the Invention

From 1981 to date, there have been more than eight thousand (8,000) people diagnosed as having acquired immune deficiency syndrome (AIDS) [N.Y. Times. A-11 January 11, 1985]. AIDS has been characterized by the onset of severe opportunistic infections secondary to an effect on the body's immune system [Gottlieb. M.S. et al., "Pneumocystis Carinii Pneumonia and Mucosal Candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency", N. Eng. J. Med. 305, 1426-1431 (1981)]. The disease has been found in male homosexuals, patients receiving blood products, intravenous drug addicts, and individuals originating from Haiti and Central Africa

[Pot, P. et al., "Acquired immunodeficiency syndrome in a heterosexual population in Zaire", Lancet 11, 65-69 (1984)]. The causative agent was suspected to be of viral origin as the epidemiological pattern of AIDS was consistent with a transmissable disease. At least three (3) retroviruses have been isolated from cultured T-cells of several patients with AIDS, or from white blood cells of persons at risk for the disease. A novel human retrovirus called lymphadenopathyassociated virus (LAV) was discovered and its properties were consistent with its etiological role in AIDS. That virus was isolated from a patient with lymphadenopathy and hence the name [Montagnier, L. et al., "A New Human T-lymphotropic retrovirus: characterization and possible role in lymphadenopathy and acquired immune deficiency syndromes. In Human T-Cell Leukemia/Lymphoma Virus, R.C. Gallo, M. Essex and L. Gross, eds. (Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory) pp. 363-370]. Other human retroviruses, specifically two subgroups of the human T-cell leukemia/lymphoma/lymphotropic virus, types I and III have been isolated [HTLV I: Poiesz, B.J. et al., "Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma", PNAS (USA) 77, 7415-7419 (1980); HTLV-III: Popovic, M. et al., "Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS", Science 224, 497-500 (1984)]. Still another virus, the AIDS-associated retrovirus (ARV), was proposed as the causative agent (Levy, J.A. et al., "Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS", Science 225, 840-842 (1984)]. Both the HTLV-III and ARV retroviruses display biological and sero-epidemiological properties similar to LAV [Levy J.A. et al., supra, Popovic, M. et al., supra]. As seen from the above, at least three (3) retroviruses have been postulated as the etiologic agent of AIDS: LAV; ARV; and, HTLV subtypes I and III.

LAV, HTLV III and ARV-II genomes have been molecularly cloned [Schüpbach, J. et al., "Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS", Science 224, 503-505 (1984); Alizon, M. et al., "Molecular Cloning of lymphadenopathy - associated virus", Nature 312, 757-760 (1984)]. The complete nucleotide sequence of the proviral genome of LAV, ARV and HTLV III has been determined [Ratner, L. et al., "Complete nucleotide sequence of the AIDS virus, HTLV III", Naure 313, 277-284 (1985); Sanchez-Pescador, R. et al., "Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2)", Science 227, 484-492 (1985); Wain-Hobson, S. et al., "Nucleotide sequence of the AIDS virus, LAV", Cell 40, 9-17 (1985)].

Shaw et al., Science <u>226</u>, 1165-1171 (1984), describes the molecular cloning and analysis of the full-length HTLV-III provinal genome comparing various DNA-clones.

Another analysis of the HTLV-III genom is shown by Muesing et al., Nature 313, 450-458 (1985).

. Chang et al., Science <u>228</u>, 93-96 (1985), describes the expression of small DNA fragments fused to DNA sequences encoding the λ Cl protein and β -galactosidase resulting in unpurified env polypeptides fused to the λ Cl protein at their amino termini and to β -galactosidase at their carboxyl termini.

One reason for the difficulty in determining the etiologic agent of AIDS was due to the reactivity of various retroviral antigens with serum samples from AIDS patients. For example, serum samples from AIDS patients have been shown to react with antigens of HTLV I and HTLV III [HTLV-I: Essex, M. et al., "Antibodies to Cell Membrane Antigens Associated with Human T-Cell Leukemia Virus in Patients with AIDS", Science 220, 859-862 (1983); HTLV-III: Sarngadharan, M.G. et al., "Antibodies Reactive With Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients With AIDS", Science 224, 506-508 (1984)]. Envelope gene products of HTLV demonstrated antigenicities cross-reactive with antibodies in sera from adult T-cell leukemia patients [Kiyokawa, T. et al., "Envelope proteins of human T-cell leukemia virus: Expression in Escherichia coli and its application to studies of env gene functions", PNAS (USA) 81, 6202-6206 (1984)]. Adult T-cell leukemias (ATL) differ from acquired immune deficiency syndrome (AIDS) in that HTLV-I causes Tcell malignancies, that is uncontrolled growth of T-cell. In AIDS rather than cell growth there is cell death. In fact this cytopathic characteristic of HTLV III was critical to determining ultimately the specific retroviral origin of the disease. Thus the etiologic agent of AIDS was isolated by use of immortalized human neoplastic T cell lines (HT) infected with the cytopathic retrovirus characteristic of AIDS, isolated from AIDS afflicted patients. Seroepidemiological assays using this virus showed a complete correlation between AIDS and the presence of antibodies to HTLV III antigens [Sarngadharan, M.G. et al., supra; Schupbach, J. et al., supra]. In addition, nearly 85% of patients with lymphadenopathy syndrome and a significant proportion of asymptomatic homosexual men in AIDS endemic areas were also found to carry circulating antibodies to HTLV III. Taken together, all these data indicate HTLV III to be the etiologic agent for AIDS.

Until the successful culturing of AIDS virus using H-9 cell line [PCT application, publication no. WO 85/04897] the env AIDS protein of the AIDS virus had not been isolated, characterized or synthesized. This in major part is due to the fact that the virus is cytopathic and thus isolation of the virus was not possible [Popovic, M. et al., supra]. Once the human T-cell line resistant to the cytopathic effects of the virus was discovered, a molecular clone of proviral DNA could be achieved.

The need for a sensitive and rapid method for the diagnosis of AIDS in human blood and its prevention by vaccination is very great. Virtually all the assays/tests presently available are fraught with errors. In fact the Center for Disease Control (CDC) has indicated that presently available tests be used solely for screening units of blood for antibody to HTLV III. The CDC went further by stating that the presently available ELISA tests can not be used for general screening of high risk pupulations or as a diagnostic test for AIDS [Federal Register 50(48), 9909, March 12, 1985]. The errors have been traced to the failure to use a specific antigenic protein of the etiologic agent for AIDS. The previously used

proteins were derived from a viral lysate. Since the lysate is made from human cells infected with the virus, i.e. the cells used to grow the virus, the lysate will contain human proteins as well as viral proteins. Thus preparation of a pure antigen of viral protein is very difficult. The antigen used produced both false positive and false negative results [Budiansky, S., "AIDS Screening, False Test Results Raise Doubts", Nature 312, 583(1984)]. The errors caused by the use of such lysate proteins/peptides can be avoided by using a composition for binding AIDS antibodies which is substantially free of the non-AIDS specific proteins. Compositions that are substantially pure AIDS envelope protein can be used as antigens.

The AIDS envelope protein of the instant invention has been established to have conserved epitopes which permit its use to screen for, diagnose and/or prevent by vaccination the infection by AIDS virus. The instant invention demonstrates that the envelope protein with its conserved epitopes includes all the variants which have been claimed as the sole etiologic agent.

The envelope AIDS protein of the present invention may be produced by conventionally known methods. The processes by which the novel protein may be produced can be divided into three groups: (1) chemical synthesis; (2) preparation of a gene prepared by chemical synthesis which is inserted into a host and a protein is produced by the host; and (3) a corresponding gene obtained biotechnically is inserted into a host and a protein is produced by the host.

In one embodiment of this invention, recombinant DNA techniques are utilized by which env AIDS DNA from a natural source is introduced into a cell to produce the env AIDS protein. One method of obtaining DNA which encodes env AIDS is to read the genetic code in reverse and synthesize an oligodideoxynucleotide which should encode the env AIDS amino acid sequence. As the env protein has not been isolated or characterized this approach cannot be pursued.

Alternatively gene expression can be obtained using recombinant DNA technology if DNA isolated from natural sources is used instead of synthetic DNA.

Summary of the Invention

25

This invention is directed to the engineering of HTLV III env gene into suitable expression vectors; transformation of host organisms with such expression vectors; and production of envelope AIDS protein (env AIDS) by culture of such transformed cells. Another aspect of the present invention relates to the isolation and use of the resulting recombinant env AIDS protein.

Another aspect of the present invention is the identification and determination of the proviral DNA sequence. More specifically, this aspect of the invention relates to determination and comparison of the proviral nucleotide sequence of the envelope genes of the purported etiologic agent of AIDS i.e. lymphadenopathy-associated virus (LAV), AIDS-associated retrovirus (ARV) and the human T-cell leukemia/lymphoma/lymphotropic virus type III (HTLV III).

A further aspect of this invention relates to a diagnostic method for testing human blood for the presence of antibodies to the env AIDS protein. This aspect of the invention overcomes the problems of all previously used blood tests for AIDS. One of the problems is the use of compositions to bind AIDS antibody which contain proteins or peptides which were not derived solely from the AIDS etiologic agent. A composition using homogeneous envelope AIDS protein of this invention overcomes the nonspecificity of the prior tests or assays. Yet another aspect of this invention is a diagnostic method for detecting and/or determining the presence of the antigen in human blood.

Another aspect of this invention is to use the env AIDS proteins of the instant invention as antigens suitable for providing protective immunity against AIDS when incorporated into a vaccine.

Brief Description of the Drawings

- Fig. 1. The nucleotide sequence of the envelope gene of the HTLV-III provinal genome (HXB-3).
- Fig. 2. Comparison of the amino acid sequence of the env protein of the five purported etiologic agents of AIDS. Amino acid sequences are aligned to give maximum homology.
- Fig. 3. Construction of the pEV/env44-640 expression plasmids. The upper left panel shows a simplified restriction site map of the 3.15 Kb EcoRI-Xhol segment of the HTLV-III genome which contains the env coding region (cross-hatched arrow). The right panel shows the structure and pertinent sequences of the pEV-vrf plasmids. The solid black region represents the synthetic ribosome binding site sequences upstream of the ATG initiation codon (overlined). See Example 2 for a detailed description of the env expression plasmid constructions.
- Fig. 4. Western blot analysis of env coded antigens produced in E. coli. Total bacterial proteins were resolved by SDS-PAGE, electro-blotted onto a nitrocellulose filter, and env encoded proteins were detected by reacting with human sera as described in Example 5: a) negative control, cells containing pJCL-E30 (p21T) induced at 42° C for 2 hours; b) uninduced control, cells containing pEV3/env44-640 maintained at 30° C; c) pEV3/env44-640; d) pEV1/env44-640; and e) pEV3/env205-640 induced at 42° C for 2 hours.
- Fig. 5. Recognition of bacterially synthesized HTLV-III env gene products by antibodies in AIDS patient sera. Bacterial lysates containing recombinant env proteins were subjected to Western blot analysis as described in Example 5.

Individual strips were then incubated with a 1000-fold dilution of individual sera followed by treatment with 1251-labeled protein A. (upper part) Serum samples were from the following donors: (lane 1) normal healthy donor; (lanes 2-18) AIDS patient sera collected from the West Coast of the USA. (Lower part) Serum samples were taken from the following donors: (lane 1) donor found to be HTLV-1(+) by Elisa using disrupted virus; (lanes 4, 5, 11 and 15) healthy, normal donors; (lanes 2, 3, 6, 8, 10, 12, 13, 14, 16, 17 and 18) AIDS patient sera from the East Coast of the USA.

Fig. 6A. The amino acid sequence of the AIDS envelope protein.

Fig. 6B. The amino acid distribution of the AIDS envelope protein.

Fig. 7. Construction of the expression vector pRC23. The Shine-Dalgarno sequence (SD) is overlined and the location of the synthetic ribosome binding site sequence in the plasmid is represented by the solid black segment. The plasmid contains the entire sequence of pBR322 and thus confers resistance to both ampicillin (amp^R) and tetracycline (tet^R).

Fig. 8. Construction of the pEV-vrf vectors. The synthetic oligonucleotides for each plasmid which were placed downstream of the SD sequence in pRC23 are shown with the locations of the restriction enzyme cleavage sites. The ATG initiation codon is overlined, and the placement of the additional A-T base pairs is designated by the rectangle. The plasmids confer resistance to ampicillin only.

Detailed Description of the Invention

In the description the following terms are employed:

Nucleotide: A monomeric unit of DNA consisting of a sugar moiety (pentose), a phosphate, and either a purine or pyrimidine base (nitrogenous heterocyclic). The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose). That combination of a base and a sugar is called a nucleoside. Each nucleotide is characterized by its base. The four DNA bases are adenine ("A"), guanine ("G"), cytosine ("C") and thymine ("T").

DNA Sequence: A linear array of nucleotides connected one to the other by phosphodiester bonds between the 3' and 5' carbons of adjacent pentoses.

Codon: A DNA sequence of three nucleotides (a triplet) which encodes through mRNA an amino acid, a translation start signal or a translation termination signal. For example, the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG encode for the amino acid leucine ("Leu"). TAG, TAA and TGA are translation stop signals and ATG is a translation start signal.

Reading Frame: The grouping of codons during translation of mRNA into amino acid sequences. During translation the proper reading frame must be maintained. For example, the sequence GCTGGTTGTAAG may be translated in three reading frames or phases, each of which affords a different amino acid sequence:

GCT GGT TGT AAG=Ala-Gly-Cys-Lys

G CTG GTT GTA AG=Leu-Val-Val

GC TGG TTG TAA G=Trp-Leu-(STOP)

<u>Polypeptide</u>: A linear array of amino acids connected one to the other by peptide bonds between the α -amino and carboxy groups of adjacent amino acids.

Genome: The entire DNA of a cell or a virus. It includes inter alia the structural genes coding for the polypeptides of the substance, as well as operator, promoter and ribosome binding and interaction sequences, including sequences such as the Shine-Dalgarno sequences.

Structural Gene: A DNA sequence which encodes through its template or messenger RNA ("mRNA") a sequence of amino acids characteristic of a specific polypeptide.

<u>Transcription</u>: The process of producing mRNA from a structural gene.

45 <u>Translation</u>: The process of producing a polypeptide from mRNA.

> Expression: The process undergone by a structural gene to produce a polypeptide. It is a combination of transcription and translation.

Plasmid: A circular double-stranded DNA molecule that is not a part of the main chromosome of an organism containing genes that convey resistance to specific antibiotics. When the plasmid is placed within a unicellular organism, the characteristics of that organism may be changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for tetracycline resistance (Tet^R) transforms a cell previously sensitive to tetracycline into one which is resistant to it. A cell transformed by a plasmid is called a "transformant".

Cloning Vehicle: A plasmid, phage DNA or other DNA sequences which are able to replicate in a host cell, which are characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without attendant loss of an essential biological function of the DNA, e.g., replication, production of coat proteins or loss of promoter or binding sites, and which contain a marker suitable for use in the identification of transformed cells, e.g., tetracycline resistance or ampicillin resistance. A cloning vehicle is often called a vector.

Cloning: The process of obtaining a population of organisms or DNA sequences derived from one such organism

6

20

25

35

30

40

or sequence by asexual reproduction.

Glutamine or Glutamic Acid.

Recombinant DNA Molecule or Hybrid DNA: A molecule consisting of segments of DNA from different genomes which have been joined end-to-end outside of living cells and have the capacity to infect some host cell and be maintained therein.

The nomenclature used to define the peptides or proteins is that used in accordance with conventional representation such that the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus to the right. By natural amino acid is meant one of the amino acids commonly occurring in natural proteins comprising Gly, Ala, Val, Leu, Ile, Ser, Thr, Lys, Arg, Asp, Asn, Glu, Gln, Cys, Met, Phe, Tyr, Pro, Trp and His. By NIe is meant norleucine, and by Nva is meant norvaline. Where L and D forms are possible, it is the L-form of the amino acid that is represented unless otherwise expressly indicated. In addition, amino acids have been designated by specific letters of the alphabet such that: A=Alanine; B = Aspartic Acid or Asparagine; C = Cysteine; D = Aspartic Acid; E = Glutamic Acid; F = Phenylalanine; G = Glycine; H = Histidine; I = Isoleucine; K = Lysine; L = Leucine; M = Methionine; N = Asparagine; P = Proline; Q = Glutamine; R = Arginine; S = Serine; T = Threonine; V = Valine; W = Tryptophan; Y = Tyrosine; Z =

In accordance with the present invention, the search for the envelope protein of the etiologic agent for acquired immune deficiency syndrome (AIDS) has led to the isolation and sequencing of the proviral gene of the AIDS virus. It has now been discovered, for what is believed to be the first time that the postulated etiologic agents of AIDS, lymphadenopathy-associated virus (LAV), AIDS-associated retrovirus (ARV) and human T-cell leukemia/lymphoma/lymphotropic virus (HTLV III) are in fact variants of the same virus. For purposes of this invention, in the specification and claims the virus causing AIDS will be referred to herein as AIDS virus. AIDS virus will be understood to include the variants which have been postulated as the causative agents of AIDS, namely LAV, ARV and HTLV III. The envelope protein of the AIDS virus (env AIDS) is a 97,200 dalton protein with 32 potential N-glycosylation sites. Nucleotide sequence analysis of the AIDS envelope gene of the putative etiologic agents of AIDS demonstrates that all the viruses are variants of the same virus. That means that there is approximately 1 to 20% divergence or variation from the sequence of the envelope gene of the triuses LAV and ARV-2. The amino acid sequence of the env AIDS is set forth in Figure 6(a). The amino acid distribution is set forth in Figure 6(b).

The nucleotide sequence of the envelope gene is shown in Figure 1. The proviral DNA sequence, using methods known to one of ordinary skill in the art such as the chemical degradation method of Maxam and Gilbert of the M13 sequencing system of Messing which is a modification of the dideoxy nucleotide chain termination method of Sanger, was analyzed to determine the location of the region coding for the envelope protein. The location of an open reading frame, i.e. a long stretch of triplet codons not interrupted by a translational stop codon, for the envelope gene was determined. The open reading frame coding for the env gene is 863 amino acids and contained an ATG codon at the eighth position from the 5' end of the reading frame. The ATG codon is known to be a universal translation-initiation codon.

The integrated proviral genome of HTLV-III was cloned from the genomic DNA of H9 cells infected with HTLV-III [Shaw, G.M. et al., "Molecular characterization of Human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome", Science 226, 1165-1171 (1984)]. Since the HTLV-III provirus was found to lack Xbal restriction sites, a genomic library was constructed by using Xbal digested H9/HTLV-III DNA. There are several methods available to one of ordinary skill in the art for screening the bacterial clones containing the AIDS env protein cDNA. These include, for example, RNA selection hybridization, differential hybridization with a synthetic probe or screening for clones that produce the desired protein by immunological or biological assays. From the genomic library, colonies of cells transformed with DNA that contains the HTLV III sequences were selected by hybridization screening of the library with HTLV III cDNA. The DNA insert of the hybridization-positive clone, HXB-3, was excised from the plasmid DNA and sequenced.

The predicted product of the env gene shares many features in common with the envelope gene products of other retroviruses. Thus, a hydrophobic region is seen in the middle of the protein (amino acids 519-534) which includes a processing site for the cleavage of the precursor protein into exterior and transmembrane proteins. Similarly, the amino terminal end contains a short stretch of hydrophobic amino acids (amino acids 17-37) which constitutes a potential signal sequence. The HTLV-III envelope precursor differs from the other retroviral envelope protein precursors in that it contains an additional stretch of 180 amino acids at the carboxy terminus.

Polymorphism within the Envelope Region of AIDS Virus

The recent publication of the nucleotide sequences of LAV, ARV-2 and HTLV-III [Ratner, L., et al., supra; Sanchez-Pescadon, R., et al., supra; Wain-Hobson, S., et al., supra] allows a detailed comparison of these various isolates obtained from AIDS patients from different parts of the world. HTLV-III clones were isolated from AIDS patient lymphocytes obtained from the east coast of the United States, while LAV was isolated from a French man and ARV was isolated from a patient in California. A comparison of the sequence data confirms the earlier observations made using restriction enzyme site analysis which showed approximately 10% variation. The present analysis shows that the vari-

ous isolates show the greatest amount of conservation in the gag and pol regions while the most divergence occurs in the env region. A comparison of the five env sequences is presented in Figure 2. With respect to the envelope gene, HTLV-III and LAV are more closely related to each other than the ARV clone. Approximately 1.6% divergence was observed between the HTLV-III (HXB-3) and LAV sequence. Among the HTLV sequences, the divergence was about 1.6%. However, approximately 1.7% divergence was observed between HTLV-III and ARV-2 and this was more pronounced in the extracellular region of the envelope gene product (Figure 2). This high rate of divergence could be due to the geographical location from where the two isolates were derived or the time of isolation of these variants. ARV-2 was isolated from the west coast of the United States more recently. The HTLV-III isolates for which the nucleotide sequences have been determined were all obtained from the east coast of the United States a year earlier. LAV was obtained from a French patient who appears to have acquired the virus in New York about the same period. The observed differences in the sequence probably reflect divergent evolution of strains separated in time or geography or both. Within the env region, the highest level of divergence is in the extracellular portion of the protein.

Expression Vector

15

A wide variety of host/cloning vehicle combinations may be employed in cloning the double-stranded DNA. For example, useful cloning vehicles may consist of segments of chromosomal, nonchromosomal and synthetic DNA sequences, such as various known bacterial plasmids, e.g. plasmids from E. coli such as pBR322, phage DNA, and vectors derived from combinations of plasmids and phage DNAs such as plasmids which have been modified to employ phage DNA or other expression control sequences or yeast plasmids. Useful hosts may include microorganisms, mammalian cells, plant cells and the like. Among them microorganisms and mammalian cells are preferably employed. As preferable microorganisms, there may be mentioned yeast and bacteria such as Escherichia coli, Bacillus subtilis, Bacillus stearothermophilus and Actinomyces. The above-mentioned vectors and hosts may also be employed for the production of a protein from a gene obtained biologically as in the instant invention. Of course, not all host/vector combinations may be equally efficient. The particular selection of host/cloning vehicle combination may be made by those of skill in the art after due consideration of the principles set forth without departing from the scope of this invention.

Furthermore, within each specific cloning vehicle, various sites may be selected for insertion of the double-stranded DNA. These sites are usually designated by the restriction endonuclease which cuts them. For example, in pBR322 the EcoRI site is located just outside the gene coding for ampicillin resistance. Various sites have been employed by others in their recombinant synthetic schemes. Several sites are well recognized by those of skill in the art. It is, of course, to be understood that a cloning vehicle useful in this invention need not have a restriction endonuclease site for insertion of the chosen DNA fragment. Instead, the vehicle could be joined to the fragment by alternative means.

The vector or cloning vehicle and in particular the site chosen therein for attachment of a selected DNA fragment to form a recombinant DNA molecule is determined by a variety of factors, e.g., number of sites susceptible to a particular restriction enzyme, size of the protein to be expressed, susceptibility of the desired protein to proteolytic degradation by host cell enzymes, contamination of the protein to be expressed by host cell proteins difficult to remove during purification, expression characteristics, such as the location of start and stop codons relative to the vector sequences, and other factors recognized by those of skill in the art. The choice of a vector and an insertion site for a particular gene is determined by a balance of these factors, not all selections being equally effective for a given case.

There are several known methods of inserting DNA sequences into cloning vehicles to form recombinant DNA molecules which are equally useful in this invention. These include, for example, direct ligation, synthetic linkers, exonuclease and polymerase-linked repair reactions followed by ligation, or extension of the DNA strand with DNA polymerase and an appropriate single stranded template followed by ligation.

The cloning vehicle or vector containing the foreign gene is employed to transform a host so as to permit that host to express the protein or portion thereof for which the hybrid DNA codes. The selection of an appropriate host is also controlled by a number of factors recognized by the art. These include, for example, compatibility with the chosen vector, toxicity of proteins encoded by the hybrid plasmid, ease of recovery of the desired protein, expression characteristics, biosafety and costs. A balance of these factors must be struck with the understanding that not all hosts may be equally effective for expression of a particular recombinant DNA molecule.

A preferred embodiment of the instant invention is to express segments of the AIDS env protein in E. coli by inserting restriction fragments isolated from the cloned proviral genome into the versatile pEV-vrf (variable reading frame) expression plasmids (for details of construction see Example 2). These versatile pEV-vrf plasmids are derivatives of pBR322 which contain the phage lambda P_L promoter, a synthetically-derived ribosome-binding site, and convenient cloning sites (EcoRI, BamHI, Clal and HindIII) just down-stream to the initiation codon (Figure 8). A set of three plasmids was constructed to accomodate all three translational reading frames. The P_L promotor is regulated by a temperature-sensitive of repressor encoded on the compatible plasmid pRK248clts [ATCC 33766; Bernard, H.U. and Helinski, D.R., "The use of the λ phage promoter P_L to promote gene expression in hybrid plasmid cloning vehicles", Meth. Enzymol. 68, 482-492 (1979)]. These expression plasmids have been used to produce substantial amounts of several het-

erologous proteins in E. coli including v-bas p21 [Lacal, J.C. et al., "Expression of Normal and Transforming H-ras genes in E. coli and purification of their encoded p21 proteins", PNAS 81, 5305-5309 (1984)] and murine interleukin-1 [Lomedico, P.T. et al., "Cloning and Expression of Murine Interleukin-1 cDNA in E. coli", Nature 312, 458-462 (1984)].

In the present synthesis the preferred initial cloning vehicle is the bacterial plasmid pBR322 (ATCC 37017) and the preferred initial restriction endonuclease sites therein are the EcorRI and HindIII sites (Figure 3). Insertion of proviral DNA contained within the genome of H9 cells into these sites provides a large number of bacterial clones each of which contains one of the proviral DNA genes or fragments thereof present in the genome of H9 cells. Only a very few of these clones will contain the gene for env AIDS or fragments thereof.

The preferred host for initial cloning and expression of the env AIDS gene in accordance with this invention is E. coli MC 1061 [Casadaban, M.J. and Cohen, S.M., "Analysis of Gene Control Signals by DNA Fusion and Cloning in E. coli", J. Mel. Biol., 138, 179-207 (1980)].

The coding sequences for amino acid residues #44 to 640 of the env protein are located downstream of the P_L promoter between the KpnI and HindIII sites on the restriction map as shown in Figure 3. Aside from the location of these convenient restriction sites, these sequences were chosen for bacterial expression experiments because they did not include the amino-terminal signal peptide as well as the hydrophobic transmembrane segment at the carboxyl end. These sequences were excluded to avoid possible toxicity problems which can occur when hydrophobic proteins are over-produced in bacterial cells. In a preferred embodiment of this invention an expression plasmid was constructed that would direct the synthesis of this segment of the env gene product (designated pEV/env 44-640), an intermediate construction was first made by inserting a 2400 bp EcoRI-HindIII fragment between the EcoRI and HindIII sites in the pEV-vrf plasmids. The HTLV-III sequences (600 bp) between the EcoRI and the KpnI site were then removed from the intermediate construction as shown in Figure 3. These plasmid constructions were carried out with all three pEV-vrf plasmids so that subsequent deletions could be made and the correct reading frame maintained. In addition, the constructions made in the incorrect reading frames served as important controls in the expression experiments described below.

In another embodiment of this invention, a second set of expression plasmids were constructed in a similar fashion by deleting sequences between EcoRI and Stul sites which occur 483 bp downstream of the env gene. Again these deletions (designated pEV/env 205-640) were made in all three reading frames. The translation termination codon used in all of the env expression plasmids is presumably an in-frame TAA located 23 bp downstream of the HindIII site in the plasmid. Thus, 8 amino acid residues at the carboxyl terminus are encoded by pBR322 sequences contained within the pEV-vrf expression plasmids.

Expression of ENV AIDS

25

There are several approaches to screen for bacterial clones containing env AIDS cDNA. These include, for example, RNA selection hybridization, differential hybridization, hybridization with a synthetic probe and screening for clones that produce the desired protein by immunological or biological assays. Two methods are available to screen using immunological assay: screening of bacterial colonies for the presence of protein using antibody; and, preferably, the bacterial lysates are electrophoresed, blotted onto a nitrocellulose paper and then probed with the antibody.

In a preferred embodiment of this invention, cultures of the E. coli strain MC 1061 transformed with pRK248clts and the pEV 1, 2, or 3/env 44-640 (or pEV 1, 2 or 3/env 205-640) were grown in M9 medium at 30° C to mid-log phase and then induced by shifting to 42° C for 2 hr. Samples of the bacterial cultures were then taken and subjected to SDS-poly-acrylamide gel electrophoresis, followed by Western blot analysis to detect env proteins. The protein blots were treated with antisera to env AIDS proteins isolated either from immunized rabbits or from AIDS patients previously shown to contain high titer antibodies to AIDS antigens. This was followed by incubation with ¹²⁵I-labelled Staphylococcous aureus protein A, washing and autoradiography. Similar results were obtained with both sera except that the human serum was found to contain much higher titers of anti-HTLV-III antibodies and was devoid of all background reactivity with the E. coli proteins. For this reason human antibodies were used in all subsequent characterization.

Figure 4 shows the pattern of reactivity of the env AIDS proteins synthesized in bacteria (recombinant proteins) with anti-HTLV-III antibodies. The open reading frame in pEV3/env 44-640 encodes a protein that should migrate as a 68 Kd band on the gel. In fact, a 68 Kd band is observed in the lane corresponding to the induced cells containing pEV3/env 44-640 (lane C). However, in addition to the 68 Kd band, these cells synthesized proteins of 35 Kd, 25 Kd and 17 Kd which specifically cross-reacted with anti-HTLV-III antibodies. No HTLV-III cross-reacting bands are evident in the uninduced control (Lane b) or in a second negative control sample (Lane a) of induced cells containing a plasmid that directs the synthesis of v-bas p21 oncogene product (Lacal, J.C. et al., supra). The appearance of multiple bands synthesized from the env gene sequences was an unexpected result. Another unexpected result was the synthesis of env gene products from the plasmid (pEV1/env 44-640) where the insert was placed in the wrong reading frame with respect to the initiator codon immediately downstream of the P_L promoter (Lane d). In this case, E. coli cells containing plasmid pEV1/env. 44-640 synthesized a 63 Kd protein in addition to the 35 Kd, 25 Kd and 17 Kd proteins. These results could be readily explained when the nucleotide sequence of the envelope gene (Fig. 1) was examined. About 155

bases downstream to the KpnI site is an ATG codon which appeared to be utilized for the synthesis of the env gene product by the expression plasmid pEV1/env 44-640. Internal translation initiation is also the likely explanation for the appearance of the 35Kd, 25Kd and 17Kd proteins. Initiation codons which are preceded by so-called Shine-Dalgarno sequences (AGGA) are found within the env coding region at locations that are consistent with the sites of the observed protein products.

To confirm the above interpretation and to rule out the possibility that the smaller proteins are not formed as a result of premature termination or from proteolytic cleavage of the larger product, another deletion mutant in which sequences between the KpnI and StuI sites were deleted were constructed. This expression plasmid contains the coding sequences from amino acid positions 205-640 which could code for a protein of 49 Kd. Analysis of the proteins induced from E. coli harboring this plasmid verified that, in fact, these cells synthesize a 49 Kd protein in addition to the 35 Kd, 25 Kd and 17 Kd proteins (lane e, Fig. 4). From these results, it was concluded that pEV3/env 44-640 expression plasmid directs the synthesis of a 68 Kd protein in addition to several additional smaller polypeptides (i.e., 35Kd, 25Kd and 17Kd) produced from all of the env expression plasmids resulting from internal translation initiation within the env gene.

15 Screening of AIDS SERA

Because anti-HTLV-III antibodies are found in more than 90% of the AIDS patients, it was of interest to see if the bacterially synthesized env gene products could be used as diagnostic tools for the detection of these antibodies. For this analysis, total cell protein from an induced bacterial culture was fractionated by SDS-PAGE and transferred to a nitrocellulose filter by Western blotting technique. Strips of the filter containing transferred proteins were reacted with 1000-fold diluted human sera, and the antigen-antibody complexes formed were detected by incubation of the strips with 125-I-labelled Staphylococus aureus protein A followed by autoradiography. Prominent bands corresponding to reaction of the antibody to the 68 Kd, 35 Kd, 25 Kd and 17 Kd proteins were consistently observed when the serum used was from patients with AIDS syndrome. The results of such assays with different human sera are presented in Figure 5. The negative controls used were normal human sera and serum from a patient with HTLV-I infection. No reaction was observed with sera from healthy individuals or from HTLV-I infected individuals. The patient sera were derived from all parts of the United States including California and all AIDS patients' sera tested so far were found to be positive. The results suggest that these antibodies are mainly directed against the protein back-bone of the molecule.

It appears, therefore, that the env gene products constitute the best diagnostic reagents for the detection of AIDS associated antibodies. The env gene product of the instant invention encompasses a large portion of the protein molecule and contains both the conserved and divergent portions of the molecule. In spite of the divergence observed between HTLVIII and ARV-2 sequences the recombinant env proteins of the instant invention synthesized by the bacteria react with AIDS patient sera derived from both geographical locations of the United States. One hundred percent (100%) of AIDS patient sera (50 individual samples, 25 derived from the East Coast of the United States and 25 derived from California) tested showed high reactivity. This is strong evidence for the presence of conserved epitopes within the molecule against which the immune system could mount an antibody reaction. The human immune system may thus be mounting an immune response against conserved epitopes of the envelope molecule, as suggested by the reactivity of the AIDS patient sera. The observed divergence between various isolates of HTLV-III thus may not pose a problem for the use of recombinant protein as a vaccine. The 68Kd protein is ideally suited for such a purpose since it encompasses a large portion of the gene product and has the unique structural feature of containing both the extracellular hydrophilic region and the membrane associated hydrophobic regions. This structural feature makes it well suited for encapsulation into liposomes which have been used as vehicles for vaccination against other vital envelope proteins.

Based on these discoveries it is proposed that in the practice of screening blood for AIDS only AIDS envelope protein or a variant of said protein be utilized. Utilizing the env AIDS protein of the instant invention, human blood can be screened for the presence of antibodies to the AIDS virus. This and other techniques are readily determined, once, as taught for the first time by the present invention, the envelope AIDS protein has been recognized to be the envelope protein of the etiologic agent of AIDS. The foregoing and other objects, features and advantages of the invention will be apparent from the following examples of preferred embodiments of the invention.

50 <u>Example 1</u>

Molecular cloning and nucleotide sequence analysis of the HTLV-III proviral genome.

The integrated proviral genome of HTLV-III was recently cloned from the genomic DNA of H9 cells infected with HTLV-III [Shaw, G.M. et al., supra]. The proviral genome which was obtained by using Xbal digested H9/HTLV-III DNA contained two internal EcoRI sites within the viral genome and two additional sites in the cloning vector λ JI. These sites were used for further subcloning of the three DNA fragments of 5.5Kb, 4.5Kb and 1.1Kb into pBR322 (ATCC No. 37017). Nucleotide sequence analysis of the proviral genome was determined by the chemical degradation method of Maxam, A.M. and Gilbert, W., "Sequencing end-labelled DNA with base-specific chemical cleavages", Meth. Enzymol.

65, 499-560 (1980). For the sequence analysis, DNA inserts from the three subclones were isolated by electroelution and further cleaved with appropriate restriction enzymes. The DNA fragments were labelled at their 5'ends with γ-32P-ATP using polynucleotide kinase, or at their 3' ends with α-32P-NTP by filling in with DNA polymerase I (Klenow fragment). The DNA fragments labelled at the two ends were cleaved with a second enzyme and the fragments labelled at a single end were purified on 5% acrylamide gels and used for sequence analysis. For the sequence analysis of the env gene, a shotgun approach was utilized where the 4.5 EcoRI fragment was cleaved with one of the following enzymes: BgIII, HindIII, XhoI, AvaII, HinfI and Sau3A and the restriction fragments labeled and sequenced as described above. The nucleotide sequence of the envelope gene used in the present invention is shown in Figure 1.

Example 2

Construction of pEV/env 44-640

pRC2 is a derivative of pBR322 containing a unique Bgl II site adjacent (on the amp^R side) to the EcoRI site in the plasmid. This plasmid was constructed in the following manner. 20 μg of pBR322 plasmid DNA were digested with EcoRI and then split into two reactions. In one, the protruding 5' single-stranded termini were removed with SI nuclease; in the other reaction, the termini were filled-in by inorporating deoxynucleotides with the Klenow fragment of DNA polymerase I. Both reactions were terminated by phenol extraction followed by ethanol precipitation. Approximately 1 μg of DNA from each reaction was mixed with 90 pmoles of phosphorylated BgIII linkers (CAGATCTG, purchased from Collaborative Research) and incubated with T4 DNA ligase at 15° C for 18 hours. The ligation products were then digested with BgIII and PstI and subjected to gel electrophoresis in 1% agarose. The 3600 bp and 760 bp fragments from both reactions were recovered from the gel. For the construction of pRC2, the 3600 bp from the Klenow reaction was ligated to the 760 bp fragment from the SI reaction. To construct a plasmid with the BgIII site on the other side of EcoRI (tet^R side), designated pRCI, the 3600 bp fragment from the S1 reaction was ligated to the 760 bp fragment from the Klenow reaction. E. coli strain RRI (ATCC No. 31343) was transformed with the ligation mixtures, and transformants were selected on LB agar plates containing 50 μg/ml ampicillin. Transformants containing the expected plasmid constructions were identified by restriction analysis of the isolated plasmid DNA. DNA sequence analysis confirmed that the SI nuclease treatment precisely removed the 5' single-stranded termini.

pRC23 (see Figure 7) was constructed by inserting into pRC2 a 250 bp Bglll-HaelII fragment containing the λ P_L promoter joined to a pair of complementary synthetic oligonucleotides comprising a model ribosome-binding site (RBS). The HaelII site is located within the 5' non-coding region of the λ N gene 115 bp downstream of the P_L transcriptional initiation site. Approximately 1 μ g of a 450 bp Bglll-HpaI fragment isolated from phage λ DNA was digested with HaelII. 200 ng of the resulting digestion products were mixed with 60 pmoles each of phosphorylated synthetic oligonucleotides containing the model RBS. The ligated molecules were digested with Bglll and EcoRI and separated on a 5% polyacrylamide gel. The 270 bp ligation product was recovered from the gel, mixed with gel purified pRC2 vector that had been digested with Bglll and EcoRI, and incubated with T4 DNA ligase at 15° C for 15 hours. The ligation mixture was used to transform strain RRI(pRK248Clts). Transformants selected on ampicillin-containing medium were screened by restriction analysis of the isolated plasmid DNA. The expected plasmid construction, pRC23, was confirmed by further restriction enzyme digestions and by DNA sequence analysis across the EcoRI junction (Fig. 7).

For the construction of the pEV-vrf set of plasmids (see Figure 8), plasmid pRC23 was digested with EcoRI and HindIII and the pRC23/EcoRI-HindIII vector isolated by preparative agarose gel electrophoresis. The mixture of synthetic oligonucleotides (32, 33, and 34 nucleotides) was combined with the mixture of the complementary sequences, heated to 58° C for 5 minutes in 150 mM NaCI, and cooled slowly to allow annealing. 0.1 pmoles of the synthetic duplexes were added to 0.07 pmoles of the pRC23/EcoRI-HindIII vector and incubated with T4 DNA ligase at 15° C for 15 hours. Strain RRI (λ cl857) was transformed with the ligation products. Six ampicillin resistant transformants were selected for DNA sequence analysis. Of the six, two contained the expected sequence for pEV-vrf1, one for pEV-vrf2, and three for pEV-vrf3 (Fig. 3).

For the expression of the AIDS env gene, one µg of a 2400 bp EcoRI - HindIII DNA fragment, which was isolated from the cloned HTLV-III proviral genome by preparative agarose gel electrophoresis, was mixed with 0.1 µg of EcoRI - HindIII digested vector DNA (pEV-vrf1, -2, or -3). After heating at 65° C for 3 minutes, the mixtures were chilled on ice, and 20 µl ligation reactions were assembled, containing 50 mM Tris-HCl (pH 7.4), 10 mM MgCl₂, 10 mM DTT, 0.3 mM ATP, and 200 units of T₄ DNA ligase. After incubation at 15° C for 4 hours, the reactions were terminated by heating at 65° C for 5 minutes. The ligation products were used to transform E. coli strain MC1061 containing plasmid pRK248clts. Transformants were selected on Luria broth agar containing 50 µg/ml ampicillin at 30° C for 18 hours. Plasmid DNA was isolated from 1 ml of each culture and subjected to restriction analysis. All 12 isolates contained the expected plasmid construction. These intermediate constructions were then used to make pEV1, -2, and -3/env 44-640 by deleting the 600 bp between the EcoRI and KpnI sites as described below.

Approximately 0.5 μg of plasmid DNA was digested with KpnI and EcoRI. The resulting termini were then treated with the Klenow fragment of DNA polymerase I in the presence of all four deoxyribonucleotides (at 100 μM) at 37° C for

30 minutes. This step results in the "filling-in" of the 5' overhang of the EcoRI terminus and the removal of the 3'overhang of the KpnI terminus. Upon recirculization of the linear plasmid and blunt-end ligation of these termini, an EcoRI site is regenerated. Transformants containing plasmids with the expected deletion were identified by restriction analysis.

A second set of deletion derivatives, designated pEV/env 205-640 was constructed in a similar fashion. A portion of the linear plasmid that had been digested with EcoRI and KpnI and treated with Klenow, as described above, was further digested with StuI. Again, upon recircularization and blunt-end ligation, the EcoRI site was regenerated; however, an additional 483 bp of env coding sequences were removed.

10 Example 3

Bacteriai Growth and Induction of env Gene Expression

Cultures of E. coli strain MC 1061 transformed with plasmid pRK248clts and the pEV1, -2, or -3/env plasmids were grown in M9 medium containing 0.5% glucose and 0.5% casamino acids at 30° C to mid-log phase and then induced by shifting to 42° C for 2 hr. The cells were collected by centrifugation and processed as described in Examples 4 and 5.

Example 4

20 Expression and Purification of Env AiDS

A homogeneous recombinant viral env AIDS was purified according to the following procedure. The env AIDS protein expressed by a microbe tends to associate with the membrane fractions of the host microbe, principally the inner membrane of the microbe. The following purification method was designed to deal with this finding.

This purification method comprises:

- (a) lysis of transformed microbial cells producing recombinant env AIDS protein;
- (b) separation of env AIDS associated cellular membranes from other cellular components;
- (c) extraction of env AIDS from associated membranes; and
- (d) chromatographic purification of the resultant extraction solution containing env AIDS to yield a substantially pure recombinant viral env protein.

More specifically, the preferred purification method for the preparation of substantially pure recombinant viral env protein comprises:

35

25

30

- (a) cultivating a transformed organism containing a DNA sequence which codes for viral env protein;
- (b) causing a culture of the transformed organism of step (a) to accumulate the env protein;
- (c) lysing the culture of transformed organisms of step (b) to form a cell lysate mixture;
- (d) isolating the cell membrane components of the cell lysate mixture of step (c);
- (e) washing the isolated cell membrane components with an extraction solution to yield a wash solution containing env protein; and
- (f) chromatographically purifying the wash solution of step (e) to yield a substantially pure env AIDS protein.

In carrying out this method it is preferred that the cells be lysed by sonification, although it is forseeable that other known methods such as enzyme or mechanical lysis could also be used. It is preferred that the cell membrane component, specifically the inner and outer membranes, be isolated from other cellular components by methods such as centrifugation. It has been found that env AIDS expressed by the transformed microorganism tends to become associated with the cellular membranes. Therefore, isolation of these membranes during the purification process ensures high purification levels and high purity env AIDS at the end of the purification procedure.

Once the cell membranes are isolated from the lysate mixture, they are washed with an extraction solution, preferably salt solutions and a detergent to yield a second solution containing approximately 50% env AIDS protein. Preferably the cell membranes are washed in four separate steps with the salt solutions and detergent although it is forseeable that certain of these steps could be combined, rearranged or eliminated. The first step of washing the cell membrane may be done with a salt solution, preferably 1M NaCl. In the second step the cell membrane is washed with a detergent solution, preferably 1% Triton X-100. In the third step, the cell membrane is washed with another salt solution, 1.75M to 3.5M guanidine HCl. The final wash is also with a salt solution preferably about 7M Guanidine HCl. The wash solution which results from the fourth and final wash comprises about 50% env AIDS.

The final 50% env AIDS wash solution is then further purified by a chromatography step, preferably reverse phase high performance liquid chromatography (HPLC). The HPLC step yields env AIDS protein in a substantially 100% pure

form. It is also foreseeable that monoclonal antibody affinity chromatography columns utilizing env AIDS polyclonal or monoclonal antibodies, could be used as an alternative to HPLC.

Example 5

Polyacrylamide gel electrophoresis and Western blot analysis

Cells were lysed by resuspending the cell pellets (approximately 10⁸ cells) in TG buffer (10 mM Tris, pH 7.4, 10% glycerol), mixed with an equal volume of 2 x sample buffer [Laemmli, U.K., "Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4", Nature 227, 680-685 (1970)] and incubated at 95° C for five (5) minutes. Cell debris were pelleted by centrifugation and the cleared lysates were subjected to SDS-PAGE analysis [Laemmli, U.K., supra]. For Western blot analysis, the proteins from the acrylamide gel were electroblotted onto a 0.1 µm nitrocellulose membrane (Schleicher and Schuell) for 16 hr at 50V, in 12.5 mM Tris, 96 mM glycine, 20% methanol, 0.01% SDS at pH 7.5. Processing of the blot was carried out using the methods described by Towbin, H. et al. ["Electrophoretic Transfer of Proteins From Polyacrylamide Gels to Nitrocellulose Sheets: Procedure and Some Applications", Proc. Natl. Acad. Sci. U.S.A., 76, 4350-4354, (1979)]. For treatment with the human sera, the blots were incubated with a 1000 fold dilution of the sera in antibody buffer (20 mM sodium phosphate buffer, pH 7.5, containing 0.5 M NaCl, 1% BSA and 0.05% Tween 20) for 2-6 hr. The blots were then washed twice with phosphate buffered saline containing 0.05% Tween 20 and then incubated with 125-I-labelled Staphylococous aureus protein A for an additional period of 1 hr. The blot was then washed twice in PBS-Tween 20 buffer, dried and autoradiographed.

Example 6

Immunization with Env Protein of AIDS Virus

25

It is clear that in spite of the divergence observed between HTLVIII and ARV-2 sequences, the recombinant proteins synthesized by the bacteria react well with AIDS patients' sera derived from both geographical locations of the United States. One hundred percent (100%) of the AIDS patients' sera tested showed high reactivity (50 individual samples, 25 from the east coast of the United States and 25 from the west coast of the United States). Thus all the env proteins contain at least one conserved epitope. All of the human sera from AIDS patients tested contained antibodies to the env proteins of the instant invention. This strongly suggests that these env proteins with the conserved epitopes would be immunogenic in man.

It will be readily appreciated that the env proteins of the instant invention can be incorporated into vaccines capable of inducing protective immunity against the AIDS virus. By methods known in the art, the specific amino acids conprising the epitopes of the env protein may be determined. Peptides may then be synthesized, comprising an amino acid sequence corresponding to an epitope of an env AIDS protein either in monomeric or multimeric form. These synthetic peptides may then be incorporated into vaccines capable of inducing protective immunity against AIDS virus. Techniques for enhancing the antigenicity of such peptides include incorporation into a multimeric structure, binding to a highly immunogenic protein carrier, for example, keyhold limpet hemocyanin, or diphtheria toxoid, and administration in combination with adjuvants or any other enhancers of immune response. In addition, the vaccine composition may comprise antigens to provide immunity against other diseases in addition to AIDS.

An amino acid sequence corresponding to an epitope of an env protein either in monomeric or multimeric form (peptide) may be obtained by chemical synthetic means or by purification from biological sources including genetically modified microorganisms or their culture media. The peptide may be combined in an amino acid sequence with other peptides including fragments of other proteins, as for example, when synthesized as a fusion protein, or linked to other antigenic or non-antigenic peotides of synthetic or biological origin. The term "corresponding to an epitope of a environtein" will be understood to include the practical possibility that, in some instances, amino acid sequence variations of a naturally occurring peptide may be antigenic and confer protective immunity against AIDS infection. Possible sequence variations include, without limitation, amino acid substitutions, extensions, deletions, interpolations and combinations thereof. Such variations fall within the contemplated scope of the invention provided the peptide containing them is antigenic and antibodies elicited by such peptide cross-react with naturally occurring env protein or non-variant repeated peptides of env protein, to an extent sufficient to provide protective immunity when administered as a vaccine. Such vaccine compositions will be combined with a physiologically acceptable medium. The size and shape of epitopes found in carbohydrate antigens have been extensively studied, but less is known about the structure of epitopes from protein molecules. Some epitopes of protein antigens have been defined at the level of their tertiary structure. In every instance, the epitopes were formed not by the primary sequences alone, but by the juxtaposition of residues brought together by the folding of the polypeptide chain(s) of the native molecule. In addition, the structure of the 68Kd env protein of the instant invention makes it particularly well suited for use as a vaccine. The 68Kd env protein comprises a large portion of the gene product which (a) was shown to be reactive with all the AIDS sera tested; and (b) has the

unique structural feature of containing both an extracellular hydrophilic region and the transmembrane hydrophobic regions. The latter structural feature makes it well suited for use as a vaccine using liposome encapsulation to create a vehicle for administration.

Routes of administration, antigen dose, number and frequency of injections are all matters of optimization within the scope of ordinary skill in the art, particularly in view of the fact that there is experience in the art in providing protective immunity by the injection of other related antigens to provide immunity in other viral infections. It is anticipated that the principal value of providing immunity to AIDS infection will be for those individuals who have had no previous exposure to AIDS, e.g., individuals who are in the high risk population, such as homosexuals, drug addicts and people from Haiti and Central America and individuals who may be receiving blood transfusions. It is also anticipated that temporary immunity for infants may be provided by immunization of mothers during pregnancy.

Example 7

Diagnostic Test for AIDS

15

It is clear that the env gene proteins of the instant invention may be used as diagnostic reagents for the detection of AIDS-associated antibodies. It is also apparent to one of ordinary skill that a diagnostic assay for AIDS using polyclonal or monoclonal antibodies to the AIDS env protein of the instant invention may be used to detect the presence of the AIDS virus in human blood. In one embodiment a competition immunoassay is used where the antigenic substance, in this case the AIDS virus, in a blood sample competes with a known quantity of labelled antigen, in this case labelled AIDS env protein, for a limited quantity of antibody binding sites. Thus, the amount of labelled antigen bound to the antibody is inversely proportional to the amount of antigen in the sample. In another embodiment, an immunometric assay may be used wherein a labelled AIDS-env antibody is used. In such an assay, the amount of labelled antibody which complexes with the antigen-bound antibody is directly proportional to the amount of antigen (AIDS virus) in the blood sample. In a simple yes/no assay to determine whether the AIDS virus is present in blood, the solid support is tested to detect the presence of labelled antibody. In another embodiment, monoclonal antibodies to AIDS env protein may be used in an immunometric assay. Such monoclonal antibodies may be obtained by methods well known in the art, particularly the process of Milstein and Kohler reported in Nature 256, 495-497 (1975).

The immunometric assay method is as follows: Duplicate samples are run in which 100 μ l of a suspension of antibody immobilized on agarose particles is mixed with 100 μ l of serum and 100 μ l of soluble ¹²⁵I-labelled antibody. This mixture is for specified times ranging from one quarter hour to twenty four hours. Following the incubation periods the agarose particles are washed by addition of buffer and then centrifuged. After removal of the washing liquid by aspiration, the resulting pellet of agarose particles is then counted for bound ¹²⁵I-labelled antibody. The counts obtained for each of the complexes can then be compared to controls.

While the invention has been described in terms of certain preferred embodiments, modifications obvious to one with ordinary skill in the art may be made without departing from the scope of the invention. For example, it is understood that the env AIDS DNAs described herein represent only the precise structure of two naturally occurring gene segments. It is expected that slightly modified alleles will be found encoding for similarly functioning proteins, and such gene segments and proteins are considered to be equivalents for the purpose of this invention. It is also suspected that other variants in addition to those described herein will be found and that the envelope protein of said variants will differ slightly. These variant envelope proteins are likewise considered within the scope of the invention. DNA having equivalent codons is considered within the scope of the invention, as are synthetic gene segments that encode homologous proteins of the viral envelope.

Various features of the invention are set forth in the following claims.

Claims

Claims for the following Contracting States: BE, CH, DE, FR, GB, IT, LI, NL, SE

 An envelope protein fragment of an acquired immune deficiency syndrome (AIDS) virus, essentially free of other proteins, with the amino acid sequence:

ValTrpLysGluRla Thr Thr Leu Phe Cys Ala Ser Asp Ala Lys Ala Tyr Asp Thr Glu Val His Asn Val Trp Ala Thr Charles and Charles andHisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysVallysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer PheGluProlleProlleHisTyrCysAlaProAlaGlyPheAlalleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsnAsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly ${\tt AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn}$ LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp ASNHISThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

5

10

15

20

25

30

35

40

45

50

55

Oi

CysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMSTArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn, AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

OI

5

10

15

25

30

45

METArgGInAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

20 0

METTYRAlaProProIle SerGlyGlnIleArgCySSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

35 or

METArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGinGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer.

- 2. An expression vector comprising a gene coding for an envelope protein fragment of an AIDS virus as defined in claim 1 downstream of a promoter sequence enabling transcription, translation and thus expression of said envelope protein fragment in a host cell.
- An expression vector according to claim 2, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC ATGTGGAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC AXTAGTAGTAGCGGGGAATGATAATGGAGAAGGAGAGATAAAAACTGCTCTTTCAATATCRGCACA GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGGAGTTTGTTACAATAGGAAAAATAGGA **ARTATGAGACAAGCACATTGTRACATTAGTAGAGCRARATGGRATGCCACTTTRARACAGATAGCTAGC** aaattaagabacaatttogaaataataaaacaataatetttaagcaatctotcagagoggogaccoagaa ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC **AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATCGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGGGGAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG** AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

or an equivalent thereof, coding for said envelope protein fragment.

10

15

20

25

30

50

55

4. An expression vector according to claim 2, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

TGTCCAAAGGTATCC

TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAAAAGACG TTCRATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCARCTCARCTGCTGTTRAATGGCRGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG RATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA **AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAAAA GARARAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

25

10

15

20

or an equivalent thereof, coding for said fragment.

5. An expression vector according to claim 2, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

30

35

AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGGCCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCRTGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAARTTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

45

or an equivalent thereof, coding for said envelope protein fragment.

An expression vector according to claim 2, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

ATGTATGCCCCTCCCATC

AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGAGTGGTGGTAATAACAAC **ANTOGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA** GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTCGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGGGGAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTCCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

or an equivalent thereof coding for said envelope protein fragment.

7. An expression vector according to claim 2, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

20

25

10

15

ATGAGGGACAATTGGAGAAGTGAATTATATAAA tataaagtagtaaaaattgaaccattaggagtagcacccaaggcaaagagaagagtggtgcagaga GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA ANACTARTTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

30

8. An expression vector according to any one of claims 2 to 7, which is a plasmid capable of replication in gram-negative and/or gram-positive bacteria.

35

- 9. An expression vector according to claim 8 which is capable of replication in an E. coli strain.
- An expression vector according to claim 8 which is capable of replication in a B. subtilis strain.
- 11. The expression vector pEV1. -2. or -3/env 44-640.
 - 12. The expression vector pEV1. -2. or -3/env 205-640.
 - 13. A transformant carrying an expression vector as claimed in any one of claims 2 to 12.

- 14. A transformant according to claim 13 which is an E. coli strain.
- 15. A transformant according to claim 14 which is an E. coli MC 1061 strain.
- 16. A transformant according to claim 13 which is a B. subtilis strain.
 - 17. A transformant according to claim 13 which is a mammalian cell.
- 18. A method of producing an envelope protein fragment of an acquired immune deficiency syndrome virus as claimed 55 in claim 1 comprising:

transforming a host cell with an expression vector as claimed in any one of claims 2 to 12: culturing said host cell so that said AIDS env protein fragment is expressed; and extracting and isolating said AIDS env protein fragment.

- 19. A method according to claim 18, wherein the expression vector is pEV1, -2 or -3/env 44-640.
- 20. A method according to claim 18, wherein the expression vector is pEV1, -2 or- -3/env 205-640.
- 21. A method of testing human blood for the presence of antibodies to the viral etiologic agent of AIDS which comprises mixing a composition containing an envelope protein fragment of an AIDS virus as claimed in claim 1 with a sample of human blood and determining whether said envelope AIDS protein fragment binds to AIDS antibodies present in the blood sample.
- 10 22. A method according to claim 21 which comprises the use of the Western Blotting Analysis.
 - 23. A method according to claim 21 which comprises the use of an ELISA-technique, wherein an envelope protein fragment of an AIDS virus as claimed in claim 1 is coated on a solid phase and contacted with the sample and after washing contacted with an enzyme-labeled non-human IgG.
 - 24. A method according to claim 21, wherein the Double-Antigen-Method is used.
 - 25. A method for the determination of AIDS virus, wherein antibodies against an envelope protein fragment of an AIDS virus according to claim 1 are used.
 - 26. A method according to claim 25, wherein the antigen in the sample and a protein fragment as claimed in claim 1 in labeled form compete with an antibody against a protein fragment as claimed in claim 1.
- 27. A method according to cam 25, wherein a sandwich method is performed using two antibodies against a protein fragment as claimed in claim 1.
 - 28. A method according to claim 27, wherein one antibody is on a solid phase and the other antibody is labeled.
 - 29. A method according to claim 27, wherein two different monoclonal antibodies are used.
 - 30. A vaccine eliciting immunity to AIDS comprising as an active ingredient a protein fragment as claimed in claim 1.
 - 31. Antibodies raised against a protein fragment as claimed in claim 1.
- 35 32. The antibodies of claim 31 which are monoclonal antibodies.
 - 33. The use of a protein fragment as claimed in claim 1 for the preparation of a protective immunisation vaccine.
 - 34. The use of a protein fragment as claimed in claim 1 for testing human blood for the presence of AIDS virus.

Claims for the following Contracting State: AT

45

50

55

 A process for the preparation of an envelope protein fragment of an acquired immune deficiency syndrome (AIDS) virus, essentially free of other proteins, comprising:

transforming a host cell with an expression vector comprising a gene coding for an envelope protein fragment of an AIDS virus with the amino acid sequence:

ValTrpLvsGluAla ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr ${\tt HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn}$ METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerlleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProlleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn <u>AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly</u> AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu ${\tt IleValThr His Ser Phe Asn Cys Gly Gly Glu Phe Phe Tyr Cys Asn Ser Thr Gln Leu Phe Asn Ser}$ ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGinGlnLeuLeuGlyIleTrpGlyCysSerGly Lysleu Ile CysThr Thr Ala Val Protrp Asn Ala Ser Trp Ser Asn Lys Ser Leu Glu Gln Ile TrpAsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

5

10

15

20

25

30

35

40

45

50

55

CysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu ${\tt IleValThr KisSer Phe Asn CysGlyGlyGluPhe Phe Tyr CysAsn Ser Thr Gln Leu Phe Asn Ser}$ ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArqCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

Or

20

25

30

35

40

5

10

15

METTYrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg

GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp

AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

or

METArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

45

downstream of a promoter sequence enabling transcription, translation and expression of said envelope protein fragment in said host cell; culturing said host cell so that said envelope protein fragment of an AIDS virus is expressed; and extracting and isolating said envelope protein fragment of an AIDS virus.

- 50 2. A process according to claim 1, wherein the host cell is a bacterium.
 - 3. A process according to claim 2, wherein the bacterium is E. coli.
 - 4. A process according to claim 3, wherein the plasmid is pEV1, -2, or -3/env 44-640.

- 5. A process according to claim 3, wherein the plasmid is pEV1, -2, or -3/env 205-640.
- A process for the preparation of an expression vector comprising a gene coding for an envelope protein fragment of an AIDS virus, which process comprises constructing an expression vector having an insertion site, wherein a

gene coding for an envelope protein fragment of an AIDS virus as defined in claim 1 may be inserted which insertion site is downstream of a promoter sequence enabling transcription, translation and thus expression of said envelope protein fragment in a host cell.

 A process according to claim 6, characterized in that as said gene coding for an envelope protein fragment of an AIDS virus a gene comprising the nucleotide sequence

GTGTGGAAGGAAGCA ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCAAAAAGTAGTATTGGTAAATGTGACAGAAATTTTAAC ATGTGGAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC **AATAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAACTGCTCTTTCAATATCAGCACA** GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCAGG AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA **ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC aatgggtccgagatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaa Gaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggc GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGGGGAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG gcaagaatectggctgtggaaagataectaaaggateaacagetectggggatttggggttgetetgga **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG**

or an equivalent, coding therefore is used.

10

15

20

25

30

35

45

55

8. A process according to claim 6, characterized in that as said gene coding for an envelope protein fragment of an AIDS virus a gene comprising the nucleotide sequence

AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

TGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA 10 ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAGCTGTTTAATAGT CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC à a togot cogagatot teagaco togago gogo gata togo go acaat togaga acta ta ta ta a a 15 GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGGGGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA 20 AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG aatcacacgacgtggatggagtgggacagagaaattaacaattacacaagc

or an equivalent coding therefore is used.

9. A process according to claim 6, characterized in that as said gene coding for an envelope protein fragment of an AIDS virus a gene comprising the nucleotide sequence

or an equivalent coding therefore is used.

10. A process according to claim 6, characterized in that as said gene coding for an envelope protein fragment of an AIDS virus a gene comprising the nucleotide sequence

55

30

ATGTATGCCCCTCCCATC

or an equivalent coding therefore is used.

10

15

11. A process according to claim 6, characterized in that as said gene coding for an envelope protein fragment of an AIDS virus a gene comprising the nucleotide sequence

or an equivalent coding therefore is used.

- 12. A process according to any one of claims 6 to 11, wherein the expression vector is a plasmid capable of replication in gram-negative bacteria.
- 35 13. A process according to claim 12, wherein the plasmid is capable of replication in an E. coli strain.
 - 14. A process for the preparation of a transformant carrying an expression vector comprising a gene coding for an envelope protein fragment of an AIDS virus, which process comprises transforming a microorganism with an expression vector obtained according to any one of claims 6 to 13 and cultivating the transformed microorganism.
 - 15. A procss according to claim 14, wherein the microorganism is an E. coli strain.
 - 16. A process according to claim 15, wherein the microorganism is an E. coli MC 1061 strain.
- 45 17. A process of testing human blood for the presence of antibodies to the viral etiologic agend of AIDS which process comprises mixing a composition containing an envelope protein fragment of an AIDS virus obtained according to claim 1 with a sample of human blood and determining whether said envelope AIDS protein fragment binds to AIDS antibodies present in the blood sample.
- 50 18. A process according to claim 17 which comprises the use of the Western Blotting Analysis.
 - 19. A process according to claim 17 which comprises the use of an Elisa-technique, wherein an envelope protein fragment of an AIDS virus obtained according to claim 1 is coated on a solid phase and contacted with the sample and after washing contacted with an enzyme-labeled non-human IgG.

20. A process according to claim 17, wherein the Double-Antigen-Method is used.

A process for the determination of AIDS virus, wherein antibodies against an envelope protein fragment of an AIDS virus obtained according to claim 1 are used.

- 22. A process according to claim 21, wherein the antigen in the sample and a protein fragment obtained according to claim 1 in labeled form compete with an antibody against a protein fragment obtained according to claim 1.
- 23. A process according to claim 21, wherein a sandwich method is performed using two antibodies against a protein fragment obtained according to claim 1.
 - 24. A method according to claim 23, wherein one antibody is on a solid phase and the other antibody is labeled.
 - 25. A method according to claim 23, wherein two different monoclonal antibodies are used.

10

30

35

45

50

55

- 26. An envelope protein fragment of an AIDS virus whenever prepared by a process as claimed in any one of claims 1 to 5.
- 27. An expression vector comprising a gene coding for an envelope protein fragment of an AIDS virus whenever prepared by a process as claimed in any one of claims 6 to 13.
 - 28. A transformant carrying an expression vector comprising a gene coding for an envelope protein fragment of an AIDS virus whenever prepared by a process as claimed in any one of claims 14 to 16.
- 29. An expression vector comprising a gene coding for an envelope protein fragment of an AIDS virus as defined in claim 1 downstream of a promoter sequence enabling transcription, translation and thus expression of said envelope protein fragment in a host cell.
- **30.** An expression vector according to claim 29, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC ATGTGGAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC aatagtagtagceggagaatgataatggagaaaggagagataaaaaactgctctttcaatatcagcaca GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG **ANTACANGANANANTCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACANTAGGANANATAGGA AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** CCATGCAGAATAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

or an equivalent thereof. coding for said envelope protein fragment.

31. An expression vector according to claim 29, wherein said gene coding for an envelope protein fragment for an AIDS virus is a gene comprising the nucleotide sequence:

TGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCCGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCRACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG ANTACAAGANAANAACCGTATCCAGAGGGGACCAGGGAGCATTTGTTACAATAGGAAANATAGGA 10 **ARATTRAGAGARCRATTTGGARATRATRARACRATARTCTTTRAGCRATCCTCAGGAGGGGACCCAGRA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** CCRTGCRGAATAARACATTTATAAACRTGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC 15 AGCCGACAATTAGATGTTCATCAAATATTACAGCGCTGCTATTAACAAGAGATGGTGGTAATAACAAC **AATGGGTCCGAGATCTTCAGACCTGGAGGAGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC 20 GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGGGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

or an equivalent thereof, coding for said envelope protein fragment.

5

25

50

55

32. An expression vector according to claim 29, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA 35 attgtaacgcacagttttaattgtggacgggaatttttctactgtaattcaacaccaactgttaatagt CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC aatgggteegagatetteagaeetggaggagatatgagggaeaattggagagtgaattatataaa GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGGGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

or an equivalent thereof, coding for said envelope protein fragment.

33. An expression vector according to claim 29, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

ATGTATGCCCCTCCCATC

or an equivalent thereof. coding for said envelope protein fragment.

10

15

30

35

34. An expression vector according to claim 29, wherein said gene coding for an envelope protein fragment of an AIDS virus is a gene comprising the nucleotide sequence:

- 35. An expression vector according to any one of claims 29 to 34 which is a plasmid capable of replication in gram-negative bacteria.
 - 36. An expression vector according to claim 35 which is capable of replication in an E. coli strain.
 - 37. The expression vector pEV1, -2, or -3/env 44-640.
- 40 38. The expression vector pEV1, -2, or -3/env 205-640.
 - 39. A transformant carrying an expression vector as claimed in any one of claims 29-38.
 - 40. A transformant according to claim 39 which is an E. coli strain.
 - 41. A transformant according to claim 40 which is an E. coli MC 1061 strain.
 - 42. Antibodies raised against a protein fragment obtained according to claims 1 to 5 and 26.
- 50 43. The antibodies of claim 42 which are monoclonal antibodies.
 - 44. A vaccine eliciting immunity to AIDS comprising as an active ingredient a protein fragment obtained according to claims 1 to 5 and 26.
- 55 45. The use of a protein fragment as claimed in claim 1 for the preparation of a protective immunisation vaccine.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LI, NL, SE,

 Ein Hüllproteinfragment eines Erworbenen-Immunschwäche-Syndrom-(AIDS)-Virus, weitgehend frei von anderen Proteinen, mit der Aminosäuresequenz:

ValTrpLysGluAla ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr 10 ${\tt HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn}$ METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerileArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn 15 AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGinLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr 20 AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArqGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer 25 ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProcysArglieLysGlnPhelleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProlle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg 30 GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly $\verb|AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnAsnAsn||$ LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp 35 AshHisThrThrTrpMETGluTrpAspArgGluIleAshAshTyrThrSer

40 oder

55

50

Cysprolysvalses PheGluProlleProlleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr 5 AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArglleLysGlnPhelleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProlle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys 15 TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly 20 LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

25 oder

METArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer 30 ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArglleLysGlnPhelleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProlle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGlullePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg 35 GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp 40 AsaHisTarTarTrpMETGluTrpAspArgGluIleAsaAsaTyrThrSer

45 oder

50

55

METTYrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

oder

META: GASPASNTIPAR GSERGIULEUTYILYS TYFLYSVALVALLYSILEGIUPROLEUGIYVALALAPROTH: LYSALALYSAR GARGVALVALGINAR GIULYSAR GALAVALGIYILEGIYALALEUPHELEUGIYPHELEUGIYALAALAGIYSETHIMETGIY ALAALASERMETTHILEUTHIVALGINALAAR GGINLEULEUSERGIYILEVALGINGINGINASAS NEULEUAR GALAU GIUALAGINGINHISLEULEUGINLEUTHIVALTIPGIYILELYSGINLEUGIN ALAAR GILELEUALAVALGIUAR GTYFLEULYSAS PGINGINLEULEUGIYILETIPGIYCYSSERGIY LYSLEUILECYSTHITHIALAVALPROTIPASNALASERTIPSERASNLYSSERLEUGIUGINILETIP ASNHISTHITHITTIPMETGIUTIPASPAR GGIUILEASNASNTYTTHISER.

15

10

5

- 2. Ein Expressionsvektor enthaltend ein Gen kodierend für ein Hüllproteinfragment von einem AIDS-Virus gemäss Anspruch 1, abwärts von einer Promotorsequenz die die Transkription, Translation und damit die Expression des besagten Hüllproteinfragments in einer Wirtszelle ermöglicht.
- 20 3. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:

GTGTGGAAGGAAGCA

accaccactetattttgtgcatcagatgcttaaagcatatgatacagaggtacataatgt<u>ttggcca</u>ca 25 CATGCCTGTGTACCCACAGACCCCAACACAACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC ATGTCGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC aatagtagtagccggagaatgataatcgagaaaggagataaaaaactgctctttcaatatcagcaca AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT 30 GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGGATTCTAAAATGTAATAAGACG TTCRATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG 35 **AATACAAGAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA** AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAGCTGTTTAATAGT 40 CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAAATATTACAGGGCTGCTATTAACAAGAGATGGTGAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGGGGGGGGGAGATATGAGGGGACAATTGGAGAAGTGAATTATATAAA 45 GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCRAGRATCCTCGCTGTGGRAAGRTACCTRAAGGRTCRACRGCTCCTGGGGRTTTGGGGTTGCTCTGGR aaactaatitocaccactoctotocottogaatoctagttogagtaataaatctctogaacagatttog 50 AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

oder ein Äquivalent davon kodierend für das besagte Hüllproteinfragment.

55

4. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:

TGTCCAAAGGTATCC

TTTGAGCCAATTCCCATACATTATTGTGCCCCGGGCTTGTTTTTGCGATTCTAAAAATGTAATAATAAGACG TTCRATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCRACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG GRCARTCCTARACCRTRATAGTACAGCTGRACACRTCTGTRGRARATTRATTGTRCARGRCCCRRCARC **AATACAAGAAAAAATCCGTATCCAGAGGGGACCAGGGGAGAGATTTGTTACAATAGGAAAAATAGGA** aatatgagacragcacattgtaacattagtagagcaraatggaatgccactttaaaacagatagctagc AAATTAAGAGAACAATTTOGAAATAATAAAACAATAATCTTTAAGCAATCCTCTGAGAGCGCGCCCAGAA <u>A TTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT</u> ACTTCGTTTAATAGTACTTCGAGTACTGAAGGGTCRAATAACACTGAAGGRAGTGACAACAATCACACTC CCRTGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC GAAAAAGGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGGGGAACAGCATCTGTTGCAAGTCACAGTCTGGGGGATCAAGCAGCTCCAG GCAAGAATCCTCGCTGTGGAAAGATACCTAAAGGATCAACACCTCCTGGGGATTTTGGGGTTTGCTCTCTGA AAACTAXTTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAATTACAATTACACAAGC**

oder ein Äquivalent davon kodierend für das besagte Hüllproteinfragment.

- 5. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:
- 30 **ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT** acttogtttaatagtacttogagtactgaaggtcaaataacactgaaggaagtgacacaatcacactc CCRTGCAGAATARAACATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC 35 AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC DODDIKTDK-DOKSDOK-DOK-DOK-DOKTOTTD-DTTTD-DKDDKTAKDDDTD-DKDAAAAAD OCAGCOTCAATGACCCTGACGCTACAGACGACAATTATTGTCTGTATAGTGCAGCAGCAGCAGAACAA TTGCTGAGGCTATTGAGGGGCAACAGCTTTTTTTTAAACTGAGATCTGCAGATCAAGCAGCTCAAG GCRAGAATCCTGGGTGTGGAAAGATACCTAAAGGATCAACACTCCTGGGGTTTGCGGTTTGCTCTGGA AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

oder ein Äquivalent davon kodierend für das besagte Hüllproteinfragment.

6. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:

55

45

5

10

15

20

ATGTATGCCCCTCCCATC

15

10

oder ein Äquivalent davon kodierend für das besagte Hüllproteinfragment.

7. Ein Expressionsvektor gemäss Anspruch 2, worin das besagte, für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die folgende Nukleinsäuresequenz enthält:

20

atgacccactattccagaagtcaattatataa

30

35

25

- 8. Ein Expressionsvektor gemäss einem der Ansprüche 2 bis 7, der ein Plasmid ist, das sich in gram-negativen und/oder gram-positiven Bakterien replizieren kann.
- 9. Ein Expressionsvektor gemäss Anspruch 8, welcher fähig ist, in einem E. coli Stamm zu replizieren.
- 10. Ein Expressionsvektor gemäss Anspruch 8, welcher fähig ist, in einem B. subtilis Stamm zu replizieren.

4O

- 11. Der Expressionsvektor pEV1, -2, oder -3/env 44-640.
- 12. Der Expressionsvektor pEV1, -2, oder -3/env 205-640.
- 45 13. Ein Transformant der einen Expressionsvektor gemäss einem der Ansprüche 2 bis 12 trägt.
 - 14. Ein Transformant gemäss Anspruch 13, der ein E. coli Stamm ist.
 - 15. Ein Transformant gemäss Anspruch 13, der ein E. coli MC 1061 Stamm ist.

50

- 16. Ein Transformant gemäss Anspruch 13, der ein B. subtilis Stamm ist.
- 17. Ein Transformant gemäss Anspruch 13, welcher eine Säugetierzelle ist.
- 18. Ein Verfahren zur Herstellung eines wie in Anspruch 1 beanspruchten Hüllproteinfragments eines Erworbenen-Immunschwäche-Syndrom-Virus gekennzeichnet durch:

Transformieren einer Wirtszelle mit einem Expressionsvektor wie in einem der Ansprüche 2 bis 12 beansprucht; Kultivieren besagter Wirtszelle, so dass besagtes AIDS env Proteinfragment exprimiert wird;

und Extrahieren und Isolieren des besagten AIDS env Proteinfragments.

- 19. Ein Verfahren gemäss Anspruch 18, worin der Expressionsvektor pEV1, -2 oder -3/env 44-640 ist.
- Ein Verfahren gemäss Anspruch 18, worin der Expressionsvektor pEV1, -2 oder -3/env 205-640 ist.
 - 21. Ein Verfahren zum Testen von humanem Blut auf das Vorhandensein des viralen Verursachers von AIDS, gekennzeichnet durch Mischen einer Zusammensetzung enthaltend ein Hüllproteinfragment eines AIDS Virus gemäss Anspruch 1 mit einer Probe von humanem Blut und Bestimmen ob das besagte Hüllproteinfragment an in der Blutprobe vorhandene AIDS Antikörper bindet.
 - 22. Ein Verfahren gemäss Anspruch 21, gekennzeichnet durch die Verwendung der Western Blot Analyse umfasst.
- 23. Ein Verfahren gemäss Anspruch 21, gekennzeichnet durch die Verwendung einer ELISA Technik, wobei ein Hüllproteinfragment eines AIDS Virus gemäss Anspruch 1 auf eine Festphase aufgebracht wird, mit der Probe in Kontakt gebracht wird und nach Waschen mit einem enzymmarkiertem nicht-humanem IgG zusammengebracht wird.
 - 24. Ein Verfahren gemäss Anspruch 21, worin das Doppel-Antigen-Verfahren verwendet wird.
- 25. Ein Verfahren zur Bestimmung von AIDS-Viren, worin Antik\u00f6rper gegen das H\u00fcllproteinfragment eines AIDS-Virus gem\u00e4ss Anspruch 1 verwendet werden.
 - 26. Ein Verfahren gemäss Anspruch 25, worin das Antigen in der Probe und ein Proteinfragment gemäss Anspruch 1 welches markiert ist, um einen Antikörper gegen ein Proteinfraument gemäss Anspruch 1 konkurrieren.
 - 27. Ein Verfahren gemäss Anspruch 25, worin ein Sandwichverfahren unter Verwendung von zwei Antikörpern gegen ein Proteinfragment gemäss Anspruch 1 durchgeführt wird.
- 28. Ein Verfahren gemäss Anspruch 27, worin ein Antikörper an der Festphase ist und der andere Antiköper markiert 30 ist.
 - 29. Ein Verfahren gemäss Anspruch 27, worin zwei verschiedene monoklonale Antikorper verwendet werden.
- 30. Ein Immunität gegen AIDS bewirkender Impfstoff, enthaltend als aktiven Bestandteil ein Proteinfragment gemäss Anspruch 1.
 - 31. Antikörper erzeugt gegen ein Proteinfragment gemäss Anspruch 1.
 - 32. Die Antikörper gemäss Anspruch 31, welche monoklonale Antiköper sind.
 - Die Verwendung eines Proteinfragments gemäss Anspruch 1 für die Herstellung eines schützenden immunisierenden Impfstoffs.
- 34. Die Verwendung eines Proteinfragments gemäss Anspruch 1 zum Testen von humanem Blut auf das Vorhandensein von AIDS-Viren.

Patentansprüche für folgenden Vertragsstaat : AT

 Verfahren für die Herstellung eines Hüllproteinfragments eines Erworbenen-Immunschwäche-Syndrom-(AIDS)-Virus, welches im wesentlichen frei von anderen Proteinen ist, gekennzeichnet durch:

Transformieren einer Wirtszelle mit einem Expressionsvektor enthaltend ein Gen kodierend für ein Hüllproteinfragment eines AIDS-Virus mit der Aminosäuresequenz:

55

50

10

ValTrpLysGluAla-

ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HisAlaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AshSerSerSerGlyArgMETIleMETGluLysGlyGluLleLysAshCysSerPheAshIleSerThr SerileArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspileIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerValIleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArqSerValAsnPheThr AspasnalalysthrileileValGinLeuAsnthrSerValGluIleAsnCysthrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTYrLYS TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

oder

5

10

15

20

25

30

35

40

45

50

55

CysProLysValSer

PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLySCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArqLysLysIleArqIleGinArqGlyProGlyArqAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArqGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLySGlnLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AshHisThrThrTrpMETGluTrpAspArgGluIleAshAshTyrThrSer

oder

METArgGinAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArqAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

oder

20

25

15

10

METTYTAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

oder

35

40

METArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

45

50

abwärts von einer Promotorsequenz, die die Transkription, Translation und damit die Expression des Hüllproteinfragments in einer Wirtszelle ermöglicht; Kulfivieren der Wirtszelle, so dass das Hüllproteinfragment eines AIDS-Virus expremiert wird; und Extrahieren und Isolieren des Hüllproteinfragments von einem AIDS-Virus.

- 2. Ein Verfahren gemäss Anspruch 1, worin die Wirtszelle ein Bakterium ist.
- 3. Ein Verfahren gemäss Anspruch 2, worin das Bakterium E. coli ist.

- 4. Ein Verfahren gemäss Anspruch 3, worin das Plasmid pEV1, -2 oder 3/env 44-640 ist.
- 5. Ein Verfahren gemäss Anspruch 3, worin das Plasmid pEV1, -2 oder 3/env 205-640 ist.

- 6. Ein Verfahren für die Herstellung eines Expressionsvektors enthaltend ein Gen kodierend für ein Hüllproteinfragment eines AIDS-Virus, gekennzeichnet durch das Konstruieren eines Expressionsvektors mit einer Inserierungsstelle, worin das in Anspruch 1 definierte Gen kodierend für ein Hüllproteinfragment eines AIDS-Virus inseriert werden kann, wobei die Inserierungsstelle aufwärts einer Promotorsequenz liegt, die die Transkription, Translation und damit Expression des Hüllproteinfragments in einer Wirtszelle ermöglicht.
- 7. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllproteinfragment eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

GTGTGGAAGGAAGCA ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCAAGAAGTAGTATTCGTAAATGTGACAGAAATTTTAAC ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC AATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAACTGCTCTTTCAATATCAGCACA AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTCGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCRATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCRACTCRACTGCTGTTRAATGGCRGTCTRGCRGARGARGAGGGTAGTAATTRGATCTGTCAATTTCRCG AATACRAGAAAAAATCCGTATCCRGAGGGGACCRGGGAGGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTRACGCACAGTTTTRATTGTGGAGGGGAATTTTTCTRCTGTRATTCRACACAACTGTTTRATAGT ACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGGAAGTGACACAATCACACTC CCRTGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC ARTGGGTCCGAGATCTTCAGACCTGGAGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCRGCGTCRATGACGCTGACGGTRCRGGCCAGACRATTATTGTCTCGTATAGTGCAGCAGCAGAACRAT TTGCTGRGGGCTATTGRGGGCGCRACRGCRTCTGTTGCRACTCRCAGTCTGGGGCRTCRAGCRGCTCCRG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA ARACTRATTTGCRCCRCTGCTGCCTTGGRATGCTRGTTCGAGTARTARATCTCTGGRACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGGAAATTAACAATTACACAAGC

oder ein dafür kodierendes Aequivalent verwendet wird.

5

10

15

20

25

30

35

40

45

50

55

8. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllproteinfragment eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

TGTCCARAGGTATCC

TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCRACTCRACTGCTGTTRAATGGCAGTCTRGCAGRAGRAGAGGTAGTRATTRGATCTGTCRATTTCRCG GREARTGETRARRCERTRATRGTRERGETGRRERCECTTGTRGRARTTRRTTGTRERAGRECECRRERRE **AATACAAGAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA ABATTRAGRGRACRATTTGGRARTRATARARCRATARTCTTTRAGCRATCCTCRGGRGGGGRCCCRGRA** ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACACTGTTTAATAGT CCATGCAGAATAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTTCCCATC **AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA** GAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTARTTTGCACCACTGCTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC**

oder ein dafür kodierendes Aequivalent verwendet wird.

5

10

15

20

25

30

35

45

55

9. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllproteinfragment eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

oder ein dafür kodierendes Aequivalent verwendet wird.

10. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllproteinfragment eines AIDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

ATGTATGCCCCTCCCATC

oder ein dafür kodierendes Aequivalent verwendet wird.

5

10

15

30

35

50

11. Ein Verfahren gemäss Anspruch 6, dadurch gekennzeichnet, dass als Gen, welches für ein Hüllproteinfragment eines AlDS-Virus kodiert, ein Gen enthaltend die Nukleotidsequenz:

oder ein dafür kodierendes Aequivalent verwendet wird.

- Ein Verfahren gemäss einem der Ansprüche 6 bis 11, worin der Expressionsvektor ein Plasmid ist, das zur Replikation in gram-negtiven Bakterien f\u00e4hig ist.
- 13. Ein Verfahren gemäss Anspruch 12, worin das Plasmid zur Replikation in einen E.coli Stamm fähig ist.
- 14. Ein Verfahren für die Herstellung eines Transformanten, der einen Expressionsvektor enthaltend ein Gen kodierend für ein Hüllproteinfragment eines AIDS-Virus trägt, welches Verfahren Transformieren eines Mikroorganismus mit einem Expressionsvektor gemäss einem der Ansprüche 6 bis 13 und Kultivieren des transformierten Mikroorganismus umfasst.
 - 15. Ein Verfahren gemäss Anspruch 14, worin der Mikroorganismus ein E.coli Stamm ist.
- 45 16. Ein Verfahren gemäss Anspruch 15, worin der Mikroorganismus eine E. coli MC 1061 Stamm ist.
 - 17. Ein Verfahren zum Testen von humanem Blut auf das Vorhandensein des viralen Verursachers von AIDS, gekennzeichnet durch Mischen einer Zusammensetzung enthaltend ein Hüllproteinfragment eines AIDS-Virus erhalten gemäss Anspruch 1 mit einer Probe von humanem Blut und Bestimmen, ob das Hüllproteinfragment an in der Blutprobe vorhandene AIDS Antikörper bindet.
 - 18. Ein Verfahren gemäss Anspruch 17, gekennzeichnet durch die Verwendung der Western Blot Analyse.
- Ein Verfahren gemäss Anspruch 17, gekennzeichnet durch die Verwendung einer ELISA-Technik, wobei ein Hüll proteinfragment eines AIDS-Virus erhalten gemäss Anspruch 1 auf eine Festphase aufgebracht, mit der Probe in Kontakt gebracht und nach Waschen mit einem enzymmarkierten nicht-humanem IgG zusammengebracht wird.
 - 20. Verfahren gemäss Anspruch 17, worin die Doppel-Antigen-Methode verwendet wird.

- Ein Verfahren zur Bestimmung von AIDS-Viren, worin Antik\u00f6rper gegen das gem\u00e4ss Anspruch 1 erhaltene H\u00fcllproteinfragment eines AIDS-Virus verwendet werden.
- 22. Ein Verfahren gemäss Anspruch 21, worin das Antigen in der Probe und ein Proteinfragment erhalten gemäss Anspruch 1, welches markiert ist, um einen Antikörper gegen ein Proteinfragment erhalten gemäss Anspruch 1 konkurrieren.

5

35

55

- 23. Ein Verfahren gemäss Anspruch 21, worin ein Sandwichverfahren unter Verwendung von zwei Antikörpern gegen ein gemäss Anspruch 1 erhaltenes Proteinfragment durchgeführt wird.
- 24. Ein Verfahren gemäss Anspruch 23, worin ein Antikörper an der Festphase ist und der andere Antikörper markiert ist.
- 25. Ein Verfahren gemäss Anspruch 23, worin zwei verschiedene monoklonale Antikörper verwendet werden.
- 26. Ein Hüllproteinfragment von einem AIDS-Virus, hergestellt durch ein Verfahren gemäss einem der Ansprüche 1 bis 5.
- 27. Ein Expressionsvektor, enthaltend ein Gen kodierend für ein Hüllproteinfragment eines AIDS-Virus, hergestellt durch ein Verfahren gemäss einem der Ansprüche 6 bis 13.
 - 28. Ein Transformant tragend einen Expressionsvektor enthaltend ein Gen kodierend für ein Hüllproteinfragment eines AIDS-Virus, hergestellt durch ein Verfahren gemäss einem der Ansprüche 14 bis 16.
- 29. Ein Expressionsvektor enthaltend ein Gen kodierend für ein Hüllproteinfragment von einem AIDS-Virus gemäss Anspruch 1, abwärts von einer Promotorsequenz, die die Transkription, Translation und damit die Expression des besagten Hüllproteinfragments in einer Wirtszelle ermöglicht.
- 30. Ein Expressionsvektor gemäss Anspruch 29, worin das für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTCGTAAATGTGACAGAAAATTTTAAC ATGTGGAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCRTGTGTRAARTTRACCCCRCTCTGTGTTRGTTTRAAGTGCRCTGRTTTGRAGARTGRTRCTRATRCC AATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT GATACTACCACCTATACCTTCACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAATGTAATAAAAAAAGAGG TTCRATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTRAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCAGG GACARTGCTARARCCRTRATAGTACAGCTGRACACRTCTGTAGARATTARTTGTACRAGACCCARCRAC AATACAAGAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AARTTRAGAGAACRATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAGTGTTTAATAGT ACTICGTTTRATACTACTTCGAGTACTGRAGGGTCRAATRACACTGRAGGAAGTGACACRATCACACTC CCRTGCRGAATAAACRATTTATAAACRTGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCCTCCCRTC AGCCGACRARITAGRIGITCRICRARITATIRCAGGGCTGCTRITARCARGRGRIGGTGGTRATARCARC ANTGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA GAAAAAAGAGCAGTCCGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACCGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA **AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG** AATCACACGACGTCGATCGAGTGGGACAGAGAAATTAACAATTACACAAGC

10

15

25

30

50

55

oder ein Aequivalent davon kodierend für das besagte Hüllproteinfragment enthält.

31. Ein Expressionsvektor gemäss Anspruch 29, worin das besagte, für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

TGTCCARAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCRACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG ARTACAAGAAAAAATCCGTATCCAGAGGGGACCAGGGAGGGCATTTGTTACAATAGGAAAAATAGGA **ARATTRAGAGAACRATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA** ATTOTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCRTGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCRTC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGGATATGAGGGACAATTGGAGAAGTGAATTATATAAA GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

10

15

25

30

35

40

45

55

oder ein Aequivalent davon kodierend für das besagte Hüllproteinfragment enthätt.

32. Ein Expressionsvektor gemäss Anspruch 29, worin das für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

oder ein Aequivalent davon kodierend für das besagte Hüllproteinfragment enthält.

33. Ein Expressionsvektor gemäss Anspruch 29, worin das besagte, für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

ATGTATGCCCCTCCCATC

AGCGGACAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC
AATGGGTCCGAGATCTTCAGACCTCGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAAAA
TATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCCACCAAGGCAAAGAGAAGAGAGTGGTGCAGAGA
GAAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGAACAATTATGGTCTGGTATAGTGCAGCAGCAGAACAAT
TTGCTGAGGGCTATTGAGGGCCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG
GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCACAGCTCCTGGGGTTTTCGGACTCTGGA
AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTTGGAGTAATAAATCTCTGGAACAGATTTGG
AAACTAATTTGCACCACTGCTGTGCCTTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG
AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

oder ein Aequivalent davon kodierend für das besagte Hüllproteinfragment enthält.

34. Ein Expressionsvektor gemäss Anspruch 29, worin das für ein Hüllproteinfragment eines AIDS-Virus kodierende Gen ein Gen ist, das die Nukleotidsequenz:

30

35

45

5

10

15

- 35. Ein Expressionsvektor gemäss einem der Ansprüche 29 bis 34, der ein Plasmid ist, das sich in gram-negativen Bakterien replizieren kann.
- 36. Ein Expressionsvektor gemäss Anspruch 35, welcher fähig ist, in einen E. coli Stamm zu replizieren.
- 37. Der Expressionsvektor pEV1, -2, oder -3/env 44-640.
- 40 38. Der Expressionsvektor pEV1, -2, oder -3/env 205-640.
 - Ein Transformant der einen Expressionsvektor gemäss einem der Ansprüche 29 bis 38 trägt.

AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

- Ein Transformant gemäss Anspruch 39, der ein E. coli Stamm ist.
- 41. Ein Transformant gemäss Anspruch 40, der ein E. coli MC 1061 Stamm ist.
- 42. Antikörper erzeugt gegen ein wie gemäss Ansprüchen 1 bis 5 und 26 erhaltenes Proteinfragment.
- 50 43. Die Antikörper von Anspruch 42, welche monoklonale Antikörper sind.
 - 44. Ein Impfstoff der Immunität gegen AIDS bewirkt, enthaltend als aktiven Bestandteil ein Proteinfragment erhalten gemäss Ansprüchen 1 bis 5 und 26.
- 45. Die Verwendung eines wie in Anspruch 1 beanspruchten Proteinfragments zur Herstellung eines schützenden, immunisierenden Impfstoffes.

Revendications

10

15

20

25

30

35

Revendications pour les Etats contractants sulvants : BE, CH, DE, FR, GB, IT, LI, NL, SE

5 1. Fragment d'une protéine d'enveloppe d'un virus du syndrome de l'immunodéficience acquise (SIDA), pratiquement exempte d'autres protéines, ayant la séquence d'aminoacides suivante :

ValTrpLysGluAla ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HisklaCysValProThrAspProAsnProGlnGluValValLeuValAsnValThrGluAsnPheAsn METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerSerGlyArgMETIleHETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThcThrSerTyrThrLeuThrSerCysAsnThrSerValIleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlangileLeuAlaValGluhrgTyrLeuLyshspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

ou

40

45

50

Cysprolysvalser PheGluProlleProlleHisTyrCysAlaProAlaGlyPheAlalleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArqSerValAsnPheThr AspAsnAlaLysThrIleIleValGlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly <u>AsnMETArqGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer</u> LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu ProCysArgIleLysGlnPhelleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspHETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThfLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AlaArqIleLeuAlaValGluArqTyrLeuLysAspGinGinLeuLeuGiyIleTrpGlyCysSerGly

LysLeulleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp

AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

ou

25

30

35

40

45

50

55

5

10

15

20

HETArgGInAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGinIleAlaSer
LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

ou

METTYrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

ou

METArgAspAsnTrpArgSerGluLeuTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer.

10

5

- Vecteur d'expression comprenant un gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA telle que définie dans la revendication 1 en aval d'une séquence de promoteur permettant la transcription, la traduction et, par conséquent, l'expression de ce fragment de cette protéine d'enveloppe dans une culture hôte.
- 3. Vecteur d'expression selon la revendication 2, dans lequel ce gène codant pour un fragment d'une protéine d'enve-20 loppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

GTGTGGAAGGAAGCA

ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC 25 ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG CCATGTGTAAAATTAACCCCACTCTGTGTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC AATAGTAGTAGCCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC 30 TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG AATACAAGAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA 35 AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTARCGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG 45 GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG **AATCACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC**

50

ou un équivalent de celle-ci codant pour ledit fragment de la protéine d'enveloppe.

4. Vecteur d'expression selon la revendication 2, dans lequel ce gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

TGTCCAAAGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACG AATACAAGAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA AAATTAAGAGAACAATTTGGAAATAATAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATAAA GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTCGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA AAACTAATTTGCACCACTGCTGCGTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACGTGGATGGAGTGGGACAGAGAATTAACAATTACACAAGC

ou un équivalent de celle-ci codant pour ledit fragment de la protéine d'enveloppe.

5. Vecteur d'expression selon la revendication 2, dans lequel ce gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivantes :

- ou un équivalent de celle-ci codant parmi ledit fragment de la protéine d'enveloppe.
 - 6. Vecteur d'expression selon la revendication 2, dans lequel le gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

55

50

10

15

20

25

30

ATGTATGCCCCTCCCATC

15

10

ou un équivalent de celle-ci codant pour ledit fragment de la protéine d'enveloppe.

7. Vecteur d'expression selon la revendication 2, dans lequel ce gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

20

25

ATGAGGACAATTGGAGAAGTAATTATAAA
TATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCACCAAGGCAAAGAAGAAGAGTGGTGCAGAGA
GAAAAAAGAGCAGTGGGAATTAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGCAGCACCACTATGGGC
GCAGCGTCAATGACGCTGACGGCTACAGCCAGCAGCAACTATTGTTGCTGAGGCTTTTGAGGCGCAACAACTAT
TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTACAGGTCTGGGGATTTAGCGCTCCAG
GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGATTTGCGCTTCCTCTGGA
AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGAACAGATTTGG
AATCACACGACTGGTAGTGGAGGAGAGAGATTAACAATTACACAAGC

30

- 8. Vecteur d'expression selon l'une quelconque des revendication 2 à 7; qui est un plasmide capable de se répliquer dans des bactéries gram-négatives et/ou gram-positives.
 - 9. Vecteur d'expression selon la revendication 8, qui est capable de se répliquer dans une souche d'E.coli.
 - 10. Vecteur d'expression selon la revendication 8, qui est capable de se répliquer dans une souche de B. subtilis.

40

- 11. Vecteur d'expression pEV1, -2 ou -3/env. 44-640
- 12. Vecteur d'expression pEV1, -2 ou 3/env. 205-640.
- 45 13. Transformant portant un vecteur d'expression selon l'une quelconque des revendications 2 à 12.
 - 14. Transformant selon la revendication 13, qui est une souche d'E.coli.
 - 15. Transformant selon la revendication 14, qui est une souche d'E.∞li MC 1061.

50

- 16. Transformant selon la revendication 13, qui est une souche de B.subtilis.
- 17. Transformant selon la revendication 13, qui est une cellule de mammifère.
- 18. Procédé de préparation d'un fragment d'une protéine d'enveloppe d'un virus du syndrome d'immunoficience acquise selon la revendication 1, consistant à :

transformer une cellule hôte avec un vecteur d'expression selon l'une quelconque des revendications 2 à 12; cultiver cette cellule hôte de façon que ce fragment de cette protéine d'enveloppe du SIDA soit exprimée; et

extraire et isoler ce fragment de cette protéine d'enveloppe du SIDA.

- 19. Procedé selon la revendication 19, dans lequel le vecteur d'expression est pEV1, -1, -2 ou -3/env.44-640
- Procédé selon la revendication 19, dans lequel le vecteur d'expression est pEV1, -2 ou -3/env. 205-640.
 - 21. Procédé de détection dans le sang humain de la présence d'anticorps pour l'agent étiologique viral du SIDA, qui consiste à mélanger une composition contenant un fragment d'une protéine d'enveloppe d'un virus du SIDA, selon la revendication 1, avec un échantillon de sang humain et de déterminer si ce fragment de cette protéine d'enveloppe du SIDA se lie aux anticorps du SIDA présents dans l'échantillon de sang.
 - 22. Procédé selon la revendication 21 qui consiste à utiliser l'analyse par "Western Blotting".

10

25

50

- 23. Procédé selon la revendication 21 qui comprend l'utilisation d'une technique ELISA, dans laquelle un fragment d'une protéine d'enveloppe d'un virus du SIDA, selon la revendication 1, est appliquée sur une phase solide et mise en contact avec l'échantillon et, après lavage, mise en contact avec une IgG non humaine marquée par une enzyme.
 - 24. Procédé selon la revendication 21, dans lequel on utilise la Méthode du Double Antigène.
 - 25. Procédé pour la détermination du virus du SIDA, dans lequel on utilise des anticorps contre un fragment d'une protéine d'enveloppe d'un virus du SIDA, selon la revendication 1.
 - 26. Procédé selon la revendication 25, dans lequel l'antigène présent dans l'échantillon et un fragment d'une protéine selon la revendication 1, sous forme marquée entrent en compétition avec un anticorps contre un fragment d'une protéine selon la revendication 1.
 - 27. Procédé selon la revendication 25, dans lequel on applique une méthode sandwich en utilisant deux anticorps contre un fragment d'une protéine selon la revendication 1.
 - 28. Procédé selon la revendication 27, dans lequel un anticorps est sur une phase solide et l'autre anticorps est marqué.
 - 29. Procédé selon la revendication 27, dans lequel on utilise deux anticorps monoclonaux différents.
 - Vaccin déclenchant l'immunité au SIDA comprenant comme ingrédient actif un fragment d'une protéine selon la revendication 1.
 - 31. Anticorps formés contre un fragment d'une protéine selon la revendication 1.
 - 32. Anticorps selon la revendication 1, qui sont des anticorps monoclonaux.
 - 33. Utilisation d'un fragment d'une protéine selon la revendication 1, pour la préparation d'un vaccin d'immunisation protectrice.
 - 34. Utilisation d'un fragment d'une protéine selon la revendication 1 pour détecter dans le sang humain la présence du virus du SIDA.

Revendications pour l'Etat contractant suivant : AT

- 1. Procédé pour préparer un fragment d'une protéine d'enveloppe d'un virus du syndrome de l'immunodéficience acquise (SIDA), essentiellement exempte d'autres protéines, qui consiste :
- à transformer une cellule hôte avec un vecteur d'expression comprenant un gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA ayant la séquence d'acides aminés suivante :

ValTrpLysOluAla ThirthrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HISALACYEVALPROTHEASPPROASHPROCLINGLUVALVALLEUVALASHVALTHEGLUASHPHEASH METT:pLysAsnAspHETValGluClnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr ASNS@rS@rS@rGlyArgMETIleMETCluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SarIleArgOlyLysValGlnLysOluTyrAlaPherheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSar Phc3lurrolleProlleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIloArgProValVal SerThrCl::LouLouLouAsnOlySerLeuAlaOluGluOluValValIlaArgSorValAsnPhaThr AsphsnAlaLysThrIleIleValOlnLeuAsnThrSerValGluIleAsnCysThrArgProAsnAsn RanThrArgLysLysFleArgIleGlnArgGlyProGlyArgAlaPhevalThrIleGlyLysIleGly AschieTargGlnAlaHisCysAsnIleSecArgAlsLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLeuArgGluJlnPheGlyAsnAsnLysThrIleIlePheLysOlnSerSerClyOlyAspProGlu IleValThrHisSerPhaAsnCysGlyGlyGluPhoPheTyrCysAsnSerTnrGlnLouPhaAsnSer ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLou FroCysargileLysGlnPheileAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerSlyGlnIleArgCysSerSerAsnIleThrGlyLouLouLeuThrArgAspGlyGlyAsnAsnAsn AscClySerGluIlePheArgProGlyGlyGlyAspMETArgAsoAsnTrpArgSerGluLeuTyrLYS TyrLysValValLysIlaGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPhaLouGlyAlaAlaGlySerThrMETGly AlaAlaSerMETThrLeuThrValGlnAlaArgJlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LouLouArgAlaIleGluAlaGlnClnHisLouLouGlnLouThrValTrpGlyIloLysGlnLouGln AlcArgIleLeuAlaValGluArgTyrLeuLyaAsoGlmGlmLeuLeuGlyIleTrpGlyCysSerGly LysLeufleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIlaTrp AshHistheTheTepMETGluTepAspAcqGluIleAshAshTycTheSec

ou

5

10

15

20

25

30

35

40

45

55

Cys?roLysValSer PheGluProfleProfleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisSlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr AspAsnAlaLy=ThrileIleValGlnLeuAsnThrSerValGluIleAsnCy=ThrArgProAsnAsn AsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly AsnMETArgGlnAlaHisCysAsnIleSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer LysLauArgGluGlnPheGlyAxnAxnLyaThrIteIlePheLysOlnSerSerGlyOlyAspProGlu TlevalThrHisserPheAsnCysClyClyCluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer ThrTrpPheAsnSorThrTrpSorThrOluGlySerAsnAsnThrGluGlySerAspThrIloThrLeu ProCysArgileLysGinPhelleAsnMETTrpGinGluValGlyLysAlaMETTyrAlaProProlle SerGlyGinIleArqCysSerSerAsnIleThrGlyLeuLeuLouThrArqAspGlyGlyAsnAsnAsn AshGlySerGluIlePheArgPrcGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValOlnArg GluLysRrghlaValGlyIleGlyAlaLeuPheLeuGlyPhaLeuGlyAlaAlaGlySerThrHETGly AlaAlaSerMETThrLeuThrValGinAleAr;GinLeuLeuSerGlylleValGinGinGinAsnAsn LeuteyArgAlaTleGluAlaGlnGlnHisLouLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln AleargIleLeuAlaValGluArgTyrLouLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLauIlaCysThrThrAlaValProTrpAsnAlaSarTrpSarAsnLysSarLeuGluGlnIleTrp ASNHISTHTTHTTPHETGluTrpAspArgGluIleAsnAsnTyrThrSor

ou

METArgolnAlaHisCysAsnileSerArgAlaLysTrpAsnAlaThrLeuLysGlnIleAlaSer
LysLeuArgoluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu
IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer
ThrTrpPheAsnSerThrTrpSerThrGluGlySerAsnAsnThrGluGlySerAspThrIleThrLeu
ProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle
SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLauThrArgAspGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyGlyAspHETArgAspAsnTrpArgSerGluLouTyrLys
TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLeuLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly
LysLouIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp
Asm!!sThrThrTrpMETGluTrpAspArgGluIleAxnAsnTyrThrSor

ou

20

25

5

10

15

HETTYRALAPROPROLLA
SerGlyClnIleArgCysSerSerAsnIleThrGlyLauLauLeuThrArgAxpGlyGlyAsnAsnAsn
AsnGlySerGluIlePheArgProGlyGlyAspHETArgAspAsnTrpArgSerGluLeuTyrLys
TyrLyaValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg
GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrHETGly
AlaAlaSerHETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn
LeuLeuArgAlaIleGluAlaGlnGlnHisLauLeuGlnLeuThrValTrpGlyIleLysGlnLeuGln
AlaArgIlaLauAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIlaTrpGlyCysSerGly
LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSorAsnLysSerLeuGluGlnIlaTrp
AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSer

ou

35

40

30

METACGASPASHTCPACGSCOLLEUTYLYS
TYTLYSValValLySIleGluProLouGlyValAlaProThrLysAlaLySACGACGValValGlnArg
GluLysAcgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThrMETGly
AlaAlaSerMETThrLouthrValGlnAlaAcgGlnLouLouSerGlyIleValGlnOlnGlnAsnAsn
LeuLauAcgAlaIleGluAlaGlnGlnHisLeuLeuGlnLouthrValTrpGlyIloLysGlnLouGln
AlaAcgIloLouAlaValGluAcgTyrLoutySAspOlnGlnLoutouGlyIloTrpGlyCysSerGly
LysLouIloCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLouGluGlnIloTrp
AsnHisThrTrpMETGluTrpAspAcgGluIloAxnAsnTyrThrSer

45

50

en aval d'un promoteur permettant la transcription, la traduction et l'expression du fragment de cette protéine d'enveloppe dans la cellule hôte ; à cultiver cette cellule hôte de façon à exprimer le fragment de la protéine d'enveloppe d'un virus du SIDA ; et à extraire et à isoler le fragment de la protéine d'enveloppe d'un virus du SIDA.

- 2. Procédé selon la revendication 1, dans lequel la cellule hôte est une bactérie.
- 3. Procédé selon la revendication 2, dans lequel la bactérie est E. coli.

- 4. Procédé-selon la revendication 3, dans lequel le plasmide est pEV1, -2 ou -3/env 44-640.
- 5. Procédé selon la revendication 3, dans lequel le plasmide est pEV1, -2 ou -3/env 205-640.

- 6. Procédé pour préparer un vecteur d'expression comprenant un gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA, procédé qui consiste à construire un vecteur d'expression portant un site d'insertion, dans lequel on peut insérer un gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA selon la revendication 1, le site d'insertion se trouvant en aval d'un promoteur permettant la transcription, la traduction et donc l'expression du fragment de la protéine d'enveloppe dans une cellule hôte.
- 7. Procédé selon la revendication 6, caractérisé en ce qu'on utilise en tant que gène codant pour un fragment d'une protéine d'enveloppe du virus du SIDA un gène comprenant la séquence nucléotidique suivante :

10 GTGTGGAAGGAAGCA ACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGGTACATAATGTTTGGGCCACA CA TOCCTOTOTACCOACAGACCCCAACCCACAAGAAGTACTATTOGTAAATGTGACAGAAAATTTTAAC ATGTCGAAAATGACATGGTAGAACACATGCATCAGGATATAATCAGTTTATCCGATCAAAAGCCTAAAG CCXTGTGTAAAXTTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC ANTAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAACTGCTCTTCAATATATGAGCACA ONTACTRICAGETRIACGTTGRCAAGITGTAACREETCRGTCRTTACACRGGCCTGTCCAARGGTATCC TTTGAGCCAATTCCCATACATTATTGTGCCCCCCCCTCGTTTTGCGATTCTAAAATGTAATAAGACC TTEARTGGARCAGGACCATGTACARATGTCAGCACAGTACARTGTACACATGGARTTAGCCCAGTAGTA 20 TEARCTCAACTGCTOTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG ANTACAAGAAAAAAATCCOTATCCAGAGGGGGACCAGGGAGATTTOTTACAATAGGAAAAATAGGA KADADOSADDOUKDDKOTOOTKKODKKTTTOTKKTKKOKKITKAKADOTTTKKADKDKEKI KKK 25 ATTGTAACGCACAGTTTTAATTGTGGGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT ACTIOGITTAATAGTACTIGGAGTACTGAAGGGICAAATAACACTGAAGGAAGTGACACAATCACACTC CCATCCAGAATAAACAATTTATAAACATGTCCCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AAATATATAADTOAADOTTAADADDOADTATADAEDAEDAEDAEDTOADAEDTOTTOTADAEDTEGOTAA 30 TATAAAGTAGTAAAAATTGAAGCATTAGGAGTAGCACCAAGGCAAAGAGAAGAGTGCTGCAGAGA DROOTATDADDAADDADDADDADDOTTTTDDDTTDDTTDDATAADDOTDADDADAAAAU GEASCOTCAATOACOCTOACOOTACAOGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGCAGCACAAT TTSCTGAGGGGTATTGAGGGGGAACAGCATCTGTTGCAACTCACAGTGTGGGGGCATCAAGCAGCTCCAG CCAAGAATCCTCGCTGTGGAAAGATACCTAAAGGATCAACACCTCCTCGCCATTTCGGGTTGCTCTGGA 35 ANTERCACGACUTOURTGGAGTGGGACAGAGAAATTAACAATTACACRAGC

ou on utilise un équivalent codant en conséquence.

5

40

8. Procédé selon la revendication 6, caractérisé en ce qu'on utilise en tant que gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA un gène comprenant la séquence nucléotidique suivante :

TGTCCAAAGGTATCC

TTTGAGCAATTCCCATACATTATTCCCCCCCCCCCTTTTCCCATTCTAAAATGTAATAATAAACCC TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTCRACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCRCG AXTACAAGAAAAAATCCGTATCCAGAGGGGGCGCGCGAGAGAGTTTVTTACAATAGGAAAAATAGGA *AANTTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGGCCCAGAA* 10 atiotarescaerstittaatistessassesaatittietaetstaatieaaeaacistitaatast CCATGCAGAATAAACAATTTATAAACATGTGGGAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC ASCEGACAAATTAGATETTCATCAAATATTACAGGCTGCTATTAACAAGAGAGATEGTEGTAATAACAAC ANTSGGTCCGAGATCTTCAGACCTGGAGGAGAGATATGAGGGGACAATTSGAGAAGTGANTTATATAAA 15 TATAMGTAGTALAKATATOANGTAGGAGTAGGAGCCACCAACAAAGAGAAGAGTGCAGGAGAGA GANANAGAGCAGTGGGANTAGGAGCTTTUTTCCTTCCGTTCTTGGGAGCAGCAGCAGCAGCACCATATGGGC GCAGGGTCAATGACGGTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGCCATCAAGCAGCTCCAG GCAJGARTCCTGGCTGTGGAAAGATACCTAAAGATCAACACCTCCTGGGTTGCTGGTTGCTCTGGA *ATCACACGACGTGGATGGAGTCGGACAGAGAAATTAACAATTACACAAGC

ou on utilise un équivalent codant en conséquence.

9. Procédé selon la revendication 6, caractérisé en ce qu'on utilise comme gène codant pour un fragment d'une protéine d'enveloppe du virus du SIDA un gène comprenant la séquence nucléotidique suivante :

ATTGTAACGCACAGTTTTAATTGTGGGGGGGGGGGTGATTTTAATCCACACAGTAATTTTAATAGT ACTTGGTTIANTAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGGAAGTGACACAATCACACTC CCATGCAGAATAAAACAATTTATAAACATGTCGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC AATOCOTOCOAGATOTTCAGACCTCGAGGAGGAGATATUAGGGACAATTCGAGAAGTGAATTATATAAA GURGEGTCRATGREGETRACGGTRERGGECRGRERATTRITGTCTGGTRTRGTGCRGCRGCRGRACART TIGGTGAGGGGTATTGAGGGGGAACAGGATCTGTTGCAACTGACAGTCTGGGGGCATCAAGCAGCTGCAG GCXXGAATCCTGGGTGGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTCCGGGTTGCTCTGGA AMACTANTITOCACCACTGCTGTGCCTTGGANTGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG

ou on utilise un équivalent codant en conséquence.

10. Procédé selon la revendication 6, caractérisé en ce qu'on utilise comme gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA un gène comprenant la séquence nucléotidique suivante :

55

45

5

20

25

30

ATGTATGCCCCTCCCATC

ou on utilise un équivalent codant en conséquence.

10

30

- 11. Procédé selon la revendication 6, caractérisé en ce qu'on utilise en tant que gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA un gène comprenant la séquence de nucléotides suivante :
- - ou on utilise un équivalent codant en conséquence.
 - 12. Procédé selon l'une quelconque des revendications 6 à 11, dans lequel le vecteur d'expression est un plasmide pouvant subir une réplication dans des bactéries gram-négatives.
 - 13. Procédé selon la revendication 12, dans lequel le plasmide peut subir une réplication dans une souche de E. coli.
 - 14. Procédé pour préparer un transformant portant un vecteur d'expression, qui comprend un gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA, ce procédé consistant à transformer un micro-organisme avec un vecteur d'expression obtenu selon l'une quelconque des revendications 6 à 13, et à cultiver le micro-organisme transformé.
 - 15. Procédé selon la revendication 14, dans lequel le micro-organisme est une souche de E. coli.
- 45 16. Procédé selon la revendication 15, dans lequel le micro-organisme est une souche de E. coli MC 1061.
 - 17. Procédé pour détecter dans le sang humain la présence d'anticorps contre l'agent étiologique viral du SIDA, qui consite à mélanger une composition contenant un fragment d'une protéine d'enveloppe du virus du SIDA obtenue selon la revendication 1 avec un échantillon de sang humain, et à déterminer si le fragment de la protéine d'enveloppe du SIDA se lie aux anticorps anti-SIDA présents dans l'échantillon sanguin.
 - 18. Procédé selon la revendication 17, qui consiste à utiliser une analyse par "Western Blotting".
- 19. Procédé selon la revendication 17, qui consiste à utiliser une technique de liaison enzymatique Elisa, dans laquelle un fragment d'une protéine d'enveloppe d'un virus du SIDA obtenue selon la revendication 1 est appliquée sur une phase solide et mise en contact avec l'échantillon et, après lavage, mise en contact avec une IgG non humaine marquée par une enzyme.
 - 20. Procédé selon la revendication 17, dans lequel on utilise la Méthode du Double Antigène.

- 21. Procédé pour la détermination du virus du SIDA, dans lequel on utilise des anticorps contre un fragment d'une protéine d'enveloppe d'un virus du SIDA obtenue selon la revendication 1.
- 22. Procédé selon la revendication 21, dans lequel l'antigène présent dans l'échantillon et un fragment d'une protéine obtenue selon la revendication 1 sous forme marquée entrent en concurrence avec un anticorps contre un fragment d'une protéine obtenue selon la revendication 1.
- 23. Procédé selon la revendication 21, dans lequel on utilise une méthode sandwich en utilisant deux anticorps contre un fragment d'une protéine obtenue selon la revendication 1.
- 24. Procédé selon la revendication 23, dans lequel un anticorps se trouve sur une phase solide et l'autre anticorps est marqué.
- 25. Procédé selon la revendication 23, dans lequel on utilise deux anticorps monoclonaux différents.
- 26. Fragment d'une protéine d'enveloppe d'un virus du SIDA, préparée par un procédé selon l'une quelconque des revendications 1 à 5.
- 27. Vecteur d'expression comprenant un gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA, préparée par un procédé selon l'une quelconque des revendications 6 à 13.
 - 28. Transformant portant un vecteur d'expression comprenant un gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA, préparé par un procédé selon l'une quelconque des revendications 14 à 16.
- 29. Vecteur d'expression comprenant un gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA selon la revendication 1, en aval d'un promoteur permettant la transcription, la traduction et donc l'expression du fragment de la protéine d'enveloppe dans une cellule hôte.
- 30. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

35

50

GTGTGGAAGGAAGCA

RUCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA CATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC ATOTOGAAAATGACATOGTAGAACAGATGCATGAOCATATAATCAGTTTATOGGATCAAAGCCTAAAG CCRTGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAAATACCAATAGATAAT GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC 10 TTTSRGCCANTTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG TTCARTGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCXXCTCXXCTGCTGTTAAXTOGCAOTCTAGCAOAXGAAOAGGTAGTAATTAGATCTGTCXXTTTCACG 15 NAXTTNAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGACCGGACCCAGAA ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT ACTTGGTTTXXTXGTACTTGGAGTXCTGAXGTGGACATAXCXCTGAXGTAACACTGACACAATCACTC CCATGCAGATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC 20 accochchantagatgttcatcaaatattacacccctattaacaagagatgctgtaataataacaac AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA UARRANGAGEAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGCGAGCAGCAGGAACCACTATGGGC GCAGCCTCAATGACGCTGACCGTACAGGCCAGACAATTATTGTCTCGTATAGTGCAGCAGCAGAACAAT 25 TTOCTORGOCCTATTGROCCCCRRCAGCRICTGTTGCRRCTCRCAGTCTGGGGCCRTCRRGCAGCTCCRG SCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA ULCIATITECACCACTECTETOCCTTEGAATECTASTTEGAGIAATAATETETEGAACAGATTTEG AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGC

ou l'un de ses équivalents codant pour ledit fragment de ladite protéine d'enveloppe.

30

45

50

55

35 31. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

TGTCCAAAGGTATCC

TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAATAATGACG TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA TCAACTGAACTGCTGTTAAATGGCAGTCTAGCAGAAGAGAGGTAGTAATTAGATCTGTCAATTTCACO AATACAAGAAAAATCCGTATCCAOAGGGGCCAGCGAGAGCATTTGTTACAATAGGAAAAATAGGA **ANTATOAGACANGCHCATTGTARCATTNGTAGACARANTSGAATGCCACTTTAAAACAGATAGCTAGG** AAATTAAGAGAACAATTTEGAAATAATAAACAATAATCTTTAAGCAATCCTCAGGAGGAGGCGCAGAA 10 ATTGTAACCCACAGTTTTAATTGTCGACCCAATTTTTCTACTGTAATTCAACACGTTTAATAACTACTGTTTAATAGT CCATGCAGAATAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC AGCCGACAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC 15 AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAATTAAAAA TATRANGTAGTRAANATTGAACCATTAGGAGTAGCACCCACCRAGGCRAAGAGAGAGAGTGGTGGAGAGA GANAANGNGCAGTGGGANTAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACCACTATGGGC GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAAAAAAT TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG 20 ALACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAOTTOGAGTAATAAATCTCTGGAACAGATTTOG AATCACACGACGTGGATGGAGTGGAGTGAGTGACAATTACACTAGC

ou l'un de ses équivalents codant pour ledit fragment de la protéine d'enveloppe. 25

32. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :

ATGRGRCANGCACRTTGTRACATTAGTRGRGCANAATGCARATGCCACTTTAAAACAGATAGCTAGC AAATTAAGAGAACAATTTGGAAATAATAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA ATTCTAACCCACACTTTTAATTCTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT ACTIGGITTAATAGTACTTOGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACACTC CCATGCAGAATAAAACAATTTATAAACATOTUGCAGGAAGTAGGAAAAGCAATOTATGCCCCTCCCATC ACCCGACAATTAGATGTTCATCAATATTACAGCGCTGCTATTAACAAGAGGATGGTAATAACAAC FATCCCTCCCAGATCTTCAGACCTCGAGGCCCAGATATGACCGCACAATTCGAGAAGTGAATTATAAAA TRTPARGTEGTARARATTGRACCATTROGRGTAGCRCCCRCCRAGGCARGRGRAGRGTGGTGCRGAGR GRREANAGAGCAGTGGGAATAGGACCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGCAGCACCATATGGGC GCAGCGTCAATGACGCTGACGGTACAGCCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGCAGCAAAT TTGCTGAGGGGTATTGAGGGGCAACAGCATCTGTTGCAACTCACAGTCTGGGGGCATCAAGCAGCTCCAG OCARGARICCIOGCIGIOGARAGATACCIARAGGATCARCACCICCIOGGGATITCCCGTTGCTCTGGA MACIAATTIGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAATCTCTGGAACAGATTTGG antenergacotogatogrotogrergagarattracarttaererse

ou l'un des ses équivalents codant pour ledit fragment de la protéine d'enveloppe.

33. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour un fragment d'une protéine d'enve-50 loppe d'un virus du SIDA est un gène conprenant la séquence de nucléotides suivante :

55

30

35

40

45

ATGTATGCCCCTCCCATC

- ou l'un de ses équivalents codant pour ledit fragment de la protéine d'enveloppe.
- 34. Vecteur d'expression selon la revendication 29, dans lequel le gène codant pour un fragment d'une protéine d'enveloppe d'un virus du SIDA est un gène comprenant la séquence de nucléotides suivante :
- ATGACCACATTGGAGAAGTAATTAAA

 TATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCACCAAGGCAAAGAAGTAGTAATTATAAA

 TATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCACCAAGGCAAAAAAAGAGCAGTAGGAGCAGCAGGAGCAGTATGGGC

 GAAAAAAGAGCAGTGGGAACAGCTTTGTTCCTTGGTATAGGCAGCAGCAGCAGAACAAT

 TTGTTGAGGGTTATTGAGGCGGAACAGCATTCTGTTCCAACTCTGGGGATCAAGCAGCTCCAG

 GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCACAGCTCCTGGGATTTGGGTTGCTCTGGA

 AACTAATTTGCACCACTGCTGTGCCTTGGAATGATAAAAATCTCTGGAACAGATTTGG

 AATCACACGACGTGGATGGAGTAGAAAAATTAACAATTACAAAGC
 - 35. Vecteur d'expression selon l'une quelconque des revendications 29 à 34, qui est un plasmide pouvant subir une réplication dans des bactéries grain-négatives.
 - 36. Vecteur d'expression selon la revendication 35, qui peut subir une réplication dans une souche de E. coli.
 - 37. Vecteur d'expression pEV1, -2 ou -3/env 44-640.
- 40 38. Vecteur d'expression pEV1, -2 ou -3/env 205-640.

10

15

30

- 39. Transformant portant un vecteur d'expression selon l'une quelconque des revendications 29 à 38.
- 40. Transformant selon la revendication 39, qui est une souche de E. coli.
- 41. Transformant selon la revendication 40, qui est une souche de E. coli MC 1061.
- 42. Anticorps produits contre un fragment d'une protéine obtenue selon les revendications 1 à 5 et 26.
- 50 43. Anticorps selon la revendication 42, qui sont des anticorps monoclonaux.
 - 44. Vaccin déclenchant une immunité au SIDA, comprenant comme principe actif un fragment d'une protéine obtenue selon les revendications 1 à 5 et 26.
- 45. Utilisation d'un fragment d'une protéine selon la revendication 1 pour préparer un vaccin d'immunisation protectrice.

FIGURE 1

1	ATTCTGCAACACTGCTGTTTATCCATTTTCAGAATTOGGTGTCGACATAGCAGAATAGGCGTTACTCG	69
70	ACAGAGGAGGAGCAAGAATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGC	138
139	CTARARCTGCTTGTACCARTTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTT	207
208	AAGCCTTAGGCATCTCCTATGGCAGGAAGAACCGAGACAGAC	276
277	CTCATCAAGTTTCTCTATCAAAGCAGTAAGTAATACATGTAATGCAACCTATACAAATAGCAATAGTAG	345
346	CATTAGTAGCAATAATAATAGCAATAGTTOTOTOGTCCATAGTAATCATAGAATATAGGAAAATAT	414
415	TRAGRCAAAGAAAATAGACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGA	483
484	GTGAAGGAGAATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTG	552
553	ATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAA	621
622	RCCACCACTCTATTTTGTGCATCAGATOCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA	690
691	CATGCCTGTGTACCCACAGACCCCACAGAGAGTAGTATTGGTAAATGTGACAGAAATTTTAAC	759
760	ATGTGGAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG	828
829	CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC	897
898	ARTAGTAGCOGGAGAATGATAATOGAGAAAGGAGATAAAAAACTGCTCTTTCAATATCAGCACA	966
967	AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT	1035
1036	GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC	1104
1105	TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG	1173
1174	TTCAATOGRACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA	1242
1243	TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGGTAGTAATTAGATCTGTCAATTTCACG	1311
1312	GACAATGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATT	1380
1381	ARTACAAGAAAAAAATCCGTATCCAGAGOOGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA	1449
1450	AATATGAGACAAGCACATTGTAACATTAGTAGAGCAAAATGGAATGCCACTTTAAAACAGATAGCTAGC	1518
1519	AAATTAAGAGAACAATTTGGAAATAATAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA	1587
1588	ATTGTAACGCACAGTTTTAATTGTOGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT	1656
1657	ACTTOGTTTAATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAG	1725
1726	CCATGCAGAATAAAACAATTTATAAACATGTOOCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC	1794
1795	AGCOGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC	1863
1864	AATGGGTCCGAGATCTTCAGACCTGGAGGAGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA	1932
1933	TATAAAGTAGTAAAAATTGAACCATTROGAGTAGCACCCACCCAAGGCAAAGAGAAGAGTGGTGCAGAGA	2001
2002	GAAAAAGAGCAGTOOGAATAGGAGCTTTGTTCCTTOOGTTCTTOOGAGCAGCAGCAGCACCTATGGGC	2070
2071	GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT	2139
2140	TTGCTGRGGGCTATTGRGGCGCRACAGCRTCTGTTGCRACTCRCAGTCTGGGGCRTCRAGCRGCTCCRG	2208
2209	GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGA	2277
2278	AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG	2346
2347	NATCACACGACGTGGATGGAGTGGGACAGGAAATTAACAATTACACAAGCTTAATACACTCCTTAATT	2415
2416	GAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTOGAATTAGATAAATCGGCAAGTTTG	2484
2485	TOGRATTOGTTTAACATAACAAATTOGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTG	2553
2554	GTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTGTAGTGAATAGAGTTAGGCAGGGATATTCACCATTA	2622
2623	TCGTTTCAGACCCACCTCCCAATCCCGAGGGACCCGACAGGCCCGAAGGAATAGAAGAAGGAAG	2691
2692	GAGAGAGACAGACAGATCCATTCGATTAGTGAACOGATCCTTAGCACTTATCTGGGACGATCTGCGG	2760
2761	AGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTT	2829
2830	CTGGGAGGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAATATTGGAGTCAGGAGCTA	2898
2899	AAGAATAGTGCTGTTAGCTTGCTCAATGCCACAGCTATAGCAGTAGCTGAGGGGACAGATAGGGTTATA	2967
	GANGTAGTACAAGAAGCTTATAGAGCTATTCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGG	3036
3037	ATTTTGCTATAAGATOOGTOGCAAGTOOTCAAAAAGTAGTGTGGTTGGATOGCCTGCTGTAAGGGAAAG	3105
3106	AATGAGACGAGCTGAGCCAGCAGCAGCAGCATCGGGGAGCAGCATCTCGAGA	3156

FIGURE 2 (3 pages)

					-							
	1	-										50
HXB-3												
BH-10 BH-8		•						•			F	
LAV					ĸ		I				. •	
ARV-2	· K	GTRE	en .	-		-					-	
		•									•	
	51									•	100)
HXB-3	TLF	CASDAKA	YDTEV	HNVWA	THAC	VPTD	PNPQ	EVVI	LVNVI	CENE	NMWKND	4
BH-10							•					
BH-8 LAV		•										
ARV-2		R							G		N	
		•		•								
	101											150
HXB-3	VEO	MHEDIIS	LWDOS	LKPCV	KI.TP	i LCVS1	· LKCT	DI.KI	דמירונ	NSS	SSC	2DM I ME
BH-10				J., J.			J., C.		101111			·
BH-8			•									
LAV ARV-2	•	^				_	••	G			NTNSS	E M
ARV-Z		Q				T	N	G	A		NWKEE I -	
									•			
	151							: '				200
HXB-3	KGE	KNCSFN	ISTSI	RGKVQ	KEYA	FFYKI	LDIII	PIDN	IDT	TSY	TLTS	-CNTSV
BH-10										,		
BH-8 LAV	•		K									
ARV-2			T	D I	N 1	L RN	vv		AST	N.	NYRLIE	ł R
			•	•		G 414.	• •		701		*********	
	201			. *							250)
HXB-3	TTO	CPKVSP	PPIPI	HVCAP	ACPA	I I.KC	JNETI	PNGT	ייבים ביי	MUC	TVQCTHG	,
BH-10							*****		.di Ci		rascine	•
BH-8										,		
LAV								A				
ARV-2				T				K				
	251										300)
HXB-3	IRPV	VSTQLL	LNGSL	AEEEV	VIRS	/NFTI	NAK1	riiv	OLNT	SVE	INCTRPN	ı
BH-10					1				Q			
BH-8					_				D			
LAV ARV-2	1	,			, I	-	1		Q			
v-4						, 1	•		C	A		

•	301	-							
	301		· .	350					
HXB-3 BH-10 BH-8 LAV	NNTRKKIRIQRGPGRAFVTIGKIGN S	MRQ-AHCN	ISRAKWNAT N	LKQIASKLR D D					
ARV-2	SY HTRIG	DIRK	Q N	E VK					
	351			400					
HXB-3 BH-10 BH-8 LAV	EQFGNNKT I I FKQSSGGDPE I VTHS	FNCGGEFF	YCNSTQLFN	STWPNSTW					
ARV-2	V N M	R	T	N -RLNH					
	401			450					
HXB-3	STEGSNNTEGSDTITLPCRIKQFIN	MWQEVGKA	MYAPPISGO	IRCSSNIT					
BH-10	K								
BH-8	K			•					
LAV ARV-2	K N I I			•					
ARV-2	K N I		G	S					
				•					
	451			500					
HXB-3	GLLLTRDGG-NNNNGSE I FRPGGGD	MRDNWRSE	LYKYKVVKI	EPI.GVAPTK					
BH-10	- S E								
BH-8	- S E.								
LAV	-								
ARV-2	T VT DT V		I,	1 .					
·	501			550					
HXB-3	A 180 THE TANK CANDERS OF THE CANDER	3.3.00mW03:	A CWMI MION	Dot t cotvo					
BH-10	AKRRVVQREKRAVGI-GALFLGFLG	AAGSTMGA	ASMTLTVQA	KÖLLSGIAÖ					
BH-8	-			•					
LAV	-	1	R						
ARV-2	v M	1	V L						
	551			600					
HXB-3	QQNNLLRA I EAQQHLLQLTVWG I KQLQAR I LAVERYLKDQQLLG I WGCSG								
BH-10	G	-							
BH-8	•								
LAV ARV-2		v	R						
AW 4 - 2		•	L.						

```
601
                                                          650
HXB-3
         KLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQ
BH-10
                                  NM
BH-8
                                  NM
LAV
                                  NM
ARV-2
                             D DNM
                                       QE
                                             D
                                                 NT YT
     651
                                                          700
        NQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
HXB-3
BH-10
BH-8
LAV
                                           I
ARV-2
                                S
      701
                                                          750
        VLSVVNRVRQGYSPLSFQTHLPIPRGPDRPEGIEEEGGERDRDRSIRLVN
HXB-3
BH-10
BH-8
            I
                               N
LAV
           1
                               T
ARV-2
           I
                            R
                                        D
                                                           D
      751
                                                         800
HXB-3
        GSLALIWDDLRSLCLFSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLL
BH-10
BH-8
LAV
ARV-2
                           R
                                    AA T
                                         -I H
                                                         S
      801
                                                         850
HXB-3
        QYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQEAYRAIRHIPRRIRQG
BH-10
                                            G
BH-8
                    N
                                           A
LAV
                                           GC
ARV-2
           I
                               T
                                         AR
                                                     H
                                                  L
      851 856
HXB-3
        LERILL
BH-10
BH-8
LAV
ARV-2
           L
```

" - " designates a deletion of one amino acid. An empty space denotes identity with HXB-3 sequence.





Figure 4

a b c d e

Figure 5



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18



FIGURE 6A


METArg


ValLysGluLysTyrGlnHisLeuTrpArgTrpGlyTrpArgTrpGlyThrMETLeuLeuGlyMETLeu METITECysSerAlaThrGluLysLeuTrpValThrValTyrTyrGlyValProValTrpLysGluAla ThrThrThrLeuPheCysAlaSerAspAlaLysAlaTyrAspThrGluValHisAsnValTrpAlaThr HisAlaCysValProThrAspProAsnProGinGluValValLeuValAsnValThrGluAsnPheAsn METTrpLysAsnAspMETValGluGlnMETHisGluAspIleIleSerLeuTrpAspGlnSerLeuLys ProCysValLysLeuThrProLeuCysValSerLeuLysCysThrAspLeuLysAsnAspThrAsnThr AsnSerSerGlyArgMETIleMETGluLysGlyGluIleLysAsnCysSerPheAsnIleSerThr SerIleArgGlyLysValGlnLysGluTyrAlaPhePheTyrLysLeuAspIleIleProIleAspAsn AspThrThrSerTyrThrLeuThrSerCysAsnThrSerVallleThrGlnAlaCysProLysValSer PheGluProIleProIleHisTyrCysAlaProAlaGlyPheAlaIleLeuLysCysAsnAsnLysThr PheAsnGlyThrGlyProCysThrAsnValSerThrValGlnCysThrHisGlyIleArgProValVal SerThrGlnLeuLeuLeuAsnGlySerLeuAlaGluGluGluValValIleArgSerValAsnPheThr Asp Asn Ala Lys Thr I le I le Val Glin Leu Asn Thr Ser Val Gliu I le Asn Cys Thr Arg Pro Asn Asn Lys Thr Arg Pro Asn Lys Thr Arg Pro Asn Lys Thr Asn Lys Thr Arg Pro Asn Lys Thr Arg Pro Asn Lys Thr Arg Pro Asn Lys Thr AsnAsnThrArgLysLysIleArgIleGlnArgGlyProGlyArgAlaPheValThrIleGlyLysIleGly $As \verb"metargGlnAlaHisCysAs \verb"nileSerArgAlaLysTrpAs \verb"nAlaThrLeuLysGlnIleAlaSer" \\$ LysLeuArgGluGlnPheGlyAsnAsnLysThrIleIlePheLysGlnSerSerGlyGlyAspProGlu IleValThrHisSerPheAsnCysGlyGlyGluPhePheTyrCysAsnSerThrGlnLeuPheAsnSer Thr Trp Phe Asn Ser Thr Trp Ser Thr GluGly Ser Asn Asn Thr GluGly Ser Asp Thr I le Thr LeuProCysArgIleLysGlnPheIleAsnMETTrpGlnGluValGlyLysAlaMETTyrAlaProProIle SerGlyGlnIleArgCysSerSerAsnIleThrGlyLeuLeuLeuThrArgAspGlyGlyAsnAsnAsn AsnGlySerGluIlePheArgProGlyGlyGlyAspMETArgAspAsnTrpArgSerGluLeuTyrLys TyrLysValValLysIleGluProLeuGlyValAlaProThrLysAlaLysArgArgValValGlnArg GluLysArgAlaValGlyIleGlyAlaLeuPheLeuGlyPheLeuGlyAlaAlaGlySerThr#ETGly AlaAlaSerMETThrLeuThrValGlnAlaArgGlnLeuLeuSerGlyIleValGlnGlnGlnAsnAsn LeuLeuArgAiaIleGluAlaGlnGinHisLeuLeuGlnLeuThrValTrpGlyIleLysGinLeuGln AlaArgIleLeuAlaValGluArgTyrLeuLysAspGlnGlnLeuLeuGlyIleTrpGlyCysSerGly LysLeuIleCysThrThrAlaValProTrpAsnAlaSerTrpSerAsnLysSerLeuGluGlnIleTrp AsnHisThrThrTrpMETGluTrpAspArgGluIleAsnAsnTyrThrSerLeuIleHisSerLeuIle GluGluSerGlnAsnGlnGlnGluLysAsnGluGlnGluLeuLeuGluLeuAspLysTrpAlaSerLeu TrpAsnTrpPheAsnIleThrAsnTrpLeuTrpTyrIleLysLeuPheIleMETIleValGlyGlyLeu ValGlyLeuArgIleValPheAlaValLeuSerValValAsnArgValArgGlnGlyTyrSerProLeu SerPheGinThrHisLeuProIleProArgGlyProAspArgProGluGlyIleGluGluGluGlyGly GluArgAspArgAspArgSerIleArgLeuValAsnGlySerLeuAlaLeuIleTrpAspAspLeuArg SerleuCysleuPheSerTyrHisArgleuArgAspleuLeuleuIleValThrArgIleValGluLeu LeuGlyArgArgGlyTrpGluAlaLeuLysTyrTrpTrpAsnLeuLeuGlnTyrTrpSerGlnGluLeu LysAsnSerAlaValSerLeuLeuAsnAlaThrAlaIleAlaValAlaGluGlyThrAspArgValIle GluValValGlnGluAlaTyrArgAlaIleArgHisIleProArgArgIleArgGlnGlyLeuGluArg Ileleuleu

FIGURE 6B

AMINO ACID DISTRIBUTION OF AIDS ENV PROTEIN

	<u>Name</u>	Number of	Residues
A	Alanine	47	
В	Aspartic Acid-Asparagine	c	
C	Cysteine	21	•
D	Aspartic Acid	27	. ,
E	Glutamic Acid	4.9) <u>.</u>
F	Phenylalanine	26	•
G	Glycine	58	1
H	Histidine	14	
I	Isoleucine	63	
K	Lysine	4.4	
L	Leucine	83	• •
M	Methionine	17	•
N	Asparagine	. 60	
P	Proline	29	
Q	Glutamine	42	
R	Arginine	52	,
S	Serine	57	•
T	Threonine	60	•
V	Valine	56	
W	Tryptophan	31	
Y	Tyrosine	20	
7	Clutamine Clutamic Raid	^	





This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:					
☐ BLACK BORDERS					
\square IMAGE CUT OFF AT TOP, BOTTOM OR SIDES					
☐ FADED TEXT OR DRAWING					
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING					
☐ SKEWED/SLANTED IMAGES					
COLOR OR BLACK AND WHITE PHOTOGRAPHS					
GRAY SCALE DOCUMENTS					
LINES OR MARKS ON ORIGINAL DOCUMENT					
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY					

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.